var docs;if (!docs) docs =[]; docs["55"]={"5500":"<p><b>Title</b> Salicylates / Influenza Virus Vaccine (Live/Attenuated)</p> \n<p><span style=\"color: red; font-weight: bold\">Dependencies</span> </p>\n<ul>\n <li><p><b>Age</b>: Due to the risk of Reye's syndrome, patients less than 18 years of age should not receive concomitant salicylates (e.g., aspirin) with the intranasal, live/attenuated influenza virus vaccine</p></li>\n</ul>\n<p></p> \n<p><b>Risk Rating</b> X: Avoid combination</p> \n<p><b>Summary</b> Influenza Virus Vaccine (Live/Attenuated) may enhance the adverse/toxic effect of Salicylates. Specifically, Reye's syndrome may develop. <b>Severity</b> Major <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Concomitant use of aspirin or aspirin-containing products in patients less than 18 years of age receiving intranasal influenza vaccine (live/attenuated) is contraindicated. Concomitant use of other salicylates with this vaccine should be avoided as well. Following vaccination, aspirin and/or aspirin-containing products should be avoided for 4 weeks. Specific recommendations regarding administration of non-aspirin salicylates following vaccination are not available.</p>\n<div>\n <p><b>Salicylates Interacting Members</b> Aminosalicylic Acid, Aspirin, Bismuth Subsalicylate, Choline Magnesium Trisalicylate, Choline Salicylate, Magnesium Salicylate, Salsalate, Sodium Salicylate, Triflusal</p>\n</div> \n<p><b>Discussion</b> Due to risks for Reye's syndrome in association with aspirin and wild-type influenza infection, concomitant use of the intranasal influenza vaccine (live/attenuated) with aspirin or aspirin-containing products is contraindicated in patients less than 18 years of age.<sup>1</sup> In this same patient population, the Advisory Committee on Immunization Practices (ACIP) recommends avoiding other salicylates as well with this vaccine.<sup>2</sup> The Canadian labeling recommends avoiding aspirin or aspirin-containing products for 4 weeks after vaccination with the intranasal influenza vaccine (live/attenuated).<sup>3</sup> Specific recommendations regarding administration of other salicylate products following vaccination are not available.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Prescribing information. FluMist (Influenza Vaccine, live-attenuated). Gaithersburg, MD: MedImmune LLC, July 2010.</p>\n<p>2. Centers for Disease Control and Prevention, “Prevention and Control of Influenza with Vaccines: Recommendations of the Advisory Committee on Immunization Practices (ACIP), 2010” <i>MMWR Recomm Rep</i>, 2010, 59(RR-8):1-62. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=20689501\">[PubMed 20689501]</a> </p>\n<p>3. Prescribing information. FluMist (Influenza Vaccine, live-attenuated). Mississauga, Ontario: AstraZeneca Canada, July 2010.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","5501":"<p><b>Title</b> SORAfenib / Felodipine</p> \n<p></p> \n<p><b>Risk Rating</b> B: No action needed</p> \n<p><b>Summary</b> Felodipine may increase the serum concentration of SORAfenib. <b>Severity</b> Minor <b>Reliability Rating</b> Poor </p> \n<p><b>Patient Management</b> No action needed.</p> \n<p><b>Discussion</b> A published case report describes an 80 year-old patient with hepatocellular carcinoma who experienced a 3-fold increase in sorafenib concentrations 15 days after initiation of felodipine (5 mg twice daily).<sup>1</sup> The patient had been stable on sorafenib (400 mg twice daily) for 15 days prior to felodipine initiation. <br><br>The mechanism for this possible interaction is uncertain. Felodipine is metabolized by CYP3A4 but is not known to be even a moderately potent CYP3A inhibitor. Sorafenib is metabolized via both CYP3A4-mediated metabolism and glucuronidation (via UGT1A1 and UGT1A9), but a study with the potent CYP3A4 inhibitor ketoconazole (400 mg/day) found no significant impact on sorafenib concentrations in healthy volunteers.<sup>2</sup> The authors of the case report speculate that impairment of sorafenib glucuronidation from the patient's progressive hepatocellular carcinoma might have contributed by emphasizing the role of CYP3A4 in sorafenib elimination.<sup>1</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Gomo C, Cortiat R, Faivre L, et al, “Pharmacokinetic Interaction Involving Sorafenib and the Calcium-Channel Blocker Felodipine in a Patient with Hepatocellular Carcinoma,” <i>Invest New Drugs</i>, 2010, Aug 13 (Epub ahead of print). <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=20706860\">[PubMed 20706860]</a></p>\n<p>2. Prescribing information. Nexavar (sorafenib). West Haven, CT: Bayer Pharmaceuticals Corporation, 2/2009.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","5502":"<p><b>Title</b> Lopinavir / Fosamprenavir</p> \n<p></p> \n<p><b>Risk Rating</b> X: Avoid combination</p> \n<p><b>Summary</b> Fosamprenavir may decrease the serum concentration of Lopinavir. Specifically, amprenavir (the active metabolite of fosamprenavir) may decrease the serum concentration of lopinavir. Lopinavir may decrease the serum concentration of Fosamprenavir. Specifically, lopinavir/ritonavir may decrease the serum concentration of amprenavir (the active metabolite of fosamprenavir) <b>Severity</b> Major <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Avoid concomitant use of fosamprenavir and lopinavir/ritonavir. If the combination cannot be avoided, monitor for increased adverse effects and decreases in lopinavir and amprenavir serum concentrations.</p> \n<p><b>Discussion</b> Prescribing information for fosamprenavir and lopinavir/ritonavir states that an increased rate of adverse reactions has been observed when these drugs are used concomitantly and that appropriates doses for this combination have not been established in regards to safety and efficacy.<sup>1,2</sup><br><br>According to data presented in the fosamprenavir prescribing information, the administration of fosamprenavir/ritonavir (700 mg/100 mg twice daily) with lopinavir/ritonavir (400 mg/100 mg twice daily) for 14 days decreased the AUC, maximum serum concentration (Cmax), and minimum serum concentration (Cmin) of amprenavir (the active metabolite of fosamprenavir) by 63%, 58%, and 65%, respectively, while lopinavir pharmacokinetics were unchanged.<sup>2</sup> When fosamprenavir alone (1,400 mg twice daily) was administered with lopinavir/ritonavir (533 mg/133 mg twice daily) for 14 days the AUC, Cmax, and Cmin of amprenavir decreased 26%, 13%, and 42%, respectively, when compared with fosamprenavir/ritonavir (700 mg/100 mg twice daily).<sup>2</sup> Lopinavir pharmacokinetic parameters were unchanged when compared with lopinavir/ritonavir (400 mg/ 100 mg twice daily).<sup>2</sup> <br><br>In a pharmacokinetic study conducted in 33 patients with HIV, the amprenavir AUC and Cmin were 64% and 69% lower, respectively, in patients who received fosamprenavir/ritonavir (700 mg/100 mg twice daily) and lopinavir/ritonavir (400 mg/100 mg twice daily) compared with those who received fosamprenavir/ritonavir alone.<sup>3</sup> In this same study, the lopinavir AUC and Cmin were 48% and 61% lower, respectively, in patients who received fosamprenavir/ritonavir and lopinavir/ritonavir compared with those who received lopinavir/ritonavir alone.<sup>3</sup> A pharmacokinetic study also looked at separating the doses of fosamprenavir and lopinavir/ritonavir to prevent serum concentration differences but was unsuccessful.<sup>4</sup> <br><br>The mechanism for the decrease in amprenavir serum concentrations is unknown, but may be due to displacement from plasma protein binding sites by lopinavir/ritonavir or a reduction in CYP3A4 inhibition, or boosting effect, with lopinavir/ritonavir compared with ritonavir alone.<sup>4,5</sup> The likely mechanism for the decrease seen in lopinavir serum concentrations is net induction of CYP3A4-mediated lopinavir metabolism by amprenavir or displacement of amprenavir from plasma protein binding sites.<sup>2,4</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. <i>Kaletra</i> (lopinavir/ritonavir) [prescribing information]. North Chicago, IL: AbbVie Inc; January 2015.</p>\n<p>2. <i>Lexiva</i> (fosamprenavir) [prescribing information]. Research Triangle Park, NC: ViiV Healthcare; February 2013.</p>\n<p>3. Kashuba AD, Tierney C, Downey GF, et al. Combing fosamprenavir with lopinavir/ritonavir substantially reduces amprenavir and lopinavir exposure: ACTG protocol A5143 results. <i>AIDS</i>. 2005;19(2):145-152. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=15668539\">[PubMed 15668539]</a></p>\n<p>4. Corbett AH, Patterson KB, Tien HC, et al. Dose separation does not overcome the pharmacokinetic interaction between fosamprenavir and lopinavir/ritonavir. <i>Antimicrob Agents Chemother</i>. 2006;50(8):2756-2761. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=16870769\">[PubMed 16870769]</a></p>\n<p>5. Kumar GN, Dykstra J, Roberts EM, et al. Potent inhibition of the cytochrome P-450 3A-mediated human liver microsomal metabolism of a novel HIV protease inhibitor by ritonavir: A positive drug-drug interaction. <i>Drug Metab Dispos</i>. 1999;27(8):902-908. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=10421617\">[PubMed 10421617]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","5503":"<p><b>Title</b> Lopinavir / CarBAMazepine</p> \n<p><span style=\"color: red; font-weight: bold\">Dependencies</span> </p>\n<ul>\n <li><p><b>Dose</b>: The significance of this interaction is increased with once daily regimens of lopinavir/ritonavir.</p></li>\n</ul>\n<p></p> \n<p><b>Risk Rating</b> D: Consider therapy modification</p> \n<p><b>Summary</b> CarBAMazepine may decrease the serum concentration of Lopinavir. <b>Severity</b> Major <b>Reliability Rating</b> Fair: Reported in the prescribing information </p> \n<p><b>Patient Management</b> Increased doses of lopinavir may be necessary when using these agents in combination. Do not use a once daily lopinavir/ritonavir regimen together with carbamazepine. Increase monitoring of therapeutic response in all patients using this combination.</p> \n<p><b>Discussion</b> Though specific data concerning the concurrent use of lopinavir and carbamazepine are not available, data with phenytoin, another enzyme-inducing antiepileptic drug, support the existence of this predicted drug interaction. Concurrent lopinavir/ritonavir (400 mg/100 mg twice daily) and phenytoin (300 mg daily) for 11 days (n=24) was associated with a 30% lower lopinavir AUC, a 35% lower ritonavir AUC, and a 23% lower phenytoin AUC.<sup>1</sup> Minimum and maximum concentrations of all three agents were also substantially (20-50%) lower during combined therapy. Based on this anticipated interaction, lopinavir/ritonavir prescribing information recommends avoiding the use of once daily lopinavir/ritonavir regimens with carbamazepine and recommends caution with the use of other dosing regimens.<sup>2</sup><br><br>The mechanism(s) of this multi-agent interaction remain(s) unclear. Similarly, the degree to which lopinavir and/or ritonavir contribute to the interaction is not known. Both lopinavir/ritonavir and phenytoin are known inducers of drug metabolism, which could at least partially explain the observed effects.<sup>1,2</sup> Induction of drug transport and protein binding displacement are other mechanisms that may contribute to the interaction.<sup>1,2,3</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Lim ML, Min SS, Eron JJ, et al, “Coadministration of Lopinavir/Ritonavir and Phenytoin Results in Two-Way Drug Interaction through Cytochrome P-450 Induction,” <i>J Acquir Immune Defic Syndr</i>, 2004, 36:1034-40. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=15247556\">[PubMed 15247556]</a></p>\n<p>2. Prescribing information. Kaletra (lopinavir/ritonavir). North Chicago, IL: Abbott Laboratories, June 2010.</p>\n<p>3. van der Lee MJ, Blenke AA, Rongen GA, et al, “Interaction Study of the Combined Use of Paroxetine and Fosamprenavir-Ritonavir in Healthy Subjects,” <i>Antimicrob Agents Chemother</i>, 2007, 51:4098-104. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=17846135\">[PubMed 17846135]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","5504":"<p><b>Title</b> Lopinavir / PHENobarbital</p> \n<p><span style=\"color: red; font-weight: bold\">Dependencies</span> </p>\n<ul>\n <li><p><b>Dose</b>: The significance of this interaction appears greater with a once daily lopinavir/ritonavir regimen.</p></li>\n</ul>\n<p></p> \n<p><b>Risk Rating</b> D: Consider therapy modification</p> \n<p><b>Summary</b> PHENobarbital may decrease the serum concentration of Lopinavir. <b>Severity</b> Major <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Increased doses of lopinavir may be necessary when using these agents in combination. Do not use a once daily lopinavir/ritonavir regimen together with phenobarbital. Increase monitoring of therapeutic response in all patients using this combination.</p> \n<p><b>Discussion</b> Though specific data concerning the concurrent use of lopinavir and phenobarbital are not available, data with phenytoin, another enzyme-inducing antiepileptic drug, support the existence of this predicted drug interaction. Concurrent lopinavir/ritonavir (400 mg/100 mg twice daily) and phenytoin (300 mg daily) for 11 days (n=24) was associated with a 30% lower lopinavir AUC, a 35% lower ritonavir AUC, and a 23% lower phenytoin AUC.<sup>1</sup> Minimum and maximum concentrations of all three agents were also substantially (20-50%) lower during combined therapy. Based on this anticipated interaction, lopinavir/ritonavir prescribing information recommends avoiding the use of once daily lopinavir/ritonavir regimens with phenobarbital and recommends caution with the use of other dosing regimens.<sup>2</sup><br><br>The mechanism(s) of this multi-agent interaction remain(s) unclear. Similarly, the degree to which lopinavir and/or ritonavir contribute to the interaction is not known. Both lopinavir/ritonavir and phenytoin are known inducers of drug metabolism, which could at least partially explain the observed effects.<sup>1,2</sup> Induction of drug transport and protein binding displacement are other mechanisms that may contribute to the interaction.<sup>1,2,3</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Lim ML, Min SS, Eron JJ, et al, “Coadministration of Lopinavir/Ritonavir and Phenytoin Results in Two-Way Drug Interaction through Cytochrome P-450 Induction,” <i>J Acquir Immune Defic Syndr</i>, 2004, 36:1034-40. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=15247556\">[PubMed 15247556]</a></p>\n<p>2. Prescribing information. Kaletra (lopinavir/ritonavir). North Chicago, IL: Abbott Laboratories, June 2010.</p>\n<p>3. van der Lee MJ, Blenke AA, Rongen GA, et al, “Interaction Study of the Combined Use of Paroxetine and Fosamprenavir-Ritonavir in Healthy Subjects,” <i>Antimicrob Agents Chemother</i>, 2007, 51:4098-104. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=17846135\">[PubMed 17846135]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","5505":"<p><b>Title</b> Aliskiren / Grapefruit Juice</p> \n<p></p> \n<p><b>Risk Rating</b> D: Consider therapy modification</p> \n<p><b>Summary</b> Grapefruit Juice may decrease the serum concentration of Aliskiren. <b>Severity</b> Moderate <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Avoid concomitant administration of aliskiren and grapefruit juice. Monitor for decreased aliskiren levels/effects (e.g., diminished antihypertensive effects) in patients consuming grapefruit juice. Conversely, monitor for increased aliskiren levels/effects with discontinuation of grapefruit juice. Separation of aliskiren and grapefruit juice administration by several hours may reduce the chance for interaction.</p> \n<p><b>Discussion</b> In a 2-phase crossover study of 11 healthy subjects receiving water or grapefruit juice (GFJ) (200 mL TID x 5 days) with aliskiren (150 mg single dose on day 3), GFJ decreased aliskiren Cmax 81% and AUC 61%, and delayed the time to aliskiren maximum concentration (Tmax) by 30 minutes.<sup>1</sup> Aliskiren renal clearance and plasma renin activity were not significantly different during either phase of the study. The authors suggest that GFJ delayed and reduced intestinal uptake of aliskiren by inhibiting organic anion-transporting polypeptide 2B1 (OATP2B1).<br><br>Aliskiren is a CYP3A4 isoenzyme and P-glycoprotein (P-gp) substrate.<sup>2</sup> Some in vitro studies suggest that aliskiren is also an OATP2B1 substrate.<sup>3</sup> GFJ inhibits CYP3A4 and P-gp and has been shown in vitro to inhibit OATP2B1.<sup>4</sup> A time-dependent effect of GFJ on fexofenadine (an OATP1A2 substrate) systemic exposure was noted in 12 volunteers.<sup>5</sup> Administration of GFJ (300 mL) concomitantly with, or 2 or 4 hours prior to fexofenadine (120 mg), decreased fexofenadine AUC 52%, 38%, and 4% respectively. Citing these results, some authors<sup>1</sup> suggest that similar time-dependent effects might be observed with aliskiren and GFJ and recommend against their concomitant use.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Tapaninen T, Neuvonen PJ, and Niemi M, “Grapefruit Juice Greatly Reduces the Plasma Concentrations of the OATP2B1 and CYP3A4 Substrate Aliskiren,” <i>Clin Pharmacol Ther</i>, 2010, 88(3):339-42. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=20664534\">[PubMed 20664534]</a></p>\n<p>2. Prescribing information. Tekturna (aliskiren). East Hanover, NJ: Novartis Pharmaceuticals Corporation, 08/2010.</p>\n<p>3. Vaidyanathan S, Camenisch G, Schuetz H, et al, “Pharmacokinetics of the Oral Direct Renin Inhibitor Aliskiren in Combination With Digoxin, Atorvastatin, and Ketoconazole in Healthy Subjects: The Role of P-Glycoprotein in the Disposition of Aliskiren,” <i>J Clin Pharmacol</i>, 2008, 48(11):1323-38. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=18784280\">[PubMed 18784280]</a></p>\n<p>4. Satoh H, Yamashita F, Tsujimoto M, et al, “Citrus Juices Inhibit The Function Of Human Organic Anion-Transporting Polypeptide OATP-B,” <i>Drug Metab Dispos</i>, 2005, 33(4):518-23. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=15640378\">[PubMed 15640378]</a></p>\n<p>5. Glaeser H, Bailey DG, Dresser GK, et al, “Intestinal Drug Transporter Expression and the Impact of Grapefruit Juice in Humans,” <i>Clin Pharmacol Ther</i>, 2007, 81:362-70. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=17215845\">[PubMed 17215845]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","5506":"<p><b>Title</b> Nelfinavir / Lopinavir</p> \n<p><span style=\"color: red; font-weight: bold\">Dependencies</span> </p>\n<ul>\n <li><p><b>Dose</b>: Significance of this interaction appears greater with once daily lopinavir/ritonavir.</p></li>\n</ul>\n<p></p> \n<p><b>Risk Rating</b> D: Consider therapy modification</p> \n<p><b>Summary</b> Nelfinavir may decrease the serum concentration of Lopinavir. Lopinavir may increase the serum concentration of Nelfinavir. Concentrations of the nelfinavir M8 metabolite may also be increased. <b>Severity</b> Major <b>Reliability Rating</b> Fair: Reported in the prescribing information </p> \n<p><b>Patient Management</b> Avoid once daily use of lopinavir/ritonavir when used with nelfinavir. For ADULT patients: an increased dose of lopinavir/ritonavir to 500mg/125mg (for TABLETS) or 533mg/133mg (for ORAL SOLUTION) twice daily is recommended with concurrent nelfinavir. For PEDIATRIC patients: do not use this combination in patients less than 6 months of age; see lopinavir/ritonavir prescribing information for specific dose increases in other pediatric patients. Monitor clinical response and for signs/symptoms of toxicity closely.</p> \n<p><b>Discussion</b> Mean lopinavir AUC and minimum plasma concentration (Cmin) were reduced by 27% and 38%, respectively, when lopinavir/ritonavir (400 mg/100 mg twice daily) was administered with nelfinavir (1000 mg twice daily).<sup>1</sup> In the same study, the mean nelfinavir Cmin was 86% higher, and both the mean AUC and mean Cmin of the nelfinavir M8 metabolite were increased by more than 3- and 7-fold, respectively.<br><br>The specific mechanism by which nelfinavir may decrease lopinavir concentrations is uncertain. The mechanism by which lopinavir/ritonavir increases nelfinavir/M8 concentrations is likely via inhibition of CYP3A- and/or CYP2C19-mediated metabolism.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Prescribing information. Kaletra (lopinavir/ritonavir). North Chicago, IL: Abbott Laboratories, June 2010.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","5507":"<p><b>Title</b> PHENobarbital / Methylphenidate</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Methylphenidate may increase the serum concentration of PHENobarbital. <b>Severity</b> Moderate <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Consider monitoring for increased serum concentrations/toxicity of phenobarbital if methylphenidate is initiated/dose increased, or decreased concentrations/effects if methylphenidate is discontinued/dose decreased.</p> \n<p><b>Discussion</b> One published case report describes a 5 year old boy receiving primidone (17.7 mg/kg/day orally) who experienced increases in primidone and phenobarbital concentrations following initiation of methylphenidate (10-20 mg orally twice daily, varying regimens).<sup>1</sup> Primidone and phenobarbital concentrations increased from 4.4 mg/L and 23 mg/L, respectively, at baseline to maximum concentrations of 21.5 mg/L and 39 mg/L, respectively, following methylphenidate initiation. Methylphenidate administration had no apparent impact on phenobarbital concentrations in two other children in the same report. A clinical study of 11 patients 15-53 years old receiving stable phenobarbital and/or primidone therapy showed no apparent effect of methylphenidate (30 mg orally daily) on plasma phenobarbital concentrations.<sup>2</sup><br><br>The mechanism of this possible interaction is unknown. Prescribing information for methylphenidate acknowledges the possibility of an interaction but gives no specific recommendations for monitoring or dose adjustment.<sup>3</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Garrettson LK, Perel JM and Dayton PG, “Methylphenidate Interaction With Both Anticonvulsants and Ethyl Biscoumacetate,” <i>JAMA</i>, 1969, 207(11):2053-6. [PubMed: 5818377]</p>\n<p>2. Kupferberg HJ, Jeffery W and Hunninghake DB, “Effect of Methylphenidate on Plasma Anticonvulsant Levels,” <i>Clin Pharmacol Ther</i>, 1972, 13(2):201-4. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=4552820\">[PubMed 4552820]</a></p>\n<p>3. Prescribing information. Ritalin LA (methylphenidate hydrochloride). East Hanover, New Jersey: Novartis Pharmaceuticals Corporation, May 2010.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","5508":"<p><b>Title</b> Primidone / Methylphenidate</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Methylphenidate may increase serum concentrations of the active metabolite(s) of Primidone. Specifically, phenobarbital concentrations could become elevated. Methylphenidate may increase the serum concentration of Primidone. <b>Severity</b> Moderate <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Consider monitoring for increased serum concentrations/toxicity of primidone and phenobarbital (an active metabolite of primidone) if methylphenidate is initiated/dose increased, or decreased concentrations/effects if methylphenidate is discontinued/dose decreased.</p> \n<p><b>Discussion</b> One published case report describes a 5 year old boy receiving primidone (17.7 mg/kg/day orally) who experienced increases in primidone and phenobarbital concentrations following initiation of methylphenidate (10-20 mg orally twice daily, varying regimens).<sup>1</sup> Primidone and phenobarbital concentrations increased from 4.4 mg/L and 23 mg/L, respectively, at baseline to maximum concentrations of 21.5 mg/L and 39 mg/L, respectively, following methylphenidate initiation. Methylphenidate administration had no apparent impact on phenobarbital concentrations in two other children in the same report. A clinical study of 11 patients 15-53 years old receiving stable phenobarbital and/or primidone therapy showed no apparent effect of methylphenidate (30 mg orally daily) on plasma phenobarbital concentrations.<sup>2</sup><br><br>The mechanism of this possible interaction is unknown. Prescribing information for methylphenidate acknowledges the possibility of an interaction but gives no specific recommendations for monitoring or dose adjustment.<sup>3</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Garrettson LK, Perel JM and Dayton PG, “Methylphenidate Interaction With Both Anticonvulsants and Ethyl Biscoumacetate,” <i>JAMA</i>, 1969, 207(11):2053-6. [PubMed: 5818377]</p>\n<p>2. Kupferberg HJ, Jeffery W and Hunninghake DB, “Effect of Methylphenidate on Plasma Anticonvulsant Levels,” <i>Clin Pharmacol Ther</i>, 1972, 13(2):201-4. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=4552820\">[PubMed 4552820]</a></p>\n<p>3. Prescribing information. Ritalin LA (methylphenidate hydrochloride). East Hanover, New Jersey: Novartis Pharmaceuticals Corporation, May 2010.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","5509":"<p><b>Title</b> PHENobarbital / Dexmethylphenidate</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Dexmethylphenidate may increase the serum concentration of PHENobarbital. <b>Severity</b> Moderate <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Consider monitoring for increased serum concentrations/toxicity of phenobarbital if dexmethylphenidate is initiated/dose increased, or decreased concentrations/effects if dexmethylphenidate is discontinued/dose decreased.</p> \n<p><b>Discussion</b> One published case report describes a 5 year old boy receiving primidone (17.7 mg/kg/day orally) who experienced increases in primidone and phenobarbital concentrations following initiation of racemic methylphenidate (10-20 mg orally twice daily, varying regimens).<sup>1</sup> Primidone and phenobarbital concentrations increased from 4.4 mg/L and 23 mg/L, respectively, at baseline to maximum concentrations of 21.5 mg/L and 39 mg/L, respectively, following methylphenidate initiation. Methylphenidate administration had no apparent impact on phenobarbital concentrations in two other children in the same report. A clinical study of 11 patients 15-53 years old receiving stable phenobarbital and/or primidone therapy showed no apparent effect of racemic methylphenidate (30 mg orally daily) on plasma phenobarbital concentrations.<sup>2</sup><br><br>The mechanism of this possible interaction is unknown. Prescribing information for dexmethylphenidate acknowledges the possibility of an interaction but gives no specific recommendations for monitoring or dose adjustment.<sup>3</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Garrettson LK, Perel JM and Dayton PG, “Methylphenidate Interaction With Both Anticonvulsants and Ethyl Biscoumacetate,” <i>JAMA</i>, 1969, 207(11):2053-6. [PubMed: 5818377]</p>\n<p>2. Kupferberg HJ, Jeffery W and Hunninghake DB, “Effect of Methylphenidate on Plasma Anticonvulsant Levels,” <i>Clin Pharmacol Ther</i>, 1972, 13(2):201-4. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=4552820\">[PubMed 4552820]</a></p>\n<p>3. Prescribing information. Focalin (dexmethylphenidate hydrochloride). East Hanover, New Jersey: Novartis Pharmaceuticals Corporation, August 2010.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","5510":"<p><b>Title</b> Primidone / Dexmethylphenidate</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Dexmethylphenidate may increase serum concentrations of the active metabolite(s) of Primidone. Specifically, phenobarbital concentrations could become elevated. Dexmethylphenidate may increase the serum concentration of Primidone. <b>Severity</b> Moderate <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Consider monitoring for increased serum concentrations/toxicity of primidone and phenobarbital (and active metabolite of primidone) if dexmethylphenidate is initiated/dose increased, or decreased concentrations/effects if dexmethylphenidate is discontinued/dose decreased.</p> \n<p><b>Discussion</b> One published case report describes a 5 year old boy receiving primidone (17.7 mg/kg/day orally) who experienced increases in primidone and phenobarbital concentrations following initiation of racemic methylphenidate (10-20 mg orally twice daily, varying regimens).<sup>1</sup> Primidone and phenobarbital concentrations increased from 4.4 mg/L and 23 mg/L, respectively, at baseline to maximum concentrations of 21.5 mg/L and 39 mg/L, respectively, following methylphenidate initiation. Methylphenidate administration had no apparent impact on phenobarbital concentrations in two other children in the same report. A clinical study of 11 patients 15-53 years old receiving stable phenobarbital and/or primidone therapy showed no apparent effect of racemic methylphenidate (30 mg orally daily) on plasma phenobarbital concentrations.<sup>2</sup><br><br>The mechanism of this possible interaction is unknown. Prescribing information for dexmethylphenidate acknowledges the possibility of an interaction but gives no specific recommendations for monitoring or dose adjustment.<sup>3</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Garrettson LK, Perel JM and Dayton PG, “Methylphenidate Interaction With Both Anticonvulsants and Ethyl Biscoumacetate,” <i>JAMA</i>, 1969, 207(11):2053-6. [PubMed: 5818377]</p>\n<p>2. Kupferberg HJ, Jeffery W and Hunninghake DB, “Effect of Methylphenidate on Plasma Anticonvulsant Levels,” <i>Clin Pharmacol Ther</i>, 1972, 13(2):201-4. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=4552820\">[PubMed 4552820]</a></p>\n<p>3. Prescribing information. Focalin (dexmethylphenidate hydrochloride). East Hanover, New Jersey: Novartis Pharmaceuticals Corporation, August 2010.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","5512":"<p><b>Title</b> Benzylpenicilloyl Polylysine / Antihistamines</p> \n<p></p> \n<p><b>Risk Rating</b> D: Consider therapy modification</p> \n<p><b>Summary</b> Antihistamines may diminish the diagnostic effect of Benzylpenicilloyl Polylysine. <b>Severity</b> Moderate <b>Reliability Rating</b> Fair: Reported in the prescribing information </p> \n<p><b>Patient Management</b> Treatment with systemic histamine H1 antagonists should be suspended for benzylpenicilloyl-polylysine skin testing to minimize the potential for false negative results. Delay skin testing until the systemic effects of the antihistamine have dissipated. A histamine skin test may be used to assess residual antihistaminic effects.</p>\n<div>\n <p><b>Antihistamines Interacting Members</b> Acrivastine, Bilastine, Brompheniramine, Buclizine, Carbinoxamine, Cetirizine (Systemic), Chlorpheniramine, Clemastine, Cyclizine, Cyproheptadine, Desloratadine, Dexbrompheniramine, Dexchlorpheniramine, DimenhyDRINATE, Dimethindene (Systemic), DiphenhydrAMINE (Systemic), DiphenhydrAMINE (Topical), Doxylamine, Ebastine, Emedastine (Systemic), Fexofenadine, HydrOXYzine, Ketotifen (Systemic), Levocetirizine, Loratadine, Meclizine, Mequitazine, Olopatadine (Systemic), Oxatomide, Oxomemazine, Pheniramine, Phenyltoloxamine, Pizotifen, Pyrilamine (Systemic), Rupatadine, Thonzylamine, Trimeprazine, Triprolidine</p>\n</div> \n<p><b>Discussion</b> Prescribing information for benzylpenicilloyl-polylysine warns that H1-antihistamines may attenuate the skin testing response, and therefore skin testing should be delayed until the systemic antihistaminic effects of those agents have dissipated.<sup>1</sup> Consult prescribing information for the specific antihistamine to determine duration of action.<br><br>Antihistamines can inhibit development of the wheal and flare reaction to histamine, thereby increasing the potential for false-negative skin antigen testing.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Prescribing information. Pre-Pen (benzylpenicilloyl-polylysine). Round Rock, TX: ALK-Abello, Inc., October 2009.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","5513":"<p><b>Title</b> Benzylpenicilloyl Polylysine / Alpha-/Beta-Agonists</p> \n<p></p> \n<p><b>Risk Rating</b> D: Consider therapy modification</p> \n<p><b>Summary</b> Alpha-/Beta-Agonists may diminish the diagnostic effect of Benzylpenicilloyl Polylysine. <b>Severity</b> Major <b>Reliability Rating</b> Fair: Reported in the prescribing information </p> \n<p><b>Patient Management</b> Patients receiving vasopressor medications may have a reduced response to benzylpenicilloyl-polylysine skin testing. Consider use of a histamine skin test as a positive control to assess a patient's ability to mount a wheal and flare response.</p>\n<div>\n <p><b>Alpha-/Beta-Agonists Interacting Members</b> Amezinium, DOPamine, Ephedra, EPHEDrine (Nasal), EPHEDrine (Systemic), EPINEPHrine (Systemic), Levonordefrin, Metaraminol, Norepinephrine, Pseudoephedrine<br><b>Exceptions</b> EPINEPHrine (Nasal), EPINEPHrine (Oral Inhalation), Isometheptene</p>\n</div> \n<p><b>Discussion</b> Prescribing information for benzylpenicilloyl-polylysine warns that vasopressor medications may attenuate the skin testing response.<sup>1</sup> Consider use of a histamine skin test as a positive control to assess a patient's ability to mount a wheal and flare response. <br><br>The mechanism of this interaction is unknown.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Prescribing information. Pre-Pen (benzylpenicilloyl-polylysine). Round Rock, TX: ALK-Abello, Inc., October 2009.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","5514":"<p><b>Title</b> Benzylpenicilloyl Polylysine / Alpha1-Agonists</p> \n<p></p> \n<p><b>Risk Rating</b> D: Consider therapy modification</p> \n<p><b>Summary</b> Alpha1-Agonists may diminish the diagnostic effect of Benzylpenicilloyl Polylysine. <b>Severity</b> Moderate <b>Reliability Rating</b> Fair: Reported in the prescribing information </p> \n<p><b>Patient Management</b> Patients receiving vasopressor medications may have a reduced response to benzylpenicilloyl-polylysine skin testing. Consider use of a histamine skin test as a positive control to assess a patient's ability to mount a wheal and flare response.</p>\n<div>\n <p><b>Alpha1-Agonists Interacting Members</b> Midodrine, Phenylephrine (Systemic)<br><b>Exceptions</b> Naphazoline (Nasal), Naphazoline (Ophthalmic), Oxymetazoline (Nasal), Phenylephrine (Nasal), Phenylephrine (Ophthalmic), Phenylephrine (Topical), Propylhexedrine, Xylometazoline</p>\n</div> \n<p><b>Discussion</b> Prescribing information for benzylpenicilloyl-polylysine warns that vasopressor medications may attenuate the skin testing response.<sup>1</sup> Consider use of a histamine skin test as a positive control to assess a patient's ability to mount a wheal and flare response. <br><br>The mechanism of this interaction is unknown.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Prescribing information. Pre-Pen (benzylpenicilloyl-polylysine). Round Rock, TX: ALK-Abello, Inc., October 2009.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","5515":"<p><b>Title</b> Praziquantel / CYP3A4 Inducers (Strong)</p> \n<p></p> \n<p><b>Risk Rating</b> X: Avoid combination</p> \n<p><b>Summary</b> CYP3A4 Inducers (Strong) may decrease the serum concentration of Praziquantel. <b>Severity</b> Major <b>Reliability Rating</b> Good </p> \n<p><b>Patient Management</b> Avoid concomitant use of praziquantel with strong CYP3A4 inducers. If praziquantel treatment is necessary in patients receiving rifampin, rifampin should be discontinued 4 weeks prior to initiation and may be resumed the day following praziquantel completion.</p>\n<div>\n <p><b>CYP3A4 Inducers (Strong) Interacting Members</b> Apalutamide, CarBAMazepine, Enzalutamide, Fosphenytoin, Lumacaftor, Mitotane, PHENobarbital, Phenytoin, Primidone, RifAMPin</p>\n</div> \n<p><b>Discussion</b> In single- (40mg/kg x1) and multiple-dose (25mg/kg every 8 hours x 3 doses) studies of praziquantel in healthy volunteers, rifampin pretreatment (600mg daily x 5 days) resulted in undetectable praziquantel concentrations in 7/10 and 5/10 subjects, respectively.<sup>1</sup> In those with detectable concentrations, average praziquantel AUC was 80-85% lower with rifampin, and in those without detectable praziquantel following rifampin, it was estimated that AUC was reduced by at least 89-94%. Praziquantel maximum concentrations were similarly impacted by rifampin in both single- and multi-dose studies.<sup>1</sup> In another clinical study, epileptic patients receiving stable treatment with carbamazepine (N=10) or phenytoin (N=10) had single dose praziquantel (25 mg orally) AUCs 90% and 74% lower, respectively, than matched control patients.<sup>2</sup> <br><br>In addition to the above human data, a rodent study indicated an 84% decrease in praziquantel (100 mg/kg single oral dose) AUC with phenobarbital pretreatment.<sup>3</sup><br><br>The likely mechanism of this interaction is induction of the largely CYP3A4-mediated metabolism (intestinal and/or hepatic) of praziquantel by the inducing agents. Praziquantel prescribing information contraindicates its concomitant use with strong CYP inducers such as rifampin and recommends discontinuation of rifampin 4 weeks prior to treatment initiation.<sup>4</sup> Rifampin treatment may resume the day after praziquantel treatment is completed.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Ridtitid W, Wongnawa M, Mahatthanatrakul W, et al, “Rifampin Markedly Decreases Plasma Concentrations of Praziquantel in Healthy Volunteers,” <i>Clin Pharmacol Ther</i>, 2002, 72(5):505-13. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=12426514\">[PubMed 12426514]</a></p>\n<p>2. Bittencourt PR, Gracia CM, Martins R, et al, “Phenytoin and Carbamazepine Decreased Oral Bioavailability of Praziquantel,” <i>Neurology</i>, 1992, 42(3 Pt 1):492-6. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=1549207\">[PubMed 1549207]</a></p>\n<p>3. Masimirembwa CM, Naik YS and Hasler JA, “Effects of Phenobarbital and 3-Methylcholanthrene Pretreatment on the Pharmacokinetics of Praziquantel in Rats,” <i>Eur J Drug Metab Pharmacokinet</i>, 1993, 18(3):261-4. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=8149944\">[PubMed 8149944]</a></p>\n<p>4. Prescribing information. Biltricide (praziquantel). Whitehouse Station, NJ: Merck &amp; Co., Inc., August 2010.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","5517":"<p><b>Title</b> GlyBURIDE / CycloSPORINE (Systemic)</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> CycloSPORINE (Systemic) may diminish the therapeutic effect of GlyBURIDE. GlyBURIDE may increase the serum concentration of CycloSPORINE (Systemic). <b>Severity</b> Moderate <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Consider monitoring for increased concentrations/effects of cyclosporine and possible reduced therapeutic impact of glyburide during concomitant therapy.</p> \n<p><b>Discussion</b> In a retrospective review of records from 6 renal transplant recipients, serum concentrations of cyclosporine were on average 57% higher after patients began treatment with glyburide.<sup>1</sup> However, the methodology used to assess cyclosporine concentrations before and during glyburide treatment, including blood draw timing, are not described. <br><br>In addition to possible pharmacokinetic interactions, some animal data suggest that cyclosporine and sulfonylurea antidiabetic agents may have opposing effects on glucose/glycogen metabolism and insulin/glucagon regulation,<sup>2,3,4</sup> but studies in humans have not been pursued.<br><br>The mechanism of any possible pharmacokinetic interaction between these agents is unknown. An in vitro study suggested that glyburide inhibited P-glycoprotein, a transporter involved in cyclosporine disposition, but the clinical importance of such inhibition has not been established.<sup>5</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Islam SI, Masuda QN, Bolaji OO, et al, “Possible Interaction Between Cyclosporine and Glibenclamide in Post-Transplant Diabetic Patients,” <i>Ther Drug Monit</i>, 1996, 18:624-6. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=8885130\">[PubMed 8885130]</a></p>\n<p>2. Bartlett ST, Gillison SL and Curry DL, “Cyclosporine Inhibition of Insulin Secretion: Effect of Tolbutamide and Extracellular Calcium Concentration,” <i>Transplant Proc</i>, 1990, 22(2):749-53. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=2183445\">[PubMed 2183445]</a></p>\n<p>3. Hopps V, Galione A, Vetri P, et al, “Glybenclamide and Cyclosporine A: An Interaction on Glucose Metabolism,” <i>Transplant Proc</i>, 1988, 20(3 Suppl 3):979-84. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=3133859\">[PubMed 3133859]</a></p>\n<p>4. Pollock SH, Reichbaum MI, Collier BH, et al, “Inhibitory Effect of Cyclosporine A on the Activity of Oral Hypoglycemic Agents in Rats,” <i>J Pharmacol Exp Ther</i>, 1991, 258(1):8-12. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=1906541\">[PubMed 1906541]</a></p>\n<p>5. Golstein PE, Boom A, van Geffel J, et al, “P-Glycoprotein Inhibition by Glibenclamide and Related Compounds,” <i>Pflugers Arch</i>, 1999, 437(5):652-60. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=10087141\">[PubMed 10087141]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","5518":"<p><b>Title</b> Digoxin / Tolvaptan</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Tolvaptan may increase the serum concentration of Digoxin. <b>Severity</b> Moderate <b>Reliability Rating</b> Good </p> \n<p><b>Patient Management</b> Monitor for increased digoxin concentrations/effects if tolvaptan is initiated/dose increased, or decreased concentrations/effects if tolvaptan is discontinued/dose decreased.</p> \n<p><b>Discussion</b> A study in 14 healthy subjects, coadministration of tolvaptan (60 mg orally daily) with digoxin (0.25 mg orally daily) increased digoxin maximum concentration and AUC by 27% and 18%, respectively.<sup>1</sup> Renal clearance was decreased by 59% based on 24-hour urine collection. The authors of this study also present data demonstrating P-glycoprotein (P-gp) inhibition by tolvaptan in vitro. <br><br>The likely primary mechanism of this interaction is tolvaptan inhibition of P-gp mediated digoxin transport. Tolvaptan may be a relatively selective inhibitor of renal P-gp based on the small impact on digoxin concentration relative to renal clearance.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Shoaf SE, Ohzone Y, Ninomiya SI, et al, “In Vitro P-Glycoprotein Interactions and Steady-State Pharmacokinetic Interactions Between Tolvaptan and Digoxin in Healthy Subjects,” <i>J Clin Pharmacol</i>, 2010, Aug 2. Epub. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=20679500\">[PubMed 20679500]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","5519":"<p><b>Title</b> Antiarrhythmic Agents (Class Ia) / Fingolimod</p> \n<p></p> \n<p><b>Risk Rating</b> X: Avoid combination</p> \n<p><b>Summary</b> Fingolimod may enhance the arrhythmogenic effect of Antiarrhythmic Agents (Class Ia). <b>Severity</b> Major <b>Reliability Rating</b> Fair: Reported in the prescribing information </p> \n<p><b>Patient Management</b> Fingolimod product labeling in the U.S. and Canada recommends avoiding concomitant use with class Ia antiarrhythmic agents. U.S. prescribing information lists this as contraindicated.</p>\n<div>\n <p><b>Antiarrhythmic Agents (Class Ia) Interacting Members</b> Ajmaline, Disopyramide, Procainamide, QuiNIDine</p>\n</div> \n<p><b>Discussion</b> Fingolimod product labels in both the U.S. and Canada recommend avoiding concomitant use with class Ia antiarrhythmic agents.<sup>1,2</sup> Fingolimod treatment can decrease heart rate and prolong QTc interval, which may increase the risk of arrhythmia (including torsades de pointes) during treatment with other drugs that exert these effects.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Prescribing information. Gilenya (fingolimod). East Hanover, NJ: Novartis Pharmaceuticals Corporation, April 2012.</p>\n<p>2. Product monograph. Gilenya (fingolimod). Dorval, Quebec: Novartis Pharmaceuticals Canada Inc., March 2011.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","5520":"<p><b>Title</b> Antiarrhythmic Agents (Class III) / Fingolimod</p> \n<p></p> \n<p><b>Risk Rating</b> X: Avoid combination</p> \n<p><b>Summary</b> Fingolimod may enhance the arrhythmogenic effect of Antiarrhythmic Agents (Class III). <b>Severity</b> Major <b>Reliability Rating</b> Fair: Reported in the prescribing information </p> \n<p><b>Patient Management</b> Fingolimod product labeling in the U.S. and Canada recommends avoiding concomitant use with class III antiarrhythmic agents. U.S. prescribing information lists this as contraindicated.</p>\n<div>\n <p><b>Antiarrhythmic Agents (Class III) Interacting Members</b> Amiodarone, Dofetilide, Dronedarone, Ibutilide, Sotalol, Vernakalant</p>\n</div> \n<p><b>Discussion</b> Fingolimod product labels in both the U.S. and Canada recommend avoiding concomitant use with class III antiarrhythmic agents.<sup>1,2</sup> Fingolimod treatment can decrease heart rate and prolong QTc interval, which may increase the risk of arrhythmia (including torsades de pointes) during treatment with other drugs that exert these effects.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Prescribing information. Gilenya (fingolimod). East Hanover, NJ: Novartis Pharmaceuticals Corporation, April 2012.</p>\n<p>2. Product monograph. Gilenya (fingolimod). Dorval, Quebec: Novartis Pharmaceuticals Canada Inc., March 2011.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","5522":"<p><b>Title</b> Fingolimod / Beta-Blockers</p> \n<p></p> \n<p><b>Risk Rating</b> D: Consider therapy modification</p> \n<p><b>Summary</b> Beta-Blockers may enhance the bradycardic effect of Fingolimod. <b>Severity</b> Major <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Avoid the concomitant use of fingolimod and beta-blockers if possible. If coadministration is necessary, patients should have overnight continuous ECG monitoring conducted after the first dose of fingolimod. Closely monitor patients for the development of bradycardia and other serious arrhythmias.</p>\n<div>\n <p><b>Beta-Blockers Interacting Members</b> Acebutolol, Arotinolol, Atenolol, Betaxolol (Ophthalmic), Betaxolol (Systemic), Bisoprolol, Carteolol (Ophthalmic), Carvedilol, Celiprolol, Esmolol, Labetalol, Levobunolol, Metipranolol, Metoprolol, Nadolol, Nebivolol, Oxprenolol, Penbutolol, Pindolol, Propranolol, Sotalol, Timolol (Ophthalmic), Timolol (Systemic)</p>\n</div> \n<p><b>Discussion</b> In a clinical study of 25 healthy volunteers, the heart rate nadir following fingolimod (5 mg single oral dose) was 15% lower (9 beats per minute lower) during coadministration with atenolol (50 mg orally daily for 5 days).<sup>1</sup> Fingolimod product labeling recommends avoiding use with beta-blockers if possible. If coadministration is necessary, overnight continuous ECG monitoring after the first dose is recommended.<sup>2,3</sup> Closely monitor patients for the development of bradycardia and other serious arrhythmias.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Kovarik JM, Lu M, Riviere GJ, et al. The effect on heart rate of combining single-dose fingolimod with steady-state atenolol or diltiazem in healthy subjects. <i>Eur J Clin Pharmacol</i>. 2008;64(5):457-463. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=18196225\">[PubMed 18196225]</a></p>\n<p>2. Gilenya (fingolimod) [prescribing information]. East Hanover, NJ: Novartis Pharmaceuticals Corporation; February 2016.</p>\n<p>3. Gilenya (fingolimod) [product monograph]. Dorval, Quebec, Canada: Novartis Pharmaceuticals Canada Inc; January 2016.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","5523":"<p><b>Title</b> Vaccines (Live) / Fingolimod</p> \n<p></p> \n<p><b>Risk Rating</b> X: Avoid combination</p> \n<p><b>Summary</b> Fingolimod may enhance the adverse/toxic effect of Vaccines (Live). Vaccinal infections may develop. Fingolimod may diminish the therapeutic effect of Vaccines (Live). <b>Severity</b> Major <b>Reliability Rating</b> Fair: Reported in the prescribing information </p> \n<p><b>Patient Management</b> Avoid the use of live attenuated vaccines during fingolimod treatment, and for 2 months following treatment discontinuation, due to an elevated risk of infection.</p>\n<div>\n <p><b>Vaccines (Live) Interacting Members</b> Adenovirus (Types 4, 7) Vaccine, BCG Vaccine (Immunization), Cholera Vaccine, Influenza Virus Vaccine (Live/Attenuated), Japanese Encephalitis Virus Vaccine (Live/Attenuated), Measles, Mumps, and Rubella Virus Vaccine, Measles, Mumps, Rubella, and Varicella Virus Vaccine, Poliovirus Vaccine (Live/Bivalent/Oral), Poliovirus Vaccine (Live/Trivalent/Oral), Rotavirus Vaccine, Smallpox Vaccine Live, Typhoid Vaccine, Varicella Virus Vaccine, Yellow Fever Vaccine, Zoster Vaccine (Live/Attenuated)</p>\n</div> \n<p><b>Discussion</b> Prescribing information for fingolimod recommends avoiding all live attenuated vaccines during treatment, and for 2 months following treatment, due to a possible increased risk of infection.<sup>1</sup> Fingolimod treatment is associated with decreases in circulating lymphocytes and neutrophils, and a blunted response to vaccines (e.g. 23-valent pneumococcal polysaccharide) and skin test antigens (e.g. tetanus, Candida).</p> \n<p><b>Footnotes</b> </p>\n<p>1. Prescribing information. Gilenya (fingolimod). East Hanover, NJ: Novartis Pharmaceuticals Corporation, September 2010.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","5524":"<p><b>Title</b> Vaccines (Inactivated) / Fingolimod</p> \n<p></p> \n<p><b>Risk Rating</b> D: Consider therapy modification</p> \n<p><b>Summary</b> Fingolimod may diminish the therapeutic effect of Vaccines (Inactivated). <b>Severity</b> Major <b>Reliability Rating</b> Good </p> \n<p><b>Patient Management</b> Fingolimod treatment is associated with decreases in circulating lymphocytes and neutrophils, and a reduced response to vaccines (e.g. 23-valent pneumococcal polysaccharide) and skin test antigens (e.g. tetanus, <i>Candida</i>). These effects are expected during and for 2 months following fingolimod treatment. The value of vaccination during this time is questionable, and if possible, completion of all appropriate inactivated vaccines should occur prior to initiation of fingolimod.</p>\n<div>\n <p><b>Vaccines (Inactivated) Interacting Members</b> Anthrax Vaccine Adsorbed, Diphtheria and Tetanus Toxoids, Diphtheria and Tetanus Toxoids, Acellular Pertussis, and Poliovirus Vaccine, Diphtheria and Tetanus Toxoids, Acellular Pertussis, Hepatitis B (Recombinant), Poliovirus (Inactivated), and Haemophilus influenzae B Conjugate (Adsorbed) Vaccine, Diphtheria and Tetanus Toxoids, Acellular Pertussis, Poliovirus and Haemophilus b Conjugate Vaccine, Diphtheria and Tetanus Toxoids, and Acellular Pertussis Vaccine, Diphtheria, Tetanus Toxoids, Acellular Pertussis, Hepatitis B (Recombinant), and Poliovirus (Inactivated) Vaccine, Haemophilus b Conjugate Vaccine, Hepatitis A Vaccine, Hepatitis B Vaccine (Recombinant [Adjuvanted]), Hepatitis B Vaccine (Recombinant), Influenza A Virus Vaccine (H5N1), Influenza Virus Vaccine (Inactivated), Japanese Encephalitis Virus Vaccine (Inactivated), Meningococcal (Groups A / C / Y and W-135) Diphtheria Conjugate Vaccine, Meningococcal Group B Vaccine, Meningococcal Group C-CRM197 Conjugate Vaccine, Meningococcal Polysaccharide (Groups A / C / Y and W-135) Tetanus Toxoid Conjugate Vaccine, Meningococcal Polysaccharide (Groups C and Y) and Haemophilus b Tetanus Toxoid Conjugate Vaccine, Meningococcal Polysaccharide Group C Tetanus Toxoid Conjugate Vaccine, Meningococcal Polysaccharide Vaccine (Groups A / C / Y and W-135), Papillomavirus (9-Valent) Vaccine (Human, Recombinant), Papillomavirus (Types 16, 18) Vaccine (Human, Recombinant), Papillomavirus (Types 6, 11, 16, 18) Vaccine (Human, Recombinant), Pneumococcal Conjugate Vaccine (10-Valent), Pneumococcal Conjugate Vaccine (13-Valent), Pneumococcal Conjugate Vaccine (7-Valent), Pneumococcal Polysaccharide Vaccine (23-Valent), Poliovirus Vaccine (Inactivated), Q Fever Vaccine, Rabies Vaccine, Tetanus Toxoid (Adsorbed), Tick-Borne Encephalitis Virus Vaccine (Inactivated), Travelers' Diarrhea and Cholera Vaccine, Typhoid and Hepatitis A Vaccine, Zoster Vaccine (Recombinant)</p>\n</div> \n<p><b>Discussion</b> Prescribing information for fingolimod states that vaccination may be less effective during and up to 2 months following fingolimod treatment.<sup>1</sup> Fingolimod treatment is associated with decreases in circulating lymphocytes and neutrophils, and a reduced response to vaccines (e.g. 23-valent pneumococcal polysaccharide) and skin test antigens (e.g. tetanus, <i>Candida</i>).<sup>1,2</sup> General recommendations of the Advisory Committee on Immunization Practices (ACIP) state that all age-appropriate vaccinations should be completed at least 2 weeks prior to initiation of an immunosuppressant. Patients vaccinated during or less than 14 days before starting immunosuppressive therapy should be revaccinated at least 3 months after therapy is discontinued if immune competence has been restored.<sup>3</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. <i>Gilenya</i> (fingolimod) [prescribing information]. East Hanover, NJ: Novartis Pharmaceuticals Corporation; April 2014.</p>\n<p>2. Boulton C, Meiser K, David OJ, Schmouder R. Pharmacodynamic effects of steady-state fingolimod on antibody response in healthy volunteers: a 4-week, randomized, placebo-controlled, parallel-group, multiple-dose study. <i>J Clin Pharmacol</i>. 2012;52(12):1879-1890. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=22174429\">[PubMed 22174429]</a></p>\n<p>3. National Center for Immunization and Respiratory Diseases. General recommendations on immunization - recommendations of the Advisory Committee on Immunization Practices (ACIP). [published correction appears in <i>MMWR Recomm Rep</i>. 2011;60(29):993]<i>MMWR Recomm Rep</i>. 2011;60(2):1-64. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=21293327\">[PubMed 21293327]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","5525":"<p><b>Title</b> Methotrexate / Levomefolate</p> \n<p></p> \n<p><b>Risk Rating</b> B: No action needed</p> \n<p><b>Summary</b> Levomefolate may diminish the therapeutic effect of Methotrexate. <b>Severity</b> Minor <b>Reliability Rating</b> Fair: Reported in the prescribing information </p> \n<p><b>Patient Management</b> No action required.</p> \n<p><b>Discussion</b> Levomefolate (L-5-methyl-tetrahydrofolate) is the primary dietary and circulating form of folic acid. Though specific data regarding concurrent use of levomefolate and methotrexate are not available, levomefolate prescribing information cautions that folates such as levomefolate may alter the response to folate antagonists such as methotrexate.<sup>1</sup><br><br>Of note, several reports (prospective trials and clinician surveys) with folic acid indicate that the addition of folic acid (up to 50 mg weekly) serves to reduce the side effects, but not the efficacy, of low-dose methotrexate used in the treatment of rheumatoid arthritis or psoriasis.<sup>2,3,4,5,6,7</sup> Folic acid supplementation has also been found to reduce the incidence of hyperhomocysteinemia and folate deficiency.<sup>7</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Prescribing information. Beyaz (drospirenone/ethinyl estradiol/ levomefolate calcium tablets and levomefolate calcium tablets). Wayne, NJ: Bayer HealthCare Pharmaceuticals Inc., 9/2010.</p>\n<p>2. Morgan SL, Baggott JE, Vaughn WH, et al, “Supplementation with Folic Acid During Methotrexate Therapy for Rheumatoid Arthritis. A Double-Blind, Placebo-Controlled Trial,” <i>Ann Intern Med</i>, 1994, 121(11):833-41. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=7978695\">[PubMed 7978695]</a></p>\n<p>3. Morgan SL, Baggott JE, Vaughn WH, et al, “The Effect of Folic Acid Supplementation on the Toxicity of Low-Dose Methotrexate in Patients with Rheumatoid Arthritis,” <i>Arthritis Rheum</i>, 1990, 33(1):9-18. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=2405864\">[PubMed 2405864]</a></p>\n<p>4. Kirby B, Lyon CC, Griffiths CE, et al, “The Use of Folic Acid Supplementation in Psoriasis Patients Receiving Methotrexate: A Survey in the United Kingdom,” <i>Clin Exp Dermatol</i>, 2000, 25(4):265-8. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=10971481\">[PubMed 10971481]</a></p>\n<p>5. Tiftikci A, Ozdemir A, Tarcin O, et al, “Influence of Serum Folic Acid Levels on Plasma Homocysteine Concentrations in Patients with Rheumatoid Arthritis,” <i>Rheumatol Int</i>, 2006, 26(3):191-4. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=15645233\">[PubMed 15645233]</a></p>\n<p>6. Hornung N, Ellingsen T, Stengaard-Pedersen K, et al, “Folate, Homocysteine, and Cobalamin Status in Patients with Rheumatoid Arthritis Treated with Methotrexate, and the Effect of Low Dose Folic Acid Supplement,” <i>J Rheumatol</i>, 2004, 31(12):2374-81. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=15570637\">[PubMed 15570637]</a></p>\n<p>7. Morgan SL, Baggott JE, Lee JY, et al, “Folic Acid Supplementation Prevents Deficient Blood Folate Levels and Hyperhomocysteinemia During Longterm, Low Dose Methotrexate Therapy for Rheumatoid Arthritis: Implications for Cardiovascular Disease Prevention,” <i>J Rheumatol</i>, 1998, 25(3):441-6. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=9517760\">[PubMed 9517760]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","5526":"<p><b>Title</b> PHENobarbital / Levomefolate</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Levomefolate may decrease the serum concentration of PHENobarbital. <b>Severity</b> Moderate <b>Reliability Rating</b> Fair: Reported in the prescribing information </p> \n<p><b>Patient Management</b> Monitor for decreased serum concentrations and effectiveness of phenobarbital if levomefolate is initiated/dose increased. Similarly, monitor for increases in phenobarbital concentrations (and possible toxicity) if levomefolate is discontinued/dose decreased.</p> \n<p><b>Discussion</b> Levomefolate (L-5-methyl-tetrahydrofolate) is the primary dietary and circulating form of folic acid. Though specific data regarding concurrent use of levomefolate and methotrexate are not available, levomefolate prescribing information cautions that folates such as levomefolate may alter the response to some drugs, such as phenobarbital.<sup>1</sup><br><br>Though several reports describe decreases in phenytoin concentrations and therapeutic effectiveness with concurrent folic acid or folinic acid,<sup>2,3,4,5,6,7</sup> there are considerably fewer reports on phenobarbital or primidone. One case series describes an increase in seizure frequency among a group of 26 patients with chronic epilepsy (treated with multiple drugs, including primarily phenobarbital, primidone, and phenytoin) who were given folic acid 5mg three times daily for 1-3 years.<sup>8</sup> Following addition of folic acid, seizure frequency increased in 50% of patients, though many (22/26) noted an improvement in mental status with folic acid. <br><br>The exact mechanism by which folic acid and/or folinic acid (leucovorin/levoleucovorin) or levomefolate may interact with phenobarbital or primidone is uncertain, but it has been postulated that folates enhance a metabolic pathway that is common to all of these antiepileptic agents (parahydroxylation).<sup>9</sup> In support of this theory, data for phenytoin supports a role for folic acid as a cofactor in the metabolism of phenytoin, with reports that higher folic acid concentrations increase the affinity (i.e., decreased Km) of metabolizing enzymes for phenytoin.<sup>4,5</sup> It is suspected that any levomefolate interaction with phenobarbital or primidone would occur via an identical mechanism.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Prescribing information. Beyaz (drospirenone/ethinyl estradiol/ levomefolate calcium tablets and levomefolate calcium tablets). Wayne, NJ: Bayer HealthCare Pharmaceuticals Inc., 9/2010.</p>\n<p>2. Veldhorst-Janssen NML, Boersma HH, de Krom MCFM, et al, “Oral Tegafur/Folinic Acid Chemotherapy Decreases Phenytoin Efficacy,” <i>Br J Cancer</i>, 2004, 90:745. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=14760393\">[PubMed 14760393]</a></p>\n<p>3. Baylis EM, Crowley JM, Preece JM, et al, “Influence of Folic Acid on Blood-Phenytoin Levels,” <i>Lancet</i>, 1971 i:62. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=4099219\">[PubMed 4099219]</a></p>\n<p>4. Berg MJ, Fisher LJ, Rivey MP, et al, “Phenytoin and Folic Acid Interaction: A Preliminary Report,” <i>Ther Drug Monit</i>, 1983, 5:389-94. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=6659012\">[PubMed 6659012]</a></p>\n<p>5. Berg MJ, Ebert BE, Rivey MP, et al, “Utilization of Km for Phenytoin Dosage After Folate Addition to Patient Regimen,” <i>Ther Drug Monit</i>, 1987, 9:304-5. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=3672574\">[PubMed 3672574]</a></p>\n<p>6. Inoue F, Kolabinski I, “Possible Interaction Between Phenytoin Therapy and Folate Supplement: Two Case Reports,” <i>Can J Hosp Pharm</i>, 1986, 39:16-8.</p>\n<p>7. Steinweg DL, Bentley ML, “Seizures Following Reduction in Phenytoin Level After Orally Administered Folic Acid,” <i>Neurology</i>, 2005, 64(11):1982. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=15955964\">[PubMed 15955964]</a></p>\n<p>8. Reynolds EH, Wales MB, “Effects of Folic Acid on the Mental State and Fit-Frequency of Drug-Treated Epileptic Patients,” <i>Lancet</i>, 1967, 1(7499):1086-8. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=4164775\">[PubMed 4164775]</a></p>\n<p>9. Viukari NMA, “Folic Acid and Anticonvulsants,” <i>Lancet</i>, 1968, 1(7539):980. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=4171606\">[PubMed 4171606]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","5527":"<p><b>Title</b> Primidone / Levomefolate</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Levomefolate may decrease serum concentrations of the active metabolite(s) of Primidone. Levomefolate may decrease the serum concentration of Primidone. <b>Severity</b> Moderate <b>Reliability Rating</b> Fair: Reported in the prescribing information </p> \n<p><b>Patient Management</b> Monitor for decreased serum concentrations and effectiveness of primidone and its active metabolite phenobarbital if levomefolate is initiated/dose increased. Similarly, monitor for increases in primidone and/or phenobarbital concentrations (and possible toxicity) if levomefolate is discontinued/dose decreased.</p> \n<p><b>Discussion</b> Levomefolate (L-5-methyl-tetrahydrofolate) is the primary dietary and circulating form of folic acid. Though specific data regarding concurrent use of levomefolate and methotrexate are not available, levomefolate prescribing information cautions that folates such as levomefolate may alter the response to some drugs, such as phenobarbital or primidone.<sup>1</sup><br><br>Though several reports describe decreases in phenytoin concentrations and therapeutic effectiveness with concurrent folic acid or folinic acid,<sup>2,3,4,5,6,7</sup> there are considerably fewer reports on phenobarbital or primidone. One case series describes an increase in seizure frequency among a group of 26 patients with chronic epilepsy (treated with multiple drugs, including primarily phenobarbital, primidone, and phenytoin) who were given folic acid 5mg three times daily for 1-3 years.<sup>8</sup> Following addition of folic acid, seizure frequency increased in 50% of patients, though many (22/26) noted an improvement in mental status with folic acid. <br><br>The exact mechanism by which folic acid and/or folinic acid (leucovorin/levoleucovorin) or levomefolate may interact with phenobarbital or primidone is uncertain, but it has been postulated that folates enhance a metabolic pathway that is common to all of these antiepileptic agents (parahydroxylation).<sup>9</sup> In support of this theory, data for phenytoin supports a role for folic acid as a cofactor in the metabolism of phenytoin, with reports that higher folic acid concentrations increase the affinity (i.e., decreased Km) of metabolizing enzymes for phenytoin.<sup>4,5</sup> It is suspected that any levomefolate interaction with phenobarbital or primidone would occur via an identical mechanism.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Prescribing information. Beyaz (drospirenone/ethinyl estradiol/ levomefolate calcium tablets and levomefolate calcium tablets). Wayne, NJ: Bayer HealthCare Pharmaceuticals Inc., 9/2010.</p>\n<p>2. Veldhorst-Janssen NML, Boersma HH, de Krom MCFM, et al, “Oral Tegafur/Folinic Acid Chemotherapy Decreases Phenytoin Efficacy,” <i>Br J Cancer</i>, 2004, 90:745. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=14760393\">[PubMed 14760393]</a></p>\n<p>3. Baylis EM, Crowley JM, Preece JM, et al, “Influence of Folic Acid on Blood-Phenytoin Levels,” <i>Lancet</i>, 1971 i:62. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=4099219\">[PubMed 4099219]</a></p>\n<p>4. Berg MJ, Fisher LJ, Rivey MP, et al, “Phenytoin and Folic Acid Interaction: A Preliminary Report,” <i>Ther Drug Monit</i>, 1983, 5:389-94. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=6659012\">[PubMed 6659012]</a></p>\n<p>5. Berg MJ, Ebert BE, Rivey MP, et al, “Utilization of Km for Phenytoin Dosage After Folate Addition to Patient Regimen,” <i>Ther Drug Monit</i>, 1987, 9:304-5. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=3672574\">[PubMed 3672574]</a></p>\n<p>6. Inoue F, Kolabinski I, “Possible Interaction Between Phenytoin Therapy and Folate Supplement: Two Case Reports,” <i>Can J Hosp Pharm</i>, 1986, 39:16-8.</p>\n<p>7. Steinweg DL, Bentley ML, “Seizures Following Reduction in Phenytoin Level After Orally Administered Folic Acid,” <i>Neurology</i>, 2005, 64(11):1982. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=15955964\">[PubMed 15955964]</a></p>\n<p>8. Reynolds EH, Wales MB, “Effects of Folic Acid on the Mental State and Fit-Frequency of Drug-Treated Epileptic Patients,” <i>Lancet</i>, 1967, 1(7499):1086-8. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=4164775\">[PubMed 4164775]</a></p>\n<p>9. Viukari NMA, “Folic Acid and Anticonvulsants,” <i>Lancet</i>, 1968, 1(7539):980. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=4171606\">[PubMed 4171606]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","5528":"<p><b>Title</b> Phenytoin / Levomefolate</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Levomefolate may decrease the serum concentration of Phenytoin. <b>Severity</b> Moderate <b>Reliability Rating</b> Fair: Reported in the prescribing information </p> \n<p><b>Patient Management</b> Monitor for decreased serum concentrations and effectiveness of phenytoin if levomefolate is initiated/dose increased. Similarly, monitor for increases in phenytoin concentrations (and possible toxicity) if levomefolate is discontinued/dose decreased.</p> \n<p><b>Discussion</b> Levomefolate (L-5-methyl-tetrahydrofolate) is the primary dietary and circulating form of folic acid. Though specific data regarding concurrent use of levomefolate and methotrexate are not available, levomefolate prescribing information cautions that folates such as levomefolate may alter the response to some drugs, such as phenytoin.<sup>1</sup><br><br>Serum phenytoin concentrations decreased 30% to 50% in 50 patients within one month of initiating folic acid therapy.<sup>2</sup> In small case series reports and individual case reports, the addition of folic acid at doses of 1mg have been associated with 20-23% reductions in phenytoin concentrations,<sup>3,4</sup> while addition of 5mg doses have been associated with 40-60% reductions in phenytoin concentrations.<sup>5,6</sup> Similar reductions in serum phenytoin concentrations have been reported elsewhere.<sup>7,8,9</sup> Several reports have also described an apparent lack of effectiveness following the addition of folic acid, with reports of breakthrough seizures and/or an increase in seizure episodes.<sup>2,3,6,10,11</sup><br><br>Though the detailed mechanism of this interaction has yet to be fully described, folic acid appears to function as a cofactor in the metabolism of phenytoin, with reports that higher folic acid concentration increase the affinity (i.e., decreased Km) of metabolizing enzymes for phenytoin.<sup>3,4,10,11</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Prescribing information. Beyaz (drospirenone/ethinyl estradiol/ levomefolate calcium tablets and levomefolate calcium tablets). Wayne, NJ: Bayer HealthCare Pharmaceuticals Inc., 9/2010.</p>\n<p>2. Baylis EM, Crowley JM, Preece JM, et al, “Influence of Folic Acid on Blood-Phenytoin Levels,” <i>Lancet</i>, 1971 i:62. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=4099219\">[PubMed 4099219]</a></p>\n<p>3. Berg MJ, Fisher LJ, Rivey MP, et al, “Phenytoin and Folic Acid Interaction: A Preliminary Report,” <i>Ther Drug Monit</i>, 1983, 5:389-94. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=6659012\">[PubMed 6659012]</a></p>\n<p>4. Berg MJ, Ebert BE, Rivey MP, et al, “Utilization of Km for Phenytoin Dosage After Folate Addition to Patient Regimen,” <i>Ther Drug Monit</i>, 1987, 9:304-5. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=3672574\">[PubMed 3672574]</a></p>\n<p>5. Inoue F, Kolabinski I, “Possible Interaction Between Phenytoin Therapy and Folate Supplement: Two Case Reports,” <i>Can J Hosp Pharm</i>, 1986, 39:16-8.</p>\n<p>6. Steinweg DL, Bentley ML, “Seizures Following Reduction in Phenytoin Level After Orally Administered Folic Acid,” <i>Neurology</i>, 2005, 64(11):1982. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=15955964\">[PubMed 15955964]</a></p>\n<p>7. Glazko AJ, “Antiepileptic Drugs: Biotransformation, Metabolism, and Serum Half-Life,” <i>Epilepsia</i>, 1975, 16:367. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=238831\">[PubMed 238831]</a></p>\n<p>8. Jensen ON and Olesen OV, “Subnormal Serum Folate Due to Anticonvulsive Therapy. A Double-Blind Study of the Effect of Folic Acid Treatment in Patients With Drug-Induced Subnormal Serum Folates,” <i>Arch Neurol</i>, 1970, 22:181-2. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=4902774\">[PubMed 4902774]</a></p>\n<p>9. Furlanut M, Benetello P, Avogaro A, et al, “Effects of Folic Acid on Phenytoin Kinetics in Healthy Subjects,” <i>Clin Pharmacol Ther</i>, 1978, 24:294. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=688723\">[PubMed 688723]</a></p>\n<p>10. Berg MJ, Rivey MP, Vern BA, et al, “Phenytoin and Folic Acid: Individualized Drug-Drug Interaction,” <i>Ther Drug Monit</i>, 1983, 5:395-9. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=6659013\">[PubMed 6659013]</a></p>\n<p>11. Seligmann H, Potasman I, Weller B, et al, “Phenytoin-Folic Acid Interaction: A Lesson to be Learned,” <i>Clin Neuropharmacol</i>, 1999, 22(5):268-72. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=10516876\">[PubMed 10516876]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","5529":"<p><b>Title</b> Raltitrexed / Levomefolate</p> \n<p></p> \n<p><b>Risk Rating</b> X: Avoid combination</p> \n<p><b>Summary</b> Levomefolate may diminish the therapeutic effect of Raltitrexed. <b>Severity</b> Major <b>Reliability Rating</b> Fair: Reported in the prescribing information </p> \n<p><b>Patient Management</b> Do not coadminister levomefolate with raltitrexed.</p> \n<p><b>Discussion</b> Raltitrexed is a folate analogue that inhibits thymidylate synthetase. Concurrent administration with folic acid or leucovorin (folinic acid) might interfere with the therapeutic action of raltitrexed.<sup>1</sup> Levomefolate (L-5-methyl-tetrahydrofolate) is the primary dietary and circulating form of folic acid, as a result, it is expected that levomefolate would interact with raltitrexed in a similar manner as folic acid.<sup>2</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Tomudex [package insert]. Mississauga, Ontario: AstraZeneca Canada Inc, 2001.</p>\n<p>2. Prescribing information. Beyaz (drospirenone/ethinyl estradiol/ levomefolate calcium tablets and levomefolate calcium tablets). Wayne, NJ: Bayer HealthCare Pharmaceuticals Inc., 9/2010.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","5530":"<p><b>Title</b> Lisinopril / TiZANidine</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> TiZANidine may enhance the hypotensive effect of Lisinopril. <b>Severity</b> Moderate <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Monitor closely for hypotension/bradycardia with concomitant administration of tizanidine and lisinopril.</p> \n<p><b>Discussion</b> A case report describes a dramatic reduction in blood pressure (130/85 to 66/42 mm Hg) within 2 hours of administration of a single tizanidine dose (2 mg) in a 48 year old female receiving lisinopril (10 mg daily).<sup>1</sup> An 85 year old male stable on lisinopril (40 mg daily), developed severe hypotension (BP 60/32 mm Hg) and bradycardia (HR 37 beats per minute) after receiving 3 doses of tizanidine (2 mg Q8H).<sup>2</sup> Similarly, a 10 year old male receiving lisinopril was found to be hypotensive (BP 56/24 mm Hg) 1 week after initiating tizanidine therapy.<sup>3</sup> <br><br>Tizanidine is an alpha-2 adrenergic receptor agonist that reduces CNS sympathetic outflow and has approximately 1/10-1/50 antihypertensive potency of structurally related clonidine.<sup>4</sup> It would seem prudent to monitor for enhanced or exaggerated antihypertensive effects with use of this drug in patients receiving angiotensin converting enzyme (ACE)- inhibitors (e.g., lisinopril).</p> \n<p><b>Footnotes</b> </p>\n<p>1. Kao CD, Chang JB, Chen JT, et al, “Hypotension Due to Interaction Between Lisinopril and Tizanidine,” <i>Ann Pharmacother</i>, 2004, 38(11):1840-3. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=15383642\">[PubMed 15383642]</a></p>\n<p>2. Publow SW and Branam DL, “Hypotension and Bradycardia Associated with Concomitant Tizanidine and Lisinopril Therapy,” <i>Am J Health Syst Pharm</i>, 2010, 67(19):1606-10. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=20852161\">[PubMed 20852161]</a></p>\n<p>3. Johnson TR and Tobias JD, “Hypotension Following the Initiation of Tizanidine in a Patient Treated With an Angiotensin Converting Enzyme Inhibitor for Chronic Hypertension,” <i>J Child Neurol</i>, 2000, 15(12):818-9. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=11198499\">[PubMed 11198499]</a></p>\n<p>4. Prescribing information. Zanaflex (tizanidine). Hawthorne, NY: Acorda Therapeutics, Inc., April 2008.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","5531":"<p><b>Title</b> Angiotensin-Converting Enzyme Inhibitors / TiZANidine</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> TiZANidine may enhance the hypotensive effect of Angiotensin-Converting Enzyme Inhibitors. <b>Severity</b> Moderate <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Monitor closely for hypotension/bradycardia with concomitant administration of tizanidine and angiotensin-converting enzyme (ACE)-inhibitors (e.g., lisinopril).</p>\n<div>\n <p><b>Angiotensin-Converting Enzyme Inhibitors Interacting Members</b> Alacepril, Benazepril, Captopril, Cilazapril, Enalapril, Enalaprilat, Fosinopril, Imidapril, Lisinopril*, Moexipril, Perindopril, Quinapril, Ramipril, Trandolapril, Zofenopril</p>\n <p style=\"font-size: 75%; font-style: italic;\">* Denotes agent(s) specifically implicated in clinical data. Unmarked agents are listed because they have properties similar to marked agents, and may respond so within the context of the stated interaction.</p>\n</div> \n<p><b>Discussion</b> A case report describes a dramatic reduction in blood pressure (130/85 to 66/42 mm Hg) within 2 hours of administration of a single tizanidine dose (2 mg) in a 48 year old female receiving lisinopril (10 mg daily).<sup>1</sup> An 85 year old male stable on lisinopril (40 mg daily), developed severe hypotension (BP 60/32 mm Hg) and bradycardia (HR 37 beats per minute) after receiving 3 doses of tizanidine (2 mg Q8H).<sup>2</sup> Similarly, a 10 year old male receiving lisinopril was found to be hypotensive (BP 56/24 mm Hg) 1 week after initiating tizanidine therapy.<sup>3</sup> <br><br>Tizanidine is an alpha-2 adrenergic receptor agonist that reduces CNS sympathetic outflow and has approximately 1/10-1/50 antihypertensive potency of structurally related clonidine.<sup>4</sup> It would seem prudent to monitor for enhanced or exaggerated antihypertensive/bradycardic effects with use of this drug in patients receiving angiotensin-converting enzyme (ACE)- inhibitors (e.g., lisinopril).</p> \n<p><b>Footnotes</b> </p>\n<p>1. Kao CD, Chang JB, Chen JT, et al, “Hypotension Due to Interaction Between Lisinopril and Tizanidine,” <i>Ann Pharmacother</i>, 2004, 38(11):1840-3. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=15383642\">[PubMed 15383642]</a></p>\n<p>2. Publow SW and Branam DL, “Hypotension and Bradycardia Associated with Concomitant Tizanidine and Lisinopril Therapy,” <i>Am J Health Syst Pharm</i>, 2010, 67(19):1606-10. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=20852161\">[PubMed 20852161]</a></p>\n<p>3. Johnson TR and Tobias JD, “Hypotension Following the Initiation of Tizanidine in a Patient Treated With an Angiotensin Converting Enzyme Inhibitor for Chronic Hypertension,” <i>J Child Neurol</i>, 2000, 15(12):818-9. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=11198499\">[PubMed 11198499]</a></p>\n<p>4. Prescribing information. Zanaflex (tizanidine). Hawthorne, NY: Acorda Therapeutics, Inc., April 2008.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","5533":"<p><b>Title</b> Tacrolimus (Systemic) / Ranolazine</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Ranolazine may increase the serum concentration of Tacrolimus (Systemic). <b>Severity</b> Moderate <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> When initiating ranolazine in patients already receiving tacrolimus, frequent monitoring of tacrolimus serum concentrations is warranted. The dose of tacrolimus may need to be reduced to maintain tough levels within the desired range. If ranolazine is discontinued, the tacrolimus dose may need to be increased.</p> \n<p><b>Discussion</b> A published case report describes a kidney transplant patient receiving oral tacrolimus 10 mg twice daily who was initiated on ranolazine 500 mg twice daily while in the hospital for worsening angina.<sup>1</sup> Tacrolimus concentrations had been stable for five months, and two weeks prior to admission the tacrolimus concentration was 8.1 ng/ml. The patient’s serum creatinine had also steadily increased during those two weeks prior to admission, but tacrolimus concentrations were all within range. Twenty-four hours after the first dose of ranolazine, a trough tacrolimus concentration was 17.8 ng/ml. A 70% dose reduction of tacrolimus was needed to maintain therapeutic concentrations. When ranolazine was discontinued three months later, a tacrolimus dose increase was necessary. This patient’s case was complicated by worsening kidney function and other plausible causative factors for the approximately 2-fold increase in tacrolimus concentrations. Unfortunately, a tacrolimus concentration was not drawn on hospital day zero; therefore, the exact magnitude of increase in tacrolimus concentration resulting from the addition of ranolazine cannot be determined.<br><br>While the exact mechanism of this interaction is unknown, tacrolimus is a substrate of CYP3A4 and P-glycoprotein (Pgp), and ranolazine is characterized as a weak inhibitor of CYP3A4 and a moderate inhibitor of Pgp.<sup>2</sup> The authors of the case report suggested this dual inhibition could result in increased tacrolimus bioavailability and concentrations.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Pierce DA and Reeves-Daniel AM, “Ranolazine-Tacrolimus Interaction,” <i>Ann Pharmacother</i>, 2010, Epub ahead of print (Sept 28). <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=20876828\">[PubMed 20876828]</a></p>\n<p>2. Prescribing information. Ranexa (ranolazine). Foster City, CA: Gilead Sciences, Inc., 09/2010.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","5534":"<p><b>Title</b> Selegiline / OXcarbazepine</p> \n<p><span style=\"color: red; font-weight: bold\">Dependencies</span> </p>\n<ul>\n <li><p><b>Route</b> (percutaneous): Avoidance of this combination is recommended by the manufacturer of transdermal selegiline only.</p></li>\n</ul>\n<p></p> \n<p><b>Risk Rating</b> X: Avoid combination</p> \n<p><b>Summary</b> OXcarbazepine may enhance the serotonergic effect of Selegiline. <b>Severity</b> Major <b>Reliability Rating</b> Fair: Reported in the prescribing information </p> \n<p><b>Patient Management</b> Avoid the use of oxcarbazepine during or within two weeks of stopping treatment with transdermal selegiline.</p> \n<p><b>Discussion</b> The manufacturer of transdermal selegiline lists concomitant treatment with oxcarbazepine as contraindicated.<sup>1</sup> The medication guide for patients alludes to possible serious or life-threatening reactions occurring with the combination. Oxcarbazepine and it's primary active metabolite have been shown to exert some central serotonergic effects,<sup>2,3</sup> but have not been associated with development of serotonin syndrome. No similar warnings are found in prescribing information for other selegiline products or other monoamine oxidase inhibitors.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Prescribing information. Emsam (selegiline). Napa, CA: Dey Pharma, L.P., January 2010.</p>\n<p>2. Clinckers R, Smolders I, Meurs A, et al, “Hippocampal Dopamine and Serotonin Elevations as Pharmacodynamic Markers for the Anticonvulsant Efficacy of Oxcarbazepine and 10,11-Dihydro-10-Hydroxycarbamazepine,” <i>Neurosci Lett</i>, 2005, 390(1):48-53. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=16139430\">[PubMed 16139430]</a></p>\n<p>3. Clinckers R, Smolders I, Meurs A, et al, “Quantitative in Vivo Microdialysis Study on the Influence of Multidrug Transporters on the Blood-Brain Barrier Passage of Oxcarbazepine: Concomitant Use of Hippocampal Monoamines as Pharmacodynamic Markers for the Anticonvulsant Activity,” <i>J Pharmacol Exp Ther</i>, 2005, 314(2):725-31. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=15860570\">[PubMed 15860570]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","5535":"<p><b>Title</b> Clopidogrel / Omeprazole</p> \n<p></p> \n<p><b>Risk Rating</b> D: Consider therapy modification</p> \n<p><b>Summary</b> Omeprazole may diminish the antiplatelet effect of Clopidogrel. Omeprazole may decrease serum concentrations of the active metabolite(s) of Clopidogrel. <b>Severity</b> Major <b>Reliability Rating</b> Fair: Existing data/reports are inconsistent </p> \n<p><b>Patient Management</b> Clopidogrel prescribing information recommends avoiding concurrent use with omeprazole due to the possibility that combined use may result in decreased clopidogrel effectiveness. Rabeprazole or pantoprazole may be lower-risk alternatives to omeprazole.</p> \n<p><b>Discussion</b> Several retrospective cohort studies and prospective randomized trials (n=318 to 3,132) have evaluated this possible interaction, with many reporting significantly increased risks for negative cardiac-related outcomes (6% to 18% increased incidence) and overall mortality (3% to 9% increased mortality rate) associated with concurrent use of omeprazole and clopidogrel.<sup>1,2,3,4,5,6</sup> In contrast, other clinical outcome studies (n=340 to 3,761) have reported minimal or no impact of concurrent omeprazole and clopidogrel use on cardiovascular outcomes.<sup>7,8,9,10</sup><br><br>Five meta-analyses of the available data have yielded generally similar conclusions regarding the significance of this interaction. Analyses including 7 and 16 omeprazole studies reported a statistically significant increase in the odds of major adverse cardiovascular effects (MACE) with omeprazole (OR=1.42 and 1.24, respectively).<sup>11,12</sup> An analysis of 11 PPI studies (0.5-48.9% omeprazole use in 6 of 11) reported a statistically significant increase in short-term mortality and target vessel revascularization (TVR), favoring clopidogrel alone (OR=1.55 and 1.26, respectively). Long-term MACE, MI, ST elevation and TVR also significantly favored clopidogrel alone (OR=1.37, 1.41, 1.38, and 1.28, respectively).<sup>13</sup> An analysis of 12 PPI studies (up to 100% omeprazole use) reported significant increases in MACE, MI, and stroke with PPI and clopidogrel (OR=1.28, 1.51, and 1.46, respectively).<sup>14</sup> An analysis of 6 omeprazole studies reported a non-significant increase in the risk for adverse clinical outcomes (HR=1.16).<sup>15</sup><br><br>Despite the original FDA drug safety communication recommending avoiding the use of this combination,<sup>16</sup> which was recently re-issued as a reminder,<sup>17</sup> some clinicians have published opinions questioning the recommendation.<sup>18,19</sup><br><br>Possible therapy modifications that attempt to overcome the diminished inhibition of platelet aggregation (IPA) effect of concurrent therapy have been studied. One such approach, dosing omeprazole 8-12 hours after clopidogrel, did not significantly improve IPA, <sup>1,2,3</sup> but use of higher dose clopidogrel (600 mg once, then 150 mg/day) with omeprazole 80 mg/day inhibited platelet function more than standard clopidogrel dosing with omeprazole.<sup>4</sup> Studies evaluating the cardiovascular outcomes of concurrent omeprazole and high dose clopidogrel need to be performed and evaluated before further guidance can be issued. Changing from omeprazole to pantoprazole or rabeprazole may be a better alternative. The FDA recommends pantoprazole as a possible alternative due to its weaker CYP2C19 inhibition,<sup>16,17</sup> but several meta-analyses reported a statistically significant interaction with pantoprazole of similar magnitude to that seen with omeprazole.<sup>11,12,15</sup> In contrast, rabeprazole was not associated with a statistically significant increase in the odds of MACE among clopidogrel users in 2 meta-analyses.<sup>11,12</sup><br><br>The suspected mechanism of this interaction is omeprazole-mediated inhibition of clopidogrel metabolism to its active metabolite. The AUC and maximum serum concentration (Cmax) of the active metabolite was reduced an average of 31% and 44%, respectively, with concurrent omeprazole (80 mg/day) in one study of 160 healthy volunteers.<sup>20</sup> Clopidogrel undergoes oxidative metabolism to its active metabolite in two steps. Based on enzyme kinetics in vitro, the first step appears to be catalyzed by CYP2C19 (45% estimated contribution), CYP1A2 (36%), and CYP2B6 (19%), while the second appears to be catalyzed by CYP3A4 (40%), CYP2B6 (36%), CYP2C19 (21%), and CYP2C9 (7%).<sup>21</sup> Based on in vivo evidence, activation of clopidogrel appears to depend heavily on CYP2C19 activity;<sup>22,23,24</sup> although, some data indicate a possible dependence on other enzymes including CYP3A4 and CYP2C9.<sup>25</sup> Omeprazole is a substrate of CYP2C19 (primarily), CYP2C9 and CYP3A, with in vitro data showing that omeprazole is a weak inhibitor of CYP1A2, CYP2C9, and a strong inhibitor of CYP2C19.<sup>26,27</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Ho PM, Maddox TM, Wang L, et al. Risk of adverse outcomes associated with concomitant use of clopidogrel and proton pump inhibitors following acute coronary syndrome. <i>JAMA</i>. 2009;301(9):937-944. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=19258584\">[PubMed 19258584]</a></p>\n<p>2. Pezalla E, Day D, Pulliadath I. Initial assessment of clinical impact of a drug interaction between clopidogrel and proton pump inhibitors. <i>J Am Coll Cardiol</i>. 2008;52(12):1038-1039; author reply 1039. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=18786491\">[PubMed 18786491]</a></p>\n<p>3. Evanchan J, Donnally MR, Binkley P, Mazzaferri E. Recurrence of acute myocardial infarction in patients discharged on clopidogrel and a proton pump inhibitor after stent placement for acute myocardial infarction. <i>Clin Cardiol</i>. 2010;33(3):168-171. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=20235209\">[PubMed 20235209]</a></p>\n<p>4. Juurlink DN, Gomes T, Ko DT, et al. A population-based study of the drug interaction between proton pump inhibitors and clopidogrel. <i>CMAJ</i>. 2009;180(7):713-718. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=19176635\">[PubMed 19176635]</a></p>\n<p>5. Gaglia MA Jr, Torguson R, Hanna N, et al. Relation of proton pump inhibitor use after percutaneous coronary intervention with drug-eluting stents to outcomes. <i>Am J Cardiol</i>. 2010;105(6):833-838. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=20211327\">[PubMed 20211327]</a></p>\n<p>6. Gupta E, Bansal D, Sotos J, Olden K. Risk of adverse clinical outcomes with concomitant use of clopidogrel and proton pump inhibitors following percutaneous coronary intervention. <i>Dig Dis Sci</i>. 2010;55(7):1964-1968. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=19731021\">[PubMed 19731021]</a></p>\n<p>7. Ray WA, Murray KT, Griffin MR, et al. Outcomes with concurrent use of clopidogrel and proton-pump inhibitors: a cohort study. Ann Intern Med. 2010;152(6):337-345. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=20231564\">[PubMed 20231564]</a></p>\n<p>8. O'Donoghue ML, Braunwald E, Antman EM, et al. Pharmacodynamic effect and clinical efficacy of clopidogrel and prasugrel with or without a proton-pump inhibitor: an analysis of two randomised trials. <i>Lancet</i>. 2009;374(9694):989-997. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=19726078\">[PubMed 19726078]</a></p>\n<p>9. Zairis MN, Tsiaousis GZ, Patsourakos NG, et al. The impact of treatment with omeprazole on the effectiveness of clopidogrel drug therapy during the first year after successful coronary stenting. <i>Can J Cardiol</i>. 2010;26(2):e54-e57. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=20151060\">[PubMed 20151060]</a></p>\n<p>10. Bhatt DL, Cryer BL, Contant CF, et al. Clopidogrel with or without omeprazole in coronary artery disease. <i>N Engl J Med</i>. 2010;363(20):1909-1917. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=20925534\">[PubMed 20925534]</a></p>\n<p>11. Niu Q, Wang Z, Zhang Y, et al. Combination use of clopidogrel and proton pump inhibitors increases major adverse cardiovascular events in patients with coronary artery disease: a meta-analysis. <i>J Cardiovasc Pharmacol Ther</i>. 2016; Aug 10 (Epub ahead of print). <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=27512080\">[PubMed 27512080]</a></p>\n<p>12. Kwok CS, Jeevanantham V, Dawn B, Loke YK. No consistent evidence of differential cardiovascular risk amongst proton-pump inhibitors when used with clopidogrel: meta-analysis. <i>Int J Cardiol</i>. 2013;167(3):965-974. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=22464478\">[PubMed 22464478]</a></p>\n<p>13. Bundhun PK, Teeluck AR, Bhurtu A, Huang WQ. Is the concomitant use of clopidogrel and Proton Pump Inhibitors still associated with increased adverse cardiovascular outcomes following coronary angioplasty?: a systematic review and meta-analysis of recently published studies (2012 - 2016). <i>BMC Cardiovasc Disord</i>. 2017;17(1):3. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=28056809\">[PubMed 28056809]</a></p>\n<p>14. Serbin MA, Guzauskas GF, Veenstra DL. Clopidogrel-proton pump inhibitor drug-drug interaction and risk of adverse clinical outcomes among PCI-treated ACS patients: a meta-analysis. <i>J Manag Care Spec Pharm</i>. 2016;22(8):939-947. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=27459657\">[PubMed 27459657]</a></p>\n<p>15. Sherwood MW, Melloni C, Jones WS, Washam JB, Hasselblad V, Dolor RJ. Individual proton pump inhibitors and outcomes in patients with coronary artery disease on dual antiplatelet therapy: a systematic review. J Am Heart Assoc. 2015;4(11): pii: e002245. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=26514161\">[PubMed 26514161]</a></p>\n<p>16. FDA Announces New Warning on Plavix: Avoid use with Prilosec/Prilosec OTC. November 2009. Available at: http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/2009/ucm191169.htm. Accessed September 28, 2016.</p>\n<p>17. FDA reminder to avoid concomitant use of Plavix (clopidogrel) and omeprazole. U.S. Food and Drug Administration; March 10, 2016. Available at: http://www.fda.gov/drugs/drugsafety/ucm231161.htm. Accessed September 28, 2016.</p>\n<p>18. Laine L, Hennekens C. Proton pump inhibitor and clopidogrel interaction: fact or fiction? <i>Am J Gastroenterol</i>. 2010;105(1):34-41. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=19904241\">[PubMed 19904241]</a></p>\n<p>19. Depta JP, Bhatt DL. Omeprazole and clopidogrel: Should clinicians be worried? <i>Cleve Clin J Med</i>. 2010;77(2):113-116. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=20124268\">[PubMed 20124268]</a></p>\n<p>20. Frelinger AL 3rd, Lee RD, Mulford DJ, et al. A randomized, 2-period, crossover design study to assess the effects of dexlansoprazole, lansoprazole, esomeprazole, and omeprazole on the steady-state pharmacokinetics and pharmacodynamics of clopidogrel in healthy volunteers. <i>J Am Coll Cardiol</i>. 2012;59(14):1304-1311. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=22464259\">[PubMed 22464259]</a></p>\n<p>21. Kazui M, Nishiya Y, Ishizuka T, et al. Identification of the human cytochrome P450 enzymes involved in the two oxidative steps in the bioactivation of clopidogrel to its pharmacologically active metabolite. <i>Drug Metab Dispos</i>. 2010;38(1):92-99. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=19812348\">[PubMed 19812348]</a></p>\n<p>22. Simon T, Verstuyft C, Mary-Krause M, et al. Genetic determinants of response to clopidogrel and cardiovascular events. <i>N Engl J Med</i>. 2009;360(4):363-375. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=19106083\">[PubMed 19106083]</a></p>\n<p>23. Mega JL, Close SL, Wiviott SD, et al. Cytochrome p-450 polymorphisms and response to clopidogrel. <i>N Engl J Med</i>. 2009;360(4):354-362. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=19106084\">[PubMed 19106084]</a></p>\n<p>24. Brandt JT, Close SL, Iturria SJ, et al. Common polymorphisms of CYP2C19 and CYP2C9 affect the pharmacokinetic and pharmacodynamic response to clopidogrel but not prasugrel. <i>J Thromb Haemost</i>. 2007;5(12):2429-2436. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=17900275\">[PubMed 17900275]</a></p>\n<p>25. Farid NA, Payne CD, Small DS, et al. Cytochrome P450 3A inhibition by ketoconazole affects prasugrel and clopidogrel pharmacokinetics and pharmacodynamics differently. <i>Clin Pharmacol Ther</i>. 2007;81(5):735-741. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=17361128\">[PubMed 17361128]</a></p>\n<p>26. Li XQ, Andersson TB, Ahlstrom M, Weidolf L. Comparison of inhibitory effects of the proton pump-inhibiting drugs omeprazole, esomeprazole, lansoprazole, pantoprazole, and rabeprazole on human cytochrome P450 activities. <i>Drug Metab Dispos</i>. 2004;32(8):821-827. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=15258107\">[PubMed 15258107]</a></p>\n<p>27. Ko JW, Sukhova N, Thacker D, Chen P, Flockhart DA. Evaluation of omeprazole and lansoprazole as inhibitors of cytochrome P450 isoforms. <i>Drug Metab Dispos</i>. 1997;25(7):853-862. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=9224780\">[PubMed 9224780]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","5536":"<p><b>Title</b> Clopidogrel / Esomeprazole</p> \n<p></p> \n<p><b>Risk Rating</b> D: Consider therapy modification</p> \n<p><b>Summary</b> Esomeprazole may diminish the antiplatelet effect of Clopidogrel. Esomeprazole may decrease serum concentrations of the active metabolite(s) of Clopidogrel. <b>Severity</b> Major <b>Reliability Rating</b> Fair: Existing data/reports are inconsistent </p> \n<p><b>Patient Management</b> Clopidogrel prescribing information recommends avoiding concurrent use with esomeprazole, due to the possibility that combined use may result in decreased clopidogrel effectiveness. Rabeprazole or pantoprazole may be lower-risk alternatives to esomeprazole.</p> \n<p><b>Discussion</b> Several retrospective studies (n=46 to 3,257) have reported an increased risk of negative cardiovascular-related outcomes associated with concurrent esomeprazole and clopidogrel as compared to clopidogrel therapy alone.<sup>1,2,3</sup> One found a statistically significant 7% increase in incidence of major adverse cardiac events with concurrent esomeprazole and clopidogrel.<sup>1</sup> Some of these studies only performed pooled analyses of patients taking proton pump inhibitors (PPI) (4.5% to 45.6% of PPI users taking esomeprazole) but did not perform subset analyses for the individual agents.<sup>2,3</sup> These studies found a 10% increase in recurrence of acute myocardial infarction (AMI). Similarly, a small randomized controlled trial (n=160) found that subjects treated with clopidogrel (75 mg/day) plus esomeprazole (40 mg/day; n=40) exhibited a statistically significant decrease in clopidogrel antiplatelet activity vs. subjects treated with clopidogrel without a PPI.<sup>4</sup><br><br>In contrast, other clinical outcomes studies (n=613 to 7,593) have reported no association of concurrent esomeprazole and clopidogrel use with increased risk of negative cardiovascular outcomes.<sup>5,6,7</sup> Reported hazard ratios for MI or death from these studies varied from 0.71 to 1.26 (though none were statistically significant). Some small, prospective, nonrandomized trials of the effects of concurrent esomeprazole on clopidogrel’s inhibition of platelet aggregation (IPA) activity in healthy subjects have also found no significant difference in IPA compared to clopidogrel alone.<sup>8,9</sup><br><br>The suspected mechanism of this interaction is esomeprazole-mediated inhibition of clopidogrel metabolism to its active metabolite. In fact, the AUC and maximum serum concentration (Cmax) of the active metabolite was reduced by an average of 16% and 32%, respectively, with concurrent esomeprazole (40 mg/day) in one study of 160 healthy volunteers.<sup>4</sup> Clopidogrel undergoes oxidative metabolism to its active metabolite in two steps. Based on enzyme kinetics in vitro, the first step is catalyzed by CYP2C19 (45% estimated contribution), 1A2 (36%), and 2B6 (19%), and the second is catalyzed by CYP3A4 (40%), 2B6 (36%), 2C19 (21%), and 2C9 (7%).<sup>10</sup> Based on in vivo evidence, activation of clopidogrel appears to depend heavily on CYP2C19 activity,<sup>11,12,13,14,15</sup> although some data indicate a possible dependence on other enzymes, including CYP3A4 and CYP2C9.<sup>14,16</sup>. Esomeprazole is a major substrate of CYP2C19 and CYP3A4 and a weak inhibitor of CYP2C19.<sup>17</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Kreutz RP, Stanek EJ, Aubert R, et al, “Impact of Proton Pump Inhibitors on the Effectiveness of Clopidogrel after Coronary Stent Placement: The Clopidogrel Medco Outcomes Study,” <i>Pharmacotherapy</i>, 2010, 30(8):787-96. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=20653354\">[PubMed 20653354]</a></p>\n<p>2. Evanchan J, Donnally MR, Binkley P, et al, “Recurrence of Acute Myocardial Infarction in Patients Discharged on Clopidogrel and a Proton Pump Inhibitor after Stent Placement for Acute Myocardial Infarction,” <i>Clin Cardiol</i>, 2010, 33(3):168-71. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=20235209\">[PubMed 20235209]</a></p>\n<p>3. Stockl KM, Le L, Zakharyan A, et al, “Risk of Rehospitalization for Patients Using Clopidogrel with a Proton Pump Inhibitor,” <i>Arch Intern Med</i>, 2010, 170(8):704-10. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=20421557\">[PubMed 20421557]</a></p>\n<p>4. Frelinger AL 3rd, Lee RD, Mulford DJ, et al, “A Randomized, 2-Period, Crossover Design Study to Assess the Effects of Dexlansoprazole, Lansoprazole, Esomeprazole, and Omeprazole on the Steady-State Pharmacokinetics and Pharmacodynamics of Clopidogrel in Healthy Volunteers,” <i>J Am Coll Cardiol</i>, 2012, 59(14):1304-11. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=22464259\">[PubMed 22464259]</a></p>\n<p>5. Ray WA, Murray KT, Griffin MR, et al, “Outcomes with Concurrent Use of Clopidogrel and Proton Pump Inhibitors - A Cohort Study,” <i>Ann Intern Med</i>, 2010, 152(6):337-45. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=20231564\">[PubMed 20231564]</a></p>\n<p>6. O’Donoghue ML, Braunwald E, Antman EM, et al, “Pharmacodynamic Effect and Clinical Efficacy of Clopidogrel and Prasugrel With or Without a Proton-Pump Inhibitor: An Analysis of Two Randomised Trials,” <i>Lancet</i>, 2009, 374:989-97. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=19726078\">[PubMed 19726078]</a></p>\n<p>7. Rassen JA, Choudhry NK, Avorn J, et al, “Cardiovascular Outcomes and Mortality in Patients Using Clopidogrel with Proton Pump Inhibitors after Percutaneous Coronary Intervention or Acute Coronary Syndrome,” <i>Circulation</i>, 2009, 120:2322-9. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=19933932\">[PubMed 19933932]</a></p>\n<p>8. Siller-Matula JM, Spiel AO, Lang IM, et al, “Effects of Pantoprazole and Esomeprazole on Platelet Inhibition by Clopidogrel,” <i>Am Heart J</i>, 2009, 157(1): 148.e1-5. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=19081411\">[PubMed 19081411]</a></p>\n<p>9. Gremmel T, Steiner S, Seidinger D, et al, “The Influence of Proton Pump Inhibitors on the Antiplatelet Potency of Clopidogrel Evaluated by Five Different Platelet Function Tests,” <i>J Cardiovasc Pharmacol</i>, 2010, (Epub Aug 18). <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=20729752\">[PubMed 20729752]</a></p>\n<p>10. Kazui M, Nishiya Y, Ishizuka T, et al, “Identification of the Human Cytochrome P450 Enzymes Involved in the Two Oxidative Steps in the Bioactivation of Clopidogrel to its Pharmacologically Active Metabolite,” <i>Drug Metab Dispos</i>, 2010, 38(1):92-9. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=19812348\">[PubMed 19812348]</a></p>\n<p>11. Collet JP, Hulot JS, Pena A, et al, “Cytochrome P450 2C19 Polymorphism in Young Patients Treated with Clopidogrel After Myocardial Infarction: A Cohort Study,” <i>Lancet</i>, 2009, 373(9660):309-17. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=19108880\">[PubMed 19108880]</a></p>\n<p>12. Simon T, Verstuyft C, Mary-Krause M, et al, “Genetic Determinants of Response to Clopidogrel and Cardiovascular Events,” <i>N Engl J Med</i>, 2009, 360(4):363-75. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=19106083\">[PubMed 19106083]</a></p>\n<p>13. Mega JL, Close SL, Wiviott SD, et al, “Cytochrome P-450 Polymorphisms and Response to Clopidogrel,” <i>N Engl J Med</i>, 2009, 360(4):354-62. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=19106084\">[PubMed 19106084]</a></p>\n<p>14. Brandt JT, Close SL, Iturria SJ, et al, “Common Polymorphisms of CYP2C19 and CYP2C9 Affect the Pharmacokinetic and Pharmacodynamic Response to Clopidogrel but Not Prasugrel,” <i>J Thromb Haemost</i>, 2007, 5:2429-36. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=17900275\">[PubMed 17900275]</a></p>\n<p>15. Hulot JS, Bura A, Villard E, et al, “Cytochrome P450 2C19 Loss-of-Function Polymorphism Is a Major Determinant of Clopidogrel Responsiveness in Healthy Subjects,” <i>Blood</i>, 2006, 108:2244-7. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=16772608\">[PubMed 16772608]</a></p>\n<p>16. Farid NA, Payne CD, Small DS, et al, “Cytochrome P450 3A Inhibition by Ketoconazole Affects Prasugrel and Clopidogrel Pharmacokinetics and Pharmacodynamics Differently,” <i>Clin Pharmacol Ther</i>, 2007, 81:735-41. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=17361128\">[PubMed 17361128]</a></p>\n<p>17. Li XQ, Andersson TB, Ahlstrom M, et al, “Comparison of Inhibitory Effects of the Proton Pump-Inhibiting Drugs Omeprazole, Esomeprazole, Lansoprazole, Pantoprazole, and Rabeprazole on Human Cytochrome P450 Activities,” <i>Drug Metab Dispos</i>, 2004, 32:821-7. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=15258107\">[PubMed 15258107]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","5537":"<p><b>Title</b> Clopidogrel / Lansoprazole</p> \n<p></p> \n<p><b>Risk Rating</b> D: Consider therapy modification</p> \n<p><b>Summary</b> Lansoprazole may decrease serum concentrations of the active metabolite(s) of Clopidogrel. <b>Severity</b> Major <b>Reliability Rating</b> Fair: Existing data/reports are inconsistent </p> \n<p><b>Patient Management</b> Due to the possible risk for impaired clopidogrel effectiveness with this combination, clinicians should carefully consider the need for concurrent lansoprazole therapy in patients receiving clopidogrel. Monitor response to clopidogrel closely when using clopidogrel with lansoprazole. Whether there are differences among individual proton pump inhibitors is unclear. Other acid-lowering therapies (e.g., H2-receptor antagonists, antacids, etc.) do not appear to share this interaction with clopidogrel.</p> \n<p><b>Discussion</b> Some retrospective studies (n=36 to 785) have reported an increased risk of negative cardiovascular-related outcomes associated with concurrent use of lansoprazole with clopidogrel.<sup>1,2</sup> One smaller study only performed a pooled analysis of patients taking proton pump inhibitors (only 2.2% receiving lansoprazole) and did not perform a subset analyses for individual agents.<sup>2</sup> This study found a 10% increase in recurrence of acute myocardial infarction with concurrent proton pump inhibitor and clopidogrel use as compared to clopidogrel alone. Similarly, a small randomized controlled trial (n=160) found that subjects treated with clopidogrel (75 mg/day) plus lansoprazole (30 mg/day; n=40) exhibited a statistically significant decrease in clopidogrel antiplatelet activity vs. subjects treated with clopidogrel without a PPI.<sup>3</sup><br><br>In contrast, some other clinical outcomes studies (n= 441 to 7,593) have reported no association of concurrent lansoprazole with increased risk of negative cardiovascular outcomes as compared to clopidogrel therapy alone.<sup>4,5,6</sup> Similarly, multiple small, non-clinical outcome trials (n=21 to 39) examining the effects of concurrent lansoprazole therapy on clopidogrel-mediated inhibition of platelet aggregation (IPA) activity in healthy subjects found no statistical difference in IPA compared to clopidogrel alone.<sup>7,8,9</sup><br><br>The suspected mechanism of this interaction is lansoprazole-mediated inhibition of clopidogrel metabolism to its active metabolite. In fact, the AUC and maximum serum concentration (Cmax) of the active metabolite was reduced by an average of 14% and 30%, respectively, with concurrent lansoprazole (30 mg/day) in one study of 160 healthy volunteers.<sup>3</sup> Clopidogrel undergoes oxidative metabolism to its active metabolite in two steps. Based on enzyme kinetics in vitro, the first step is catalyzed by CYP2C19 (45% estimated contribution), 1A2 (36%), and 2B6 (19%), and the second is catalyzed by CYP3A4 (40%), 2B6 (36%), 2C19 (21%), and 2C9 (7%).<sup>9</sup> Based on in vivo evidence, activation of clopidogrel appears to depend heavily on CYP2C19 activity,<sup>11,12,13,14,15</sup> although some data indicate a possible dependence on other enzymes, including CYP3A4 and CYP2C9.<sup>14,16</sup> Lansoprazole is a major substrate of CYP2C19 and CYP3A4 and moderately inhibits CYP2C19.<sup>17</sup> The AUC of the clopidogrel active metabolite was an average of 14% lower when clopidogrel (75 mg/day) was given with lansoprazole (30 mg/day x 9 days) in a study of 40 healthy volunteers.<sup>18</sup> The degree to which this impacted platelet inhibition is unclear, though the lansoprazole prescribing information describes lansoprazole as having no clinically meaningful effect on clopidogrel active metabolite exposure or clopidogrel-mediated platelet inhibition.<sup>18</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Kreutz RP, Stanek EJ, Aubert R, et al, “Impact of Proton Pump Inhibitors on the Effectiveness of Clopidogrel after Coronary Stent Placement: The Clopidogrel Medco Outcomes Study,” <i>Pharmacotherapy</i>, 2010, 30(8):787-96. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=20653354\">[PubMed 20653354]</a></p>\n<p>2. Evanchan J, Donnally MR, Binkley P, et al, “Recurrence of Acute Myocardial Infarction in Patients Discharged on Clopidogrel and a Proton Pump Inhibitor after Stent Placement for Acute Myocardial Infarction,” <i>Clin Cardiol</i>, 2010, 33(3):168-71. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=20235209\">[PubMed 20235209]</a></p>\n<p>3. Frelinger AL 3rd, Lee RD, Mulford DJ, et al, “A Randomized, 2-Period, Crossover Design Study to Assess the Effects of Dexlansoprazole, Lansoprazole, Esomeprazole, and Omeprazole on the Steady-State Pharmacokinetics and Pharmacodynamics of Clopidogrel in Healthy Volunteers,” <i>J Am Coll Cardiol</i>, 2012, 59(14):1304-11. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=22464259\">[PubMed 22464259]</a></p>\n<p>4. Ray WA, Murray KT, Griffin MR, et al, “Outcomes with Concurrent Use of Clopidogrel and Proton Pump Inhibitors - A Cohort Study,” <i>Ann Intern Med</i>, 2010, 152(6):337-45. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=20231564\">[PubMed 20231564]</a></p>\n<p>5. O’Donoghue ML, Braunwald E, Antman EM, et al, “Pharmacodynamic Effect and Clinical Efficacy of Clopidogrel and Prasugrel With or Without a Proton-Pump Inhibitor: An Analysis of Two Randomised Trials,” <i>Lancet</i>, 2009, 374:989-97. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=19726078\">[PubMed 19726078]</a></p>\n<p>6. Rassen JA, Choudhry NK, Avorn J, et al, “Cardiovascular Outcomes and Mortality in Patients Using Clopidogrel with Proton Pump Inhibitors after Percutaneous Coronary Intervention or Acute Coronary Syndrome,” <i>Circulation</i>, 2009, 120:2322-9. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=19933932\">[PubMed 19933932]</a></p>\n<p>7. Small DS, Farid NA, Payne CD, et al, “Effects of the Proton Pump Inhibitor Lansoprazole on the Pharmacokinetics and Pharmacodynamics of Prasugrel and Clopidogrel,” <i>J Clin Pharmacol</i>, 2008, 48:475-84. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=18303127\">[PubMed 18303127]</a></p>\n<p>8. Furuta T, Iwaki T, Umemura K, “Influences of Different Proton Pump Inhibitors on the Anti-Platelet Function of Clopidogrel in Relation to CYP2C19 Genotypes,” <i>Br J Clin Pharmacol</i>, 2010, 70:383-92. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=20716239\">[PubMed 20716239]</a></p>\n<p>9. Hulot JS, Wuerzner G, Bachelot-Loza C, et al, “Effect of Increased Clopidogrel Maintenance Dose or Lansoprazole Co-Administration on the Antiplatelet Responses to Clopidogrel in CYP2C19 Genotyped Healthy Subjects,” <i>J Thromb Haemostat</i>, 2010, 8:610-3. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=20040040\">[PubMed 20040040]</a></p>\n<p>10. Kazui M, Nishiya Y, Ishizuka T, et al, “Identification of the Human Cytochrome P450 Enzymes Involved in the Two Oxidative Steps in the Bioactivation of Clopidogrel to its Pharmacologically Active Metabolite,” <i>Drug Metab Dispos</i>, 2010, 38(1):92-9. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=19812348\">[PubMed 19812348]</a></p>\n<p>11. Collet JP, Hulot JS, Pena A, et al, “Cytochrome P450 2C19 Polymorphism in Young Patients Treated with Clopidogrel After Myocardial Infarction: A Cohort Study,” <i>Lancet</i>, 2009, 373(9660):309-17. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=19108880\">[PubMed 19108880]</a></p>\n<p>12. Simon T, Verstuyft C, Mary-Krause M, et al, “Genetic Determinants of Response to Clopidogrel and Cardiovascular Events,” <i>N Engl J Med</i>, 2009, 360(4):363-75. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=19106083\">[PubMed 19106083]</a></p>\n<p>13. Mega JL, Close SL, Wiviott SD, et al, “Cytochrome P-450 Polymorphisms and Response to Clopidogrel,” <i>N Engl J Med</i>, 2009, 360(4):354-62. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=19106084\">[PubMed 19106084]</a></p>\n<p>14. Brandt JT, Close SL, Iturria SJ, et al, “Common Polymorphisms of CYP2C19 and CYP2C9 Affect the Pharmacokinetic and Pharmacodynamic Response to Clopidogrel but Not Prasugrel,” <i>J Thromb Haemost</i>, 2007, 5:2429-36. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=17900275\">[PubMed 17900275]</a></p>\n<p>15. Hulot JS, Bura A, Villard E, et al, “Cytochrome P450 2C19 Loss-of-Function Polymorphism Is a Major Determinant of Clopidogrel Responsiveness in Healthy Subjects,” <i>Blood</i>, 2006, 108:2244-7. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=16772608\">[PubMed 16772608]</a></p>\n<p>16. Farid NA, Payne CD, Small DS, et al, “Cytochrome P450 3A Inhibition by Ketoconazole Affects Prasugrel and Clopidogrel Pharmacokinetics and Pharmacodynamics Differently,” <i>Clin Pharmacol Ther</i>, 2007, 81:735-41. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=17361128\">[PubMed 17361128]</a></p>\n<p>17. Li XQ, Andersson TB, Ahlstrom M, et al, “Comparison of Inhibitory Effects of the Proton Pump-Inhibiting Drugs Omeprazole, Esomeprazole, Lansoprazole, Pantoprazole, and Rabeprazole on Human Cytochrome P450 Activities,” <i>Drug Metab Dispos</i>, 2004, 32:821-7. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=15258107\">[PubMed 15258107]</a></p>\n<p>18. Prescribing information. Prevacid (lansoprazole). Deerfield, IL: Takeda Pharmaceuticals America, Inc., October 2011.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","5538":"<p><b>Title</b> Clopidogrel / Dexlansoprazole</p> \n<p></p> \n<p><b>Risk Rating</b> D: Consider therapy modification</p> \n<p><b>Summary</b> Dexlansoprazole may decrease serum concentrations of the active metabolite(s) of Clopidogrel. <b>Severity</b> Major <b>Reliability Rating</b> Fair: Existing data/reports are inconsistent </p> \n<p><b>Patient Management</b> Due to the possible risk for impaired clopidogrel effectiveness with this combination, clinicians should carefully consider the need for concurrent dexlansoprazole therapy in patients receiving clopidogrel. Monitor response to clopidogrel closely when using clopidogrel with dexlansoprazole. Whether there are differences among individual proton pump inhibitors is unclear. Other acid-lowering therapies (e.g., H2-receptor antagonists, antacids, etc.) do not appear to share this interaction with clopidogrel.</p> \n<p><b>Discussion</b> The AUC and maximum serum concentration (Cmax) of the clopidogrel active metabolite were an average of 9% and 27% lower, respectively, when clopidogrel (75 mg/day) was given with dexlansoprazole (60 mg/day x 9 days) in a study of 40 healthy volunteers.<sup>1</sup> Clopidogrel antiplatelet activity was similarly dimished by concurrent dexlansoprazole,<sup>1</sup> though the dexlansoprazole prescribing information describes dexlansoprazole as having no clinically meaningful effect on clopidogrel active metabolite exposure or clopidogrel-mediated platelet inhibition.<sup>2</sup> No trials have evaluated patients on concurrent dexlansoprazole and clopidogrel therapy and its effects on cardiovascular outcomes. However, dexlansoprazole is the R-enantiomer of the racemic product lansoprazole, and data are available evaluating lansoprazole and other proton pump inhibitors regarding possible effects on concurrent clopidogrel. Dexlansoprazole has the same metabolic and inhibition profile of cytochrome P450 enzymes as lansoprazole; therefore, dexlansoprazole is expected to produce similar outcomes as compared to lansoprazole.<br><br>Some studies evaluating concurrent lansoprazole and clopidogrel therapy found increased risks of negative cardiovascular-related outcomes (6.5-10% increase in incidence),<sup>3,4</sup> whereas others have found no significant difference in risks versus clopidogrel alone.<sup>5,6,7</sup> Additionally, lansoprazole did not decrease clopidogrel’s inhibition of platelet aggregation (IPA) activity in smaller non-clinical outcome studies of healthy subjects.<sup>8,9,10</sup><br><br>The suspected mechanism of this interaction is dexlansoprazole-mediated inhibition of clopidogrel metabolism to its active metabolite. Clopidogrel undergoes oxidative metabolism to its active metabolite in two steps. Based on enzyme kinetics in vitro, the first step is catalyzed by CYP2C19 (45% estimated contribution), 1A2 (36%), and 2B6 (19%), and the second is catalyzed by CYP3A4 (40%), 2B6 (36%), 2C19 (21%), and 2C9 (7%).<sup>11</sup> Based on in vivo evidence, activation of clopidogrel appears to depend heavily on CYP2C19 activity,<sup>12,13,14,15,16</sup> although some data indicate a possible dependence on other enzymes, including CYP3A4 and CYP2C9.<sup>15,17</sup> Dexlansoprazole is a major substrate of CYP2C19 and CYP3A4 and moderately inhibits CYP2C19.<sup>18</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Frelinger AL 3rd, Lee RD, Mulford DJ, et al, “A Randomized, 2-Period, Crossover Design Study to Assess the Effects of Dexlansoprazole, Lansoprazole, Esomeprazole, and Omeprazole on the Steady-State Pharmacokinetics and Pharmacodynamics of Clopidogrel in Healthy Volunteers,” <i>J Am Coll Cardiol</i>, 2012, 59(14):1304-11. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=22464259\">[PubMed 22464259]</a></p>\n<p>2. Prescribing information. Dexilant (dexlansoprazole). Deerfield, IL: Takeda Pharmaceuticals America, Inc., October 2011.</p>\n<p>3. Kreutz RP, Stanek EJ, Aubert R, et al, “Impact of Proton Pump Inhibitors on the Effectiveness of Clopidogrel after Coronary Stent Placement: The Clopidogrel Medco Outcomes Study,” <i>Pharmacotherapy</i>, 2010, 30(8):787-96. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=20653354\">[PubMed 20653354]</a></p>\n<p>4. Evanchan J, Donnally MR, Binkley P, et al, “Recurrence of Acute Myocardial Infarction in Patients Discharged on Clopidogrel and a Proton Pump Inhibitor after Stent Placement for Acute Myocardial Infarction,” <i>Clin Cardiol</i>, 2010, 33(3):168-71. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=20235209\">[PubMed 20235209]</a></p>\n<p>5. Ray WA, Murray KT, Griffin MR, et al, “Outcomes with Concurrent Use of Clopidogrel and Proton Pump Inhibitors - A Cohort Study,” <i>Ann Intern Med</i>, 2010, 152(6):337-45. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=20231564\">[PubMed 20231564]</a></p>\n<p>6. O’Donoghue ML, Braunwald E, Antman EM, et al, “Pharmacodynamic Effect and Clinical Efficacy of Clopidogrel and Prasugrel With or Without a Proton-Pump Inhibitor: An Analysis of Two Randomised Trials,” <i>Lancet</i>, 2009, 374:989-97. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=19726078\">[PubMed 19726078]</a></p>\n<p>7. Rassen JA, Choudhry NK, Avorn J, et al, “Cardiovascular Outcomes and Mortality in Patients Using Clopidogrel with Proton Pump Inhibitors after Percutaneous Coronary Intervention or Acute Coronary Syndrome,” <i>Circulation</i>, 2009, 120:2322-9. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=19933932\">[PubMed 19933932]</a></p>\n<p>8. Small DS, Farid NA, Payne CD, et al, “Effects of the Proton Pump Inhibitor Lansoprazole on the Pharmacokinetics and Pharmacodynamics of Prasugrel and Clopidogrel,” <i>J Clin Pharmacol</i>, 2008, 48:475-84. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=18303127\">[PubMed 18303127]</a></p>\n<p>9. Furuta T, Iwaki T, Umemura K, “Influences of Different Proton Pump Inhibitors on the Anti-Platelet Function of Clopidogrel in Relation to CYP2C19 Genotypes,” <i>Br J Clin Pharmacol</i>, 2010, 70:383-92. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=20716239\">[PubMed 20716239]</a></p>\n<p>10. Hulot JS, Wuerzner G, Bachelot-Loza C, et al, “Effect of Increased Clopidogrel Maintenance Dose or Lansoprazole Co-Administration on the Antiplatelet Responses to Clopidogrel in CYP2C19 Genotyped Healthy Subjects,” <i>J Thromb Haemostat</i>, 2010, 8:610-3. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=20040040\">[PubMed 20040040]</a></p>\n<p>11. Kazui M, Nishiya Y, Ishizuka T, et al, “Identification of the Human Cytochrome P450 Enzymes Involved in the Two Oxidative Steps in the Bioactivation of Clopidogrel to its Pharmacologically Active Metabolite,” <i>Drug Metab Dispos</i>, 2010, 38(1):92-9. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=19812348\">[PubMed 19812348]</a></p>\n<p>12. Collet JP, Hulot JS, Pena A, et al, “Cytochrome P450 2C19 Polymorphism in Young Patients Treated with Clopidogrel After Myocardial Infarction: A Cohort Study,” <i>Lancet</i>, 2009, 373(9660):309-17. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=19108880\">[PubMed 19108880]</a></p>\n<p>13. Simon T, Verstuyft C, Mary-Krause M, et al, “Genetic Determinants of Response to Clopidogrel and Cardiovascular Events,” <i>N Engl J Med</i>, 2009, 360(4):363-75. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=19106083\">[PubMed 19106083]</a></p>\n<p>14. Mega JL, Close SL, Wiviott SD, et al, “Cytochrome P-450 Polymorphisms and Response to Clopidogrel,” <i>N Engl J Med</i>, 2009, 360(4):354-62. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=19106084\">[PubMed 19106084]</a></p>\n<p>15. Brandt JT, Close SL, Iturria SJ, et al, “Common Polymorphisms of CYP2C19 and CYP2C9 Affect the Pharmacokinetic and Pharmacodynamic Response to Clopidogrel but Not Prasugrel,” <i>J Thromb Haemost</i>, 2007, 5:2429-36. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=17900275\">[PubMed 17900275]</a></p>\n<p>16. Hulot JS, Bura A, Villard E, et al, “Cytochrome P450 2C19 Loss-of-Function Polymorphism Is a Major Determinant of Clopidogrel Responsiveness in Healthy Subjects,” <i>Blood</i>, 2006, 108:2244-7. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=16772608\">[PubMed 16772608]</a></p>\n<p>17. Farid NA, Payne CD, Small DS, et al, “Cytochrome P450 3A Inhibition by Ketoconazole Affects Prasugrel and Clopidogrel Pharmacokinetics and Pharmacodynamics Differently,” <i>Clin Pharmacol Ther</i>, 2007, 81:735-41. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=17361128\">[PubMed 17361128]</a></p>\n<p>18. Li XQ, Andersson TB, Ahlstrom M, et al, “Comparison of Inhibitory Effects of the Proton Pump-Inhibiting Drugs Omeprazole, Esomeprazole, Lansoprazole, Pantoprazole, and Rabeprazole on Human Cytochrome P450 Activities,” <i>Drug Metab Dispos</i>, 2004, 32:821-7. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=15258107\">[PubMed 15258107]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","5539":"<p><b>Title</b> Clopidogrel / RABEprazole</p> \n<p></p> \n<p><b>Risk Rating</b> D: Consider therapy modification</p> \n<p><b>Summary</b> RABEprazole may decrease serum concentrations of the active metabolite(s) of Clopidogrel. <b>Severity</b> Major <b>Reliability Rating</b> Fair: Existing data/reports are inconsistent </p> \n<p><b>Patient Management</b> Due to the possible risk for impaired clopidogrel effectiveness with this combination, clinicians should carefully consider the need for concurrent rabeprazole therapy in patients receiving clopidogrel. Monitor response to clopidogrel closely when using clopidogrel with rabeprazole. Whether there are differences among individual proton pump inhibitors is unclear. Other acid-lowering therapies (e.g., H2-receptor antagonists, antacids, etc.) do not appear to share this interaction with clopidogrel.</p> \n<p><b>Discussion</b> Some retrospective studies (n= 56 to 159) have reported increased risks of negative cardiovascular-related outcomes associated with concurrent rabeprazole and clopidogrel.<sup>1,2</sup> Of note, these studies performed pooled analyses of patients taking proton pump inhibitors (15.4% to 78% using rabeprazole) and did not perform subset analyses by individual agents. In contrast, some other clinical outcomes studies (n= 3996 to 7593) have reported no association of concurrent rabeprazole and clopidogrel use with increased risk of negative cardiovascular outcomes as compared to clopidogrel therapy alone.<sup>3,4</sup> These studies similarly were not specific rabeprazole.<br><br>Some small, non-clinical outcomes trials (n= 39 to 44) examining the effects of concurrent rabeprazole therapy on clopidogrel’s inhibition of platelet aggregation (IPA) activity in healthy subjects found both reduced IPA,<sup>5</sup> and no difference,<sup>6</sup> when compared to clopidogrel alone. However, the trial that found no overall difference, did find evidence of reduced IPA in patients with CYP2C19 rapid metabolizer status.<sup>6</sup><br><br>The suspected mechanism of this interaction is rabeprazole-mediated inhibition of clopidogrel metabolism to its active metabolite. Clopidogrel undergoes oxidative metabolism to its active metabolite in two steps. Based on enzyme kinetics in vitro, the first step is catalyzed by CYP2C19 (45% estimated contribution), 1A2 (36%), and 2B6 (19%), and the second is catalyzed by CYP3A4 (40%), 2B6 (36%), 2C19 (21%), and 2C9 (7%).<sup>7</sup> Based on in vivo evidence, activation of clopidogrel appears to depend heavily on CYP2C19 activity,<sup>8,9,10,11,12</sup> although some data indicate a possible dependence on other enzymes including CYP3A4 and CYP2C9.<sup>11,13</sup> Rabeprazole is a major substrate of CYP2C19 and 3A4, a moderate inhibitor of 2C8, 2C19.<sup>14</sup> It has been reported that rabeprazole by itself is not, but its inactive metabolite rabeprazole thioether is, a potent in vitro inhibitor of CYP2C19, which could explain the possible interaction between rabeprazole and clopidogrel.<sup>14</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Gupta E, Bansal D, Sotos J, et al, “Risk of Adverse Clinical Outcomes with Concomitant Use of Clopidogrel and Proton Pump Inhibitors Following Percutaneous Coronary Intervention,” <i>Dig Dis Sci</i>, 2009. Epub 2009 Sep 3. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=19731021\">[PubMed 19731021]</a></p>\n<p>2. Stockl KM, Le L, Zakharyan A, et al, “Risk of Rehospitalization for Patients using Clopidogrel with a Proton Pump Inhibitor,” <i>Arch Intern Med</i>, 2010, 170(8):704-10. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=20421557\">[PubMed 20421557]</a></p>\n<p>3. Ray WA, Murray KT, Griffin MR, et al, “Outcomes with Concurrent Use of Clopidogrel and Proton Pump Inhibitors - A Cohort Study,” <i>Ann Intern Med</i>, 2010, 152(6):337-45. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=20231564\">[PubMed 20231564]</a></p>\n<p>4. Rassen JA, Choudhry NK, Avorn J, et al, “Cardiovascular Outcomes and Mortality in Patients Using Clopidogrel with Proton Pump Inhibitors after Percutaneous Coronary Intervention or Acute Coronary Syndrome,” <i>Circulation</i>, 2009, 120:2322-9. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=19933932\">[PubMed 19933932]</a></p>\n<p>5. Gremmel T, Steiner S, Seidinger D, et al, “The Influence of Proton Pump Inhibitors on the Antiplatelet Potency of Clopidogrel Evaluated by Five Different Platelet Function Tests,” <i>J Cardiovasc Pharmacol</i>, 2010, (Epub Aug 18). <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=20729752\">[PubMed 20729752]</a></p>\n<p>6. Furuta T, Iwaki T, Umemura K, “Influences of Different Proton Pump Inhibitors on the Anti-Platelet Function of Clopidogrel in Relation to CYP2C19 Genotypes,” <i>Br J Clin Pharmacol</i>, 2010, 70:383-92. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=20716239\">[PubMed 20716239]</a></p>\n<p>7. Kazui M, Nishiya Y, Ishizuka T, et al, “Identification of the Human Cytochrome P450 Enzymes Involved in the Two Oxidative Steps in the Bioactivation of Clopidogrel to its Pharmacologically Active Metabolite,” <i>Drug Metab Dispos</i>, 2010, 38(1):92-9. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=19812348\">[PubMed 19812348]</a></p>\n<p>8. Collet JP, Hulot JS, Pena A, et al, “Cytochrome P450 2C19 Polymorphism in Young Patients Treated with Clopidogrel After Myocardial Infarction: A Cohort Study,” <i>Lancet</i>, 2009, 373(9660):309-17. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=19108880\">[PubMed 19108880]</a></p>\n<p>9. Simon T, Verstuyft C, Mary-Krause M, et al, “Genetic Determinants of Response to Clopidogrel and Cardiovascular Events,” <i>N Engl J Med</i>, 2009, 360(4):363-75. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=19106083\">[PubMed 19106083]</a></p>\n<p>10. Mega JL, Close SL, Wiviott SD, et al, “Cytochrome P-450 Polymorphisms and Response to Clopidogrel,” <i>N Engl J Med</i>, 2009, 360(4):354-62. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=19106084\">[PubMed 19106084]</a></p>\n<p>11. Brandt JT, Close SL, Iturria SJ, et al, “Common Polymorphisms of CYP2C19 and CYP2C9 Affect the Pharmacokinetic and Pharmacodynamic Response to Clopidogrel but Not Prasugrel,” <i>J Thromb Haemost</i>, 2007, 5:2429-36. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=17900275\">[PubMed 17900275]</a></p>\n<p>12. Hulot JS, Bura A, Villard E, et al, “Cytochrome P450 2C19 Loss-of-Function Polymorphism Is a Major Determinant of Clopidogrel Responsiveness in Healthy Subjects,” <i>Blood</i>, 2006, 108:2244-7. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=16772608\">[PubMed 16772608]</a></p>\n<p>13. Farid NA, Payne CD, Small DS, et al, “Cytochrome P450 3A Inhibition by Ketoconazole Affects Prasugrel and Clopidogrel Pharmacokinetics and Pharmacodynamics Differently,” <i>Clin Pharmacol Ther</i>, 2007, 81:735-41. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=17361128\">[PubMed 17361128]</a></p>\n<p>14. Li XQ, Andersson TB, Ahlstrom M, et al, “Comparison of Inhibitory Effects of the Proton Pump-Inhibiting Drugs Omeprazole, Esomeprazole, Lansoprazole, Pantoprazole, and Rabeprazole on Human Cytochrome P450 Activities,” <i>Drug Metab Dispos</i>, 2004, 32:821-7. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=15258107\">[PubMed 15258107]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","5540":"<p><b>Title</b> Clopidogrel / Pantoprazole</p> \n<p></p> \n<p><b>Risk Rating</b> D: Consider therapy modification</p> \n<p><b>Summary</b> Pantoprazole may decrease serum concentrations of the active metabolite(s) of Clopidogrel. <b>Severity</b> Major <b>Reliability Rating</b> Fair: Existing data/reports are inconsistent </p> \n<p><b>Patient Management</b> Due to the possible risk for impaired clopidogrel effectiveness with this combination, clinicians should carefully consider the need for concurrent pantoprazole therapy in patients receiving clopidogrel. Monitor response to clopidogrel closely when using clopidogrel with pantoprazole. Whether there are differences among individual proton pump inhibitors is unclear. Other acid-lowering therapies (e.g., H2-receptor antagonists, antacids, etc.) do not appear to share this interaction with clopidogrel.</p> \n<p><b>Discussion</b> Several retrospective studies (n=659 to 1,653) have reported an increased risk of negative cardiovascular-related outcomes associated with concurrent pantoprazole and clopidogrel as compared to clopidogrel alone.<sup>1,2,3</sup> In one study, concurrent use of pantoprazole was associated with a statistically significant 11% increase in major adverse cardiac events.<sup>1</sup> In another, there was approximately a 90% increased risk for rehospitalization due to acute myocardial infarction in the subgroup of subjects taking concurrent pantoprazole and clopidogrel vs. users of clopidogrel alone.<sup>2</sup> One study reporting a 10% increase acute myocardial infarction incidence with concurrent proton pump inhibitor (PPI) use did not perform subgroup analysis according to specific PPI used, instead combining users of any PPI into one single group (42% were receiving pantoprazole).<sup>3</sup> In contrast, other clinical outcomes studies (n=734 to 4,708) have reported no association between concurrent pantoprazole and clopidogrel use with an increased risk of negative cardiovascular outcomes as compared to clopidogrel alone.<sup>4,5,6,7</sup><br><br>Some small, prospective, nonrandomized trials (n=56 to 152) examining the effects of concurrent pantoprazole therapy on clopidogrel’s inhibition of platelet aggregation (IPA) activity in healthy subjects either found no difference in IPA compared to clopidogrel alone,<sup>8</sup> or only a small (but statistically significant) decrease in IPA.<sup>9</sup> Of note, this study reporting the decrease in IPA used higher-dose (80 mg/day) pantoprazole, which is twice the normal recommended dose; therefore, it is unknown how 40 mg pantoprazole would have affected IPA in this study. The pantoprazole labeling also describes a study of 66 healthy volunteers who received clopidogrel with pantoprazole 80 mg/day in which the combination was associated with reduced inhibition of platelet aggregation that is correlated to reductions in the exposure to the active clopidogrel metabolite and of uncertain clinical significance (in one part of the label it is described as being not clinically important, but in another part of the label the clinical significance of the difference is described as being not clear).<sup>10</sup><br><br>The suspected mechanism of this interaction is pantoprazole-mediated inhibition of clopidogrel metabolism to its active metabolite. Clopidogrel undergoes oxidative metabolism to its active metabolite in two steps. Based on enzyme kinetics in vitro, the first step is catalyzed by CYP2C19 (45% estimated contribution), 1A2 (36%), and 2B6 (19%), and the second is catalyzed by CYP3A4 (40%), 2B6 (36%), 2C19 (21%), and 2C9 (7%).<sup>11</sup> Based on in vivo evidence, activation of clopidogrel appears to depend heavily on CYP2C19 activity,<sup>12,13,14,15,16</sup> although some data indicate a possible dependence on other enzymes, including CYP3A4 and CYP2C9.<sup>15,17</sup> Pantoprazole is a major substrate of CYP2C19 and is reportedly the least potent CYP2C19 inhibitor among the available PPIs.<sup>18</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Kreutz RP, Stanek EJ, Aubert R, et al, “Impact of Proton Pump Inhibitors on the Effectiveness of Clopidogrel after Coronary Stent Placement: The Clopidogrel Medco Outcomes Study,” <i>Pharmacotherapy</i>, 2010, 30(8):787-96. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=20653354\">[PubMed 20653354]</a></p>\n<p>2. Stockl KM, Le L, Zakharyan A, et al, “Risk of Rehospitalization for Patients Using Clopidogrel with a Proton Pump Inhibitor,” <i>Arch Intern Med</i>, 2010, 170(8):704-10. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=20421557\">[PubMed 20421557]</a></p>\n<p>3. Evanchan J, Donnally MR, Binkley P, et al, “Recurrence of Acute Myocardial Infarction in Patients Discharged on Clopidogrel and a Proton Pump Inhibitor after Stent Placement for Acute Myocardial Infarction,” <i>Clin Cardiol</i>, 2010, 33(3):168-71. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=20235209\">[PubMed 20235209]</a></p>\n<p>4. Ray WA, Murray KT, Griffin MR, et al, “Outcomes with Concurrent Use of Clopidogrel and Proton Pump Inhibitors - A Cohort Study,” <i>Ann Intern Med</i>, 2010, 152(6):337-45. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=20231564\">[PubMed 20231564]</a></p>\n<p>5. O’Donoghue ML, Braunwald E, Antman EM, et al, “Pharmacodynamic Effect and Clinical Efficacy of Clopidogrel and Prasugrel With or Without a Proton-Pump Inhibitor: An Analysis of Two Randomised Trials,” <i>Lancet</i>, 2009, 374:989-97. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=19726078\">[PubMed 19726078]</a></p>\n<p>6. Rassen JA, Choudhry NK, Avorn J, et al, “Cardiovascular Outcomes and Mortality in Patients Using Clopidogrel with Proton Pump Inhibitors after Percutaneous Coronary Intervention or Acute Coronary Syndrome,” <i>Circulation</i>, 2009, 120:2322-9. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=19933932\">[PubMed 19933932]</a></p>\n<p>7. Juurlink DN, Gomes T, Ko DT, et al, “A Population Based Study of Drug Interaction Between Proton Pump Inhibitors and Clopidogrel,” <i>CMAJ</i>, 2009, 180(7):713-8. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=19176635\">[PubMed 19176635]</a></p>\n<p>8. Siller-Matula JM, Spiel AO, Lang IM, et al, “Effects of Pantoprazole and Esomeprazole on Platelet Inhibition by Clopidogrel,” <i>Am Heart J</i>, 2009, 157(1): 148.e1-5. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=19081411\">[PubMed 19081411]</a></p>\n<p>9. Angiolillo DJ, Gibson CM, Cheng S, et al, “Differential Effects of Omeprazole and Patoprazole in the Pharmacodynamics and Pharmacokinetics of Clopidogrel in Healthy Subjects: Randomized, Placebo-Controlled, Crossover Comparison Studies,” <i>Clin Pharmacol Ther</i>, 2010 (Epub Sept 15). <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=20844485\">[PubMed 20844485]</a></p>\n<p>10. Protonix (pantoprazole) [prescribing information]. Philadelphia, PA: Pfizer Inc; December 2017.</p>\n<p>11. Kazui M, Nishiya Y, Ishizuka T, et al, “Identification of the Human Cytochrome P450 Enzymes Involved in the Two Oxidative Steps in the Bioactivation of Clopidogrel to its Pharmacologically Active Metabolite,” Drug Metab Dispos, 2010, 38(1):92-9. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=19812348\">[PubMed 19812348]</a></p>\n<p>12. Collet JP, Hulot JS, Pena A, et al, “Cytochrome P450 2C19 Polymorphism in Young Patients Treated with Clopidogrel After Myocardial Infarction: A Cohort Study,” Lancet, 2009, 373(9660):309-17. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=19108880\">[PubMed 19108880]</a></p>\n<p>13. Simon T, Verstuyft C, Mary-Krause M, et al, “Genetic Determinants of Response to Clopidogrel and Cardiovascular Events,” N Engl J Med, 2009, 360(4):363-75. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=19106083\">[PubMed 19106083]</a></p>\n<p>14. Mega JL, Close SL, Wiviott SD, et al, “Cytochrome P-450 Polymorphisms and Response to Clopidogrel,” N Engl J Med, 2009, 360(4):354-62. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=19106084\">[PubMed 19106084]</a></p>\n<p>15. Brandt JT, Close SL, Iturria SJ, et al, “Common Polymorphisms of CYP2C19 and CYP2C9 Affect the Pharmacokinetic and Pharmacodynamic Response to Clopidogrel but Not Prasugrel,” J Thromb Haemost, 2007, 5:2429-36. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=17900275\">[PubMed 17900275]</a></p>\n<p>16. Hulot JS, Bura A, Villard E, et al, “Cytochrome P450 2C19 Loss-of-Function Polymorphism Is a Major Determinant of Clopidogrel Responsiveness in Healthy Subjects,” Blood, 2006, 108:2244-7. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=16772608\">[PubMed 16772608]</a></p>\n<p>17. Farid NA, Payne CD, Small DS, et al, “Cytochrome P450 3A Inhibition by Ketoconazole Affects Prasugrel and Clopidogrel Pharmacokinetics and Pharmacodynamics Differently,” Clin Pharmacol Ther, 2007, 81:735-41. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=17361128\">[PubMed 17361128]</a></p>\n<p>18. Li XQ, Andersson TB, Ahlstrom M, et al, “Comparison of Inhibitory Effects of the Proton Pump-Inhibiting Drugs Omeprazole, Esomeprazole, Lansoprazole, Pantoprazole, and Rabeprazole on Human Cytochrome P450 Activities,” Drug Metab Dispos, 2004, 32:821-7. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=15258107\">[PubMed 15258107]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","5541":"<p><b>Title</b> Valsartan / Ritonavir</p> \n<p></p> \n<p><b>Risk Rating</b> B: No action needed</p> \n<p><b>Summary</b> Ritonavir may increase the serum concentration of Valsartan. <b>Severity</b> Minor <b>Reliability Rating</b> Fair: Reported in the prescribing information </p> \n<p><b>Patient Management</b> No action required.</p> \n<p><b>Discussion</b> The hepatic efflux of valsartan has been shown to be at least partially dependent on MRP2 (ABCC2).<sup>1</sup> Valsartan prescribing information cautions that inhibitors of MRP2, such as ritonavir, may increase serum concentrations of valsartan.<sup>2</sup><br><br>Considering the involvement of hepatic uptake transporters (i.e., OATP1B1, OATP1B3) and renal elimination (though generally only to a minor degree),<sup>1,2</sup> the extent to which isolated changes in MRP2 would impact valsartan is uncertain, particular in the absence of any studies or case reports of this hypothesized interaction. Similarly, the relatively wide therapeutic index of valsartan makes the clinical significance of even a modest pharmacokinetic interaction unclear.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Yamashiro W, Maeda K, Hirouchi M, et al, “Involvement of Transporters in the Hepatic Uptake and Biliary Excretion of Valsartan, a Selective Antagonist of the Angiotensin II AT1-Receptor, in Humans,” <i>Drug Metab Dispos</i>, 2006, 34(7):1247-54. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=16624871\">[PubMed 16624871]</a></p>\n<p>2. Prescribing information. Diovan (valsartan). East Hanover, NJ: Novartis Pharmaceuticals Corp., 06/2010.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","5542":"<p><b>Title</b> CNS Depressants / Droperidol</p> \n<p></p> \n<p><b>Risk Rating</b> D: Consider therapy modification</p> \n<p><b>Summary</b> Droperidol may enhance the CNS depressant effect of CNS Depressants. <b>Severity</b> Moderate <b>Reliability Rating</b> Good </p> \n<p><b>Patient Management</b> Consider dose reductions of droperidol or of other CNS agents (e.g., opioids, barbiturates) with concomitant use.</p>\n<div>\n <p><b>CNS Depressants Interacting Members</b> Acrivastine, Afloqualone, Alcohol (Ethyl), Alfentanil, ALPRAZolam, Amisulpride, Amitriptyline, Amobarbital, Amoxapine, ARIPiprazole, ARIPiprazole Lauroxil, Asenapine, Baclofen, Benperidol, Benzhydrocodone, Bilastine, Blonanserin, Brexpiprazole, Brimonidine (Ophthalmic), Brivaracetam, Bromazepam, Bromperidol, Brompheniramine, Buclizine, Buprenorphine, BusPIRone, Butabarbital, Butalbital, Butorphanol, CarBAMazepine, Carbinoxamine, Cariprazine, Carisoprodol, Cetirizine (Systemic), Chloral Betaine, Chloral Hydrate, ChlordiazePOXIDE, Chlormethiazole, Chlorpheniramine, ChlorproMAZINE, Chlorzoxazone, Cinnarizine, Clemastine, CloBAZam, ClomiPRAMINE, ClonazePAM, CloNIDine, Clorazepate, Clothiapine, CloZAPine, Codeine, Cyclizine, Cyclobenzaprine, Cyproheptadine, Dantrolene, Desflurane, Desipramine, Desloratadine, Deutetrabenazine, Dexbrompheniramine, Dexchlorpheniramine, DiazePAM, Difenoxin, Dihydrocodeine, DimenhyDRINATE, Dimethindene (Systemic), DiphenhydrAMINE (Systemic), DiphenhydrAMINE (Topical), Diphenoxylate, Dosulepin, Doxepin (Systemic), Doxepin (Topical), Doxylamine, Droperidol, Ebastine, Efavirenz, Emedastine (Systemic), Entacapone, Eperisone, Estazolam, Eszopiclone, Ethosuximide, Ethotoin, Ethyl Loflazepate, Etizolam, Ezogabine, Felbamate, FentaNYL, Fexofenadine, Flibanserin, Flunarizine, Flunitrazepam, Flupentixol, FluPHENAZine, Flurazepam, Fosphenytoin, Gabapentin, Gabapentin Enacarbil, Glutethimide, GuanFACINE, Haloperidol, Halothane, Heroin, HYDROcodone, HYDROmorphone, HydrOXYzine, Iloperidone, Imipramine, Isoflurane, Ketamine, Ketotifen (Systemic), LamoTRIgine, LevETIRAcetam, Levocetirizine, Levorphanol, Lofepramine, Loprazolam, Loratadine, LORazepam, Lormetazepam, Loxapine, Lurasidone, Maprotiline, Meclizine, Melitracen [INT], Meperidine, Meprobamate, Meptazinol, Mequitazine, Metaxalone, Methadone, Methocarbamol, Methohexital, Methotrimeprazine, Methoxyflurane, Methsuximide, Mianserin, Midazolam, Mirtazapine, Molindone, Morphine (Liposomal), Morphine (Systemic), Moxonidine, Nalbuphine, Nalfurafine, Nefopam, Nitrazepam, Nitrous Oxide, Nordazepam, Nortriptyline, OLANZapine, Olopatadine (Systemic), Opium, Opium Tincture, Orphenadrine, Oxatomide, Oxazepam, Oxomemazine, OxyCODONE, OxyMORphone, Paliperidone, Paraldehyde, Paregoric, Pentazocine, PENTobarbital, Perampanel, Periciazine, Perphenazine, Pheniramine, PHENobarbital, Phenyltoloxamine, Phenytoin, Pholcodine, Pimozide, Pipamperone [INT], Pipotiazine, Pizotifen, Pomalidomide, Prazepam, Pregabalin, Primidone, Prochlorperazine, Promazine, Promethazine, Propofol, Protriptyline, Pyrilamine (Systemic), Quazepam, QUEtiapine, Ramelteon, Remifentanil, Reserpine, Rilmenidine, RisperiDONE, Rupatadine, Scopolamine (Ophthalmic), Scopolamine (Systemic), Secobarbital, Sevoflurane, Sodium Oxybate, Stiripentol, SUFentanil, Sulpiride, Suvorexant, Tapentadol, Tasimelteon, Temazepam, Tetrabenazine, Thalidomide, Thiopental, Thioridazine, Thiothixene, Thonzylamine, TiaGABine, TiZANidine, Tofisopam, Tolcapone, Topiramate, TraMADol, Triazolam, Trifluoperazine, Trimeprazine, Trimipramine, Triprolidine, Valerian, Vigabatrin, Zaleplon, Ziconotide, Ziprasidone, Zolpidem, Zonisamide, Zopiclone, Zuclopenthixol</p>\n</div> \n<p><b>Discussion</b> Droperidol prescribing information recommends dose reductions of droperidol or of other central nervous system (CNS) depressants (e.g., opioids, barbiturates) with concomitant use due to risks for enhanced CNS effects.<sup>1</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Prescribing information. Droperidol injection. Shirley, NY: American Regent Inc., 01/09</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","5543":"<p><b>Title</b> Dabigatran Etexilate / Verapamil</p> \n<p><span style=\"color: red; font-weight: bold\">Dependencies</span> </p>\n<ul>\n <li><p><b>Indication</b>: Specific recommendations for management of this interaction may be different for those receiving dabigatran for prophylaxis following orthopedic surgery vs. those with atrial fibrillation receiving prophylaxis vs. those being treated for deep venous thrombosis or pulmonary embolism.</p></li>\n <li><p><b>International labeling</b>: Recommendations in the Canadian labeling regarding the management of this interaction are somewhat different from those in the U.S. labeling.</p></li>\n <li><p><b>Renal Function</b>: The clinical significance and recommended management of this interaction both increase considerably in patients with moderate (CrCl 30-50 mL/min) or severe (CrCl 15-30 mL/min) renal dysfunction.</p></li>\n <li><p><b>Route</b> (oral): This significance of this interaction is likely greatest for oral verapamil.</p></li>\n</ul>\n<p></p> \n<p><b>Risk Rating</b> D: Consider therapy modification</p> \n<p><b>Summary</b> Verapamil may increase serum concentrations of the active metabolite(s) of Dabigatran Etexilate. <b>Severity</b> Major <b>Reliability Rating</b> Fair: Reported in the prescribing information </p> \n<p><b>Patient Management</b> Due to the potential for increased dabigatran concentrations/effects (bleeding), dabigatran dose reductions should be considered if used with verapamil. The recommendations for management of this potential drug interaction depend on the indication for dabigatran use, patient renal function, country specific labeling recommendations and route of administration. Of note, most of these concerns appear to be specific for oral verapamil, as intravenous verapamil is not expected to interact with dabigatran to any clinically significant degree.<br><br>The U.S. prescribing information specifically recommends avoiding concurrent use of dabigatran etexilate with any P-glycoprotein inhibitor (such as verapamil) in patients with severe renal dysfunction (CrCl 15-30 mL/min) when dabigatran is used for atrial fibrillation, and in patients with moderate renal dysfunction (CrCl less than 50 ml/min) when dabigatran is used for the treatment of deep venous thrombosis (DVT) or pulmonary embolism (PE). There is no recommendation in U.S. labeling to alter administration timing in patients receiving verapamil. Some non-US labeling recommends dabigatran dose reductions when being used for prevention of venous thromboembolism following hip or knee replacement, as well as administration of dabigatran etexilate 2 hours prior to oral verapamil (regardless of indication) and avoiding simultaneous initiation of therapy or initiation of verapamil in patients already being treated with dabigatran following orthopedic surgery.</p> \n<p><b>Discussion</b> According to a large retrospective cohort study of 91,330 Taiwanese patients with non-valvular atrial fibrillation who were treated with dabigatran (49.65% of participants) or another non-vitamin K antagonist oral anticoagulant (ie, rivaroxaban or apixaban), concurrent use of the verapamil (both a moderate CYP3A4 inhibitor and a P-glycoprotein (P-gp) inhibitor) was not associated with a significant increase in the risk for major bleeding.<sup>1</sup> Several other examined combinations in this cohort study also yielded findings contrary to what would be expected based on available pharmacokinetic interaction data or known pharmacology of the drugs in question. The precise clinical meaning of these findings is unclear.<br><br>Per data included in the dabigatran labeling, the interaction between dabigatran and verapamil is sensitive to both the verapamil formulation and timing of verapamil administration.<sup>2,3</sup> When immediate-release verapamil was given 1 hour prior to dabigatran, the mean dabigatran AUC and maximum serum concentration (Cmax) were increased by around 150% and 180%, respectively.<sup>2,4</sup> However, when a sustained-release formulation was given, the mean dabigatran AUC and Cmax increased by roughly 70% and 90%, respectively.<sup>2,4</sup> Multiple verapamil doses were also associated with smaller increases in dabigatran AUC and Cmax (around 50% and 60%, respectively), and when verapamil was given 2 hours after dabigatran there was only a minor change in dabigatran concentrations (20% increase in AUC and 10% increase in Cmax).<sup>2,4</sup><br><br>Since P-glycoprotein (P-gp)-mediated efflux and renal elimination represent the primary means of dabigatran elimination, the magnitude of any P-gp related interaction may be greater in patients with diminished renal function.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Chang SH, Chou IJ, Yeh YH, et al. Association between use of non-vitamin K oral anticoagulants with and without concurrent medications and risk of major bleeding in nonvalvular atrial fibrillation. <i>JAMA</i>. 2017;318(13):1250-1259. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=28973247\">[PubMed 28973247]</a></p>\n<p>2. Pradaxa (dabigatran etexilate). [product monograph]. Burlington, Ontario, Canada: Boehringer Ingelheim Canada Ltd.; November 2016.</p>\n<p>3. Pradaxa (dabigatran etexilate). [prescribing information]. Ridgefield, CT: Boehringer Ingelheim Pharmaceuticals, Inc.; November 2015.</p>\n<p>4. Hartter S, Sennewald R, Nehmiz G, Reilly P. Oral bioavailability of dabigatran etexilate (Pradaxa) after co-medication with verapamil in healthy subjects. <i>Br J Clin Pharmacol</i>. 2013;75(4):1053-1062. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=22946890\">[PubMed 22946890]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","5544":"<p><b>Title</b> Saquinavir / Bepridil</p> \n<p></p> \n<p><b>Risk Rating</b> X: Avoid combination</p> \n<p><b>Summary</b> Bepridil may enhance the arrhythmogenic effect of Saquinavir. Saquinavir may increase the serum concentration of Bepridil. <b>Severity</b> Major <b>Reliability Rating</b> Fair: Reported in the prescribing information </p> \n<p><b>Patient Management</b> Concurrent use of saquinavir with bepridil is contraindicated.</p> \n<p><b>Discussion</b> According to saquinavir prescribing information, concurrent use of saquinavir with certain antiarrhythmics, such as bepridil, is contraindicated due to a risk for serious arrhythmias.<sup>1</sup><br><br>The specific mechanism for this interaction is uncertain, but the combination of saquinavir/ritonavir potently inhibits CYP3A4 and is expected to inhibit bepridil metabolism to some degree.<sup>1</sup> In addition, both saquinavir and bepridil have been associated with potential proarrhythmic effects.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Prescribing information. Invirase (saquinavir). South San Francisco, CA: Genentech USA, Inc., 10/2010.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","5545":"<p><b>Title</b> Dofetilide / Saquinavir</p> \n<p></p> \n<p><b>Risk Rating</b> X: Avoid combination</p> \n<p><b>Summary</b> Saquinavir may enhance the arrhythmogenic effect of Dofetilide. Saquinavir may increase the serum concentration of Dofetilide. <b>Severity</b> Major <b>Reliability Rating</b> Fair: Reported in the prescribing information </p> \n<p><b>Patient Management</b> Concurrent use of saquinavir with dofetilide is contraindicated.</p> \n<p><b>Discussion</b> According to saquinavir prescribing information, concurrent use of saquinavir with certain antiarrhythmics, such as dofetilide, is contraindicated due to a risk for serious arrhythmias.<sup>1</sup><br><br>The specific mechanism for this interaction is uncertain, but the combination of saquinavir/ritonavir potently inhibits CYP3A4 and is expected to inhibit dofetilide metabolism to some degree.<sup>1</sup> In addition, both saquinavir and dofetilide have been associated with potential proarrhythmic effects.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Prescribing information. Invirase (saquinavir). South San Francisco, CA: Genentech USA, Inc., 10/2010.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","5546":"<p><b>Title</b> Flecainide / Saquinavir</p> \n<p></p> \n<p><b>Risk Rating</b> X: Avoid combination</p> \n<p><b>Summary</b> Saquinavir may enhance the arrhythmogenic effect of Flecainide. Saquinavir may increase the serum concentration of Flecainide. <b>Severity</b> Major <b>Reliability Rating</b> Fair: Reported in the prescribing information </p> \n<p><b>Patient Management</b> Concurrent use of saquinavir with flecainide is contraindicated.</p> \n<p><b>Discussion</b> According to saquinavir prescribing information, concurrent use of saquinavir with certain antiarrhythmics, such as flecainide, is contraindicated due to a risk for serious arrhythmias.<sup>1</sup><br><br>The specific mechanism for this interaction is uncertain, but the combination of saquinavir/ritonavir potently inhibits CYP3A4 and is expected to inhibit flecainide metabolism to some degree.<sup>1</sup> In addition, both saquinavir and flecainide have been associated with potential proarrhythmic effects.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Prescribing information. Invirase (saquinavir). South San Francisco, CA: Genentech USA, Inc., 10/2010.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","5547":"<p><b>Title</b> Lidocaine (Systemic) / Saquinavir</p> \n<p></p> \n<p><b>Risk Rating</b> X: Avoid combination</p> \n<p><b>Summary</b> Saquinavir may enhance the arrhythmogenic effect of Lidocaine (Systemic). Saquinavir may increase the serum concentration of Lidocaine (Systemic). <b>Severity</b> Major <b>Reliability Rating</b> Fair: Reported in the prescribing information </p> \n<p><b>Patient Management</b> Concurrent use of saquinavir with systemic lidocaine is contraindicated.</p> \n<p><b>Discussion</b> According to saquinavir prescribing information, concurrent use of saquinavir with certain antiarrhythmics, such as lidocaine, is contraindicated due to a risk for serious arrhythmias.<sup>1</sup><br><br>The specific mechanism for this interaction is uncertain, but the combination of saquinavir/ritonavir potently inhibits CYP3A4 and is expected to inhibit lidocaine metabolism to some degree.<sup>1</sup> In addition, both saquinavir and lidocaine have been associated with potential proarrhythmic effects.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Prescribing information. Invirase (saquinavir). South San Francisco, CA: Genentech USA, Inc., 10/2010.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","5548":"<p><b>Title</b> Propafenone / Saquinavir</p> \n<p></p> \n<p><b>Risk Rating</b> X: Avoid combination</p> \n<p><b>Summary</b> Saquinavir may enhance the arrhythmogenic effect of Propafenone. Saquinavir may increase the serum concentration of Propafenone. <b>Severity</b> Major <b>Reliability Rating</b> Fair: Reported in the prescribing information </p> \n<p><b>Patient Management</b> Concurrent use of saquinavir with propafenone is contraindicated.</p> \n<p><b>Discussion</b> According to saquinavir prescribing information, concurrent use of saquinavir with certain antiarrhythmics, such as propafenone, is contraindicated due to a risk for serious arrhythmias.<sup>1</sup><br><br>The specific mechanism for this interaction is uncertain, but the combination of saquinavir/ritonavir potently inhibits CYP3A4 and is expected to inhibit propafenone metabolism to some degree.<sup>1</sup> In addition, both saquinavir and propafenone have been associated with potential proarrhythmic effects.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Prescribing information. Invirase (saquinavir). South San Francisco, CA: Genentech USA, Inc., 10/2010.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","5549":"<p><b>Title</b> TraZODone / Saquinavir</p> \n<p></p> \n<p><b>Risk Rating</b> X: Avoid combination</p> \n<p><b>Summary</b> Saquinavir may enhance the QTc-prolonging effect of TraZODone. Saquinavir may increase the serum concentration of TraZODone. <b>Severity</b> Major <b>Reliability Rating</b> Fair: Reported in the prescribing information </p> \n<p><b>Patient Management</b> Concurrent use of trazodone with saquinavir is contraindicated.</p> \n<p><b>Discussion</b> According to saquinavir prescribing information, concurrent use of saquinavir with trazodone is contraindicated due to a risk for serious arrhythmias.<sup>1</sup><br><br>The specific mechanism for this interaction is uncertain, but both drugs are independently associated with prolongation of the QT-interval and the combination of saquinavir/ritonavir potently inhibits CYP3A4 and is expected to inhibit trazodone metabolism to some degree.<sup>1</sup> In an in vitro study, saquinavir was shown to be a relatively weak inhibitor of trazodone metabolism, but ritonavir, which is nearly always used with saquinavir, was a potent inhibitor of trazodone metabolism.<sup>2</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Prescribing information. Invirase (saquinavir). South San Francisco, CA: Genentech USA, Inc., 10/2010.</p>\n<p>2. Zalma A, von Moltke LL, Granda BW, et al, “In Vitro Metabolism of Trazodone by CYP3A: Inhibition by Ketoconazole and Human Immunodeficiency Viral Protease Inhibitors,” <i>Biol Psychiatry</i>, 2000, 47(7):655-61. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=10745059\">[PubMed 10745059]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","5550":"<p><b>Title</b> Exemestane / CYP3A4 Inducers (Strong)</p> \n<p><span style=\"color: red; font-weight: bold\">Dependencies</span> </p>\n<ul>\n <li><p><b>International labeling</b>: Dosing recommendations differ between international labelings.</p></li>\n</ul>\n<p></p> \n<p><b>Risk Rating</b> D: Consider therapy modification</p> \n<p><b>Summary</b> CYP3A4 Inducers (Strong) may decrease the serum concentration of Exemestane. <b>Severity</b> Major <b>Reliability Rating</b> Fair: Reported in the prescribing information </p> \n<p><b>Patient Management</b> Exemestane U.S. product labeling recommends using an increased dose (50 mg/day) in patients receiving concurrent strong CYP3A4 inducers. Monitor patients closely for evidence of toxicity and/or inadequate clinical response. Exemestane Canadian product monograph does not recommend a dose increase with concurrent use of strong CYP3A4 inducers.</p>\n<div>\n <p><b>CYP3A4 Inducers (Strong) Interacting Members</b> Apalutamide, CarBAMazepine, Enzalutamide, Fosphenytoin, Lumacaftor, Mitotane, PHENobarbital, Phenytoin, Primidone, RifAMPin</p>\n</div> \n<p><b>Discussion</b> The exemestane AUC was decreased an average of 54% in 10 healthy postmenopausal female volunteers when exemestane (25 mg x1) was given following a 14-day course of the strong CYP3A4 inducer rifampin (600 mg/day).<sup>1</sup><br><br>The likely mechanism of this interaction is rifampin-mediated induction of exemestane metabolism via CYP3A4.<br><br>Exemestane U.S. product labeling recommends using an increased exemestane dose of 50 mg/day when used with rifampin or other strong CYP3A4 inducers.<sup>1</sup> Exemestane Canadian product monograph acknowledges the pharmacokinetic interaction with strong CYP3A4 inducers but suggests that the suppression of plasma estrogen by exemestane is not affected and does not recommend a dose increase.<sup>2</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Prescribing information. Aromasin (exemestane). New York, NY: Pfizer Inc, 3/2011.</p>\n<p>2. Product monograph. Aromasin (exemestane). Kirkland, Quebec: Pfizer Canada Inc., January 2009.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","5551":"<p><b>Title</b> Theophylline Derivatives / Isoproterenol</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Isoproterenol may decrease the serum concentration of Theophylline Derivatives. <b>Severity</b> Moderate <b>Reliability Rating</b> Good </p> \n<p><b>Patient Management</b> Monitor for decreased theophylline levels/effects with concomitant administration of isoproterenol. Monitor for increased theophylline levels/effects with isoproterenol discontinuation.</p>\n<div>\n <p><b>Theophylline Derivatives Interacting Members</b> Acebrophylline, Aminophylline*, Theophylline<br><b>Exception</b> Dyphylline</p>\n <p style=\"font-size: 75%; font-style: italic;\">* Denotes agent(s) specifically implicated in clinical data. Unmarked agents are listed because they have properties similar to marked agents, and may respond so within the context of the stated interaction.</p>\n</div> \n<p><b>Discussion</b> Aminophylline prescribing information states that intravenous (IV) isoproterenol increased theophylline clearance and decreased theophylline serum concentrations by 20%.<sup>1</sup> Theophylline serum concentrations decreased a mean 5.87 mcg/mL following initiation of isoproterenol IV infusion in 12 patients with severe status asthmaticus receiving IV infusions of aminophylline.<sup>2</sup> Upon discontinuation of isoproterenol infusion, theophylline serum concentrations increased (mean increase 5.38 mcg/mL). In 6 pediatric patients with status asthmaticus, theophylline clearance increased by a mean 19% with concomitant aminophylline and isoproterenol infusions.<sup>3</sup> The mechanism for this apparent interaction is not known.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Prescribing information. Aminophylline Injection. Shirley, NY: American Regent Inc., 1/09.</p>\n<p>2. O'’Rourke PP and Crone RK, “Effect of Isoproterenol on Measured Theophylline Levels,” <i>Crit Care Med</i>, 1984, 12(4):373-5. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=6705546\">[PubMed 6705546]</a></p>\n<p>3. Hemstreet MP, Miles MV, Rutland RO, “Effect of Intravenous Isoproterenol on Theophylline Kinetics,” <i>J Allergy Clin Immunol</i>, 1982, 69(4):360-4. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=7069071\">[PubMed 7069071]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","5552":"<p><b>Title</b> Losartan / Milk Thistle</p> \n<p></p> \n<p><b>Risk Rating</b> B: No action needed</p> \n<p><b>Summary</b> Milk Thistle may decrease serum concentrations of the active metabolite(s) of Losartan. Milk Thistle may increase the serum concentration of Losartan. <b>Severity</b> Minor <b>Reliability Rating</b> Good </p> \n<p><b>Patient Management</b> No action required.</p> \n<p><b>Discussion</b> In a clinical study of 12 healthy volunteers, administration of milk thistle extract (1 capsule standardized to 140 mg silymarin, based on silibinin concentration, orally three times daily) increased losartan (50 mg single oral dose) maximum concentration and AUC by 89% and 108%, respectively, in patients with homozygous CYP2C9*1/*1 genotype.<sup>1</sup> No significant changes in losartan pharmacokinetics were seen in patients with heterozygous CYP2C9*1/*3 genotype. AUCs of E3174, the primary active metabolite of losartan, were reduced by 17% in *1/*1 carriers and by 14% in *1/*3 carriers.<br> <br>The suspected primary mechanism of this interaction is inhibition of CYP2C9 mediated losartan metabolism by one or more components of milk thistle. Several studies have characterized inhibition of CYP2C9 by milk thistle components, particularly silibinin (a combination of silybin A and B), in vitro.<sup>2,3,4,5,6</sup> Since E3174 has greater potency than losartan and correlates more strongly with therapeutic effects, the clinical relevance of the above pharmacokinetic changes is questionable.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Han Y, Guo D, Chen Y, Chen Y, Tan ZR, Zhou HH. Effect of silymarin on the pharmacokinetics of losartan and its active metabolite E-3174 in healthy Chinese volunteers <i>Eur J Clin Pharmacol</i>. 2009;65(6):585-591. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=19221727\">[PubMed 19221727]</a></p>\n<p>2. Beckmann-Knopp S, Rietbrock S, Weyhenmeyer R, et al. Inhibitory effects of silibinin on cytochrome P-450 enzymes in human liver microsomes. <i>Pharmacol Toxicol</i>. 2000;86(6):250-256. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=10895987\">[PubMed 10895987]</a></p>\n<p>3. Sridar C, Goosen TC, Kent UM, Williams JA, Hollenberg PF. Silybin inactivates cytochromes P450 3A4 and 2C9 and inhibits major hepatic glucuronosyltransferases. <i>Drug Metab Dispos</i>. 2004;32(6):587-594. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=15155549\">[PubMed 15155549]</a></p>\n<p>4. Jancova P, Anzenbacherova E, Papouskova B, et al,. Silybin is metabolized by cytochrome P450 2C8 in vitro. <i>Drug Metab Dispos</i>. 2007;35(11):2035-2039. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=17670841\">[PubMed 17670841]</a></p>\n<p>5. Brantley SJ, Oberlies NH, Kroll DJ,Paine MF. Two flavonolignans from milk thistle (Silybum marianum) inhibit CYP2C9-mediated warfarin metabolism at clinically achievable concentrations. <i>J Pharmacol Exp Ther</i>. 2010;332(3):1081-1087. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=19934397\">[PubMed 19934397]</a></p>\n<p>6. Doehmer J, Tewes B, Klein KU, Gritzko K, Muschick H, Mengs U. Assessment of drug-drug interaction for silymarin. <i>Toxicol In Vitro</i>. 2008;22(3):610-617. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=18249085\">[PubMed 18249085]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","5553":"<p><b>Title</b> Sirolimus / Milk Thistle</p> \n<p><span style=\"color: red; font-weight: bold\">Dependencies</span> </p>\n<ul>\n <li><p><b>Additional drug/group</b> (CycloSPORINE): This possible interaction has only been observed in patients receiving cyclosporine.</p></li>\n</ul>\n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Milk Thistle may increase the serum concentration of Sirolimus. <b>Severity</b> Moderate <b>Reliability Rating</b> Poor </p> \n<p><b>Patient Management</b> Consider monitoring for increased sirolimus concentrations following silymarin (milk thistle extract) initiation/dose increase, or decreased concentrations following silymarin discontinuation/dose decrease. The specific interacting component(s) of milk thistle are unknown.</p> \n<p><b>Discussion</b> In a population pharmacokinetic analysis of renal transplant recipients, sirolimus clearance (as estimated retrospectively from trough concentrations) was approximately 35% lower in patients receiving silymarin (milk thistle extract, regimen(s) not specified).<sup>1</sup> Patients in this study were also receiving cyclosporine.<br><br>The mechanism of this possible interaction is unknown. Clinical pharmacokinetic interaction studies of milk thistle extract with indinavir, a substrate of both CYP3A4 and P-glycoprotein, suggest low interaction potential via these mechanisms.<sup>2,3,4</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Jiao Z, Shi XJ, Li ZD, et al, “Population Pharmacokinetics of Sirolimus in De Novo Chinese Adult Renal Transplant Patients,” <i>Br J Clin Pharmacol</i>, 2009, 68(1):47-60. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=19660003\">[PubMed 19660003]</a></p>\n<p>2. Mills E, Wilson K, Clarke M, et al, “Milk Thistle and Indinavir: A Randomized Controlled Pharmacokinetics Study and Meta-Analysis,” <i>Eur J Clin Pharmacol</i>, 2005, 61(1):1-7. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=15666173\">[PubMed 15666173]</a></p>\n<p>3. Piscitelli SC, Formentini E, Burstein AH, et al, “Effect of Milk Thistle on the Pharmacokinetics of Indinavir in Healthy Volunteers,” <i>Pharmacotherapy</i>, 2002, 22(5):551-6. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=12013352\">[PubMed 12013352]</a></p>\n<p>4. DiCenzo R, Shelton M, Jordan K, et al, “Coadministration of Milk Thistle and Indinavir in Healthy Subjects,” <i>Pharmacotherapy</i>, 2003, 23(7):866-70. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=12885100\">[PubMed 12885100]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","5554":"<p><b>Title</b> Theophylline Derivatives / Methotrexate</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Methotrexate may increase the serum concentration of Theophylline Derivatives. <b>Severity</b> Moderate <b>Reliability Rating</b> Good </p> \n<p><b>Patient Management</b> Monitor for increased theophylline derivative serum concentrations with methotrexate initiation/dose increase. Monitor for decreased theophylline derivative serum concentrations with methotrexate discontinuation/dose decrease.</p>\n<div>\n <p><b>Theophylline Derivatives Interacting Members</b> Acebrophylline, Aminophylline*, Dyphylline, Theophylline*</p>\n <p style=\"font-size: 75%; font-style: italic;\">* Denotes agent(s) specifically implicated in clinical data. Unmarked agents are listed because they have properties similar to marked agents, and may respond so within the context of the stated interaction.</p>\n</div> \n<p><b>Discussion</b> Theophylline prescribing information states that low dose methotrexate decreases theophylline clearance and increases theophylline serum concentrations by 20% and suggests a dose-dependent effect on the magnitude of interaction between these agents.<sup>1</sup> In asthmatic patients receiving oral theophylline or aminophylline concomitantly with methotrexate (15 mg IM weekly) (n=8) or placebo (n=7), theophylline clearance decreased by a mean of 19% in methotrexate treated patients.<sup>2</sup> In 8 adult asthmatic patients, an inverse relationship between theophylline clearance and methotrexate nonrenal clearance was noted with concomitant treatment.<sup>3</sup> The mechanism for this apparent interaction is not known. <br><br>Unlike theophylline, dyphylline does not undergo hepatic metabolism but is eliminated renally unchanged.<sup>4</sup> Dyphylline and methotrexate both undergo renal tubular secretion and may compete for renal elimination.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Prescribing information. Uniphyll (theophylline). Stamford, CT: Purdue Pharmaceutical Products L.P., March 2010.</p>\n<p>2. Glynn-Barnhart AM, Erzurum SC, Leff JA, et al, “Effect of Low-Dose Methotrexate on the Disposition of Glucocorticoids and Theophylline,” <i>J Allergy Clin Immunol</i>, 1991, 88(2):180-6. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=1880318\">[PubMed 1880318]</a></p>\n<p>3. Glynn-Barnhart AM, Erzurum SC, Leff JA, et al, “Pharmacokinetics of Low-Dose Methotrexate in Adult Asthmatics,” <i>Pharmacotherapy</i>, 1992, 12(5):383-90.<a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=1437699\">[PubMed 1437699]</a></p>\n<p>4. Prescribing information. Lufyllin (Dyphylline). Somerset, NJ: Wallace Pharmaceuticals, June 2001.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","5556":"<p><b>Title</b> Vitamin K Antagonists / Ethotoin</p> \n<p></p> \n<p><b>Risk Rating</b> D: Consider therapy modification</p> \n<p><b>Summary</b> Ethotoin may enhance the anticoagulant effect of Vitamin K Antagonists. Vitamin K Antagonists may increase the serum concentration of Ethotoin. <b>Severity</b> Major <b>Reliability Rating</b> Fair: Reported in the prescribing information </p> \n<p><b>Patient Management</b> Anticoagulant dose adjustment may be necessary when ethotoin is initiated or discontinued. Monitor anticoagulant status (i.e., INR) and for signs/symptoms of bleeding whenever this combination is used. Monitor for increased effects of warfarin, and significantly decreased effects of dicumarol, if ethotoin is initiated/dose increased, and the opposite effects if ethotoin is discontinued/dose decreased. Monitor for increased serum concentrations/toxic effects of ethotoin if a vitamin K antagonist is initiated/dose increased, or decreased serum concentrations/effects if a vitamin K antagonist is discontinued/dose decreased. These effects would most likely manifest during the first 1-2 months of therapy.</p>\n<div>\n <p><b>Vitamin K Antagonists Interacting Members</b> Acenocoumarol, Phenindione, Warfarin</p>\n</div> \n<p><b>Discussion</b> Though specific data with ethotoin are not available, considerable data exist concerning a potential complex interaction between the hydantoin derivative phenytoin and vitamin K antagonist anticoagulants, and ethotoin prescribing information cautions that similar effects could be expected with ethotoin.<sup>1</sup><br><br>PHENYTOIN IMPACT ON VITAMIN K ANTAGONISTS: One case report describes a 52% increase in prothrombin time (PT) in a warfarin-treated patient within a month of initiating phenytoin (300 mg/day) [this increase occurred in spite of a 22% decrease in warfarin dosage].<sup>2</sup> Another report describes the initial development of increased anticoagulant effects in a warfarin-treated patient and subsequent decreased anticoagulant effects (after approximately 6 days).<sup>3</sup> Several additional cases of increased/altered warfarin and acenocoumarol effects have been reported.<sup>4,5,6,7,8,9</sup> Significant decreases in the effects (commensurate with up to 75% decreases in serum concentrations) of dicumarol have been reported to occur within 1-2 months of initiating phenytoin therapy.<sup>10</sup> Several weeks can be required (post-phenytoin initiation) for dicumarol effects to normalize.<br><br>The exact mechanism(s) of these contrasting interactions is unclear. Phenytoin may cause an initial displacement of warfarin from protein binding sites, resulting in a transient increase in anticoagulant effects. These increased effects may then eventually be overcome by phenytoin induction of CYP isoenzymes involved in warfarin metabolism. As such, warfarin (aside from an initial monitoring period) would not likely cause significant clinical concern. Dicumarol, on the other hand, appears significantly affected by phenytoin. In addition, phenytoin may exert an independent effect on clotting factor concentrations and/or coagulation.<br><br>VITAMIN K ANTAGONIST IMPACT ON PHENYTOIN: Serum phenytoin concentrations (based on 300 mg/day) increased more than 2-fold in six healthy subjects within a week of initiating dicumarol.<sup>11</sup> A case report describes the development of phenytoin toxicity within a few days of initiating warfarin therapy.<sup>12</sup><br><br>The mechanism of this form of a phenytoin-vitamin K antagonist interaction is unclear. Dicumarol/warfarin may inhibit CYP2C9-mediated phenytoin metabolism.<br><br>Considering available data, it would appear as though warfarin would be a safer anticoagulant than dicumarol in phenytoin/ethotoin-treated patients.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Prescribing information. Peganone (ethotoin). Deerfield, IL: Lundbeck Inc., May 2010.</p>\n<p>2. Nappi JM, “Warfarin and Phenytoin Interaction,” <i>Ann Intern Med</i>, 1979, 90:852. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=434697\">[PubMed 434697]</a></p>\n<p>3. Levine M and Sheppard I, “Biphasic Interaction of Phenytoin and Warfarin,” <i>Clin Pharm</i>, 1984, 3:200-3. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=6723231\">[PubMed 6723231]</a></p>\n<p>4. Koch-Weser J, “Haemorrhagic Reactions and Drug Interactions in 500 Warfarin Treated Patients,” <i>Clin Pharmacol Ther</i>, 1973, 14:139.</p>\n<p>5. Taylor JW, Alexander B, and Lyon LW, “A Comparative Evaluation of Oral Anticoagulant-Phenytoin Interactions,” <i>Drug Intell Clin Pharm</i>, 1980, 14:669-73.</p>\n<p>6. Abad-Santos F, Carcas AJ, F-Capitan C, et al, “Retroperitoneal Haematoma in a Patient Treated with Acenocoumarol, Phenytoin and Paroxetine,” <i>Clin Lab Haematol</i>, 1995, 17(2):195-7. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=8536426\">[PubMed 8536426]</a></p>\n<p>7. Hassan Y, Awaisu A, Aziz NA, et al, “The Complexity of Achieving Anticoagulation Control in the Face of Warfarin-Phenytoin Interaction: An Asian Case Report,” <i>Pharm World Sci</i>, 2005, 27(1):16-9. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=15861930\">[PubMed 15861930]</a></p>\n<p>8. Meisheri YV, “Simultaneous Phenytoin and Warfarin Toxicity on Chronic Concomitant Therapy,” <i>J Assoc Physicians India</i>, 1996, 44(9):661-2. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=9251383\">[PubMed 9251383]</a></p>\n<p>9. Panegyres PK, Rischbieth RH, “Fatal Phenytoin Warfarin Interaction,” <i>Postgrad Med J</i>, 1991, 67(783):98. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=2057444\">[PubMed 2057444]</a></p>\n<p>10. Hansen JM, Siersbaek-Nielsen K, Kristensen M, et al, “Effect of Diphenylhydantoin on the Metabolism of Dicoumarol in Man,” <i>Acta Med Scand</i>, 1971, 189:15. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=4107730\">[PubMed 4107730]</a></p>\n<p>11. Hansen JM, Kristensen M, Skovsted L, et al, “Dicoumarol Induced Diphenylhydantoin Intoxication,” <i>Lancet</i>, 1966, ii:265. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=4161425\">[PubMed 4161425]</a></p>\n<p>12. Rothermich NO, “Diphenylhydantoin Intoxication,” <i>Lancet</i>, 1966, ii:640.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","5557":"<p><b>Title</b> FLUoxetine / Peginterferon Alfa-2b</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Peginterferon Alfa-2b may decrease the serum concentration of FLUoxetine. <b>Severity</b> Moderate <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Monitor for reduced response to fluoxetine when used together with peginterferon alfa-2b.</p> \n<p><b>Discussion</b> In a study of 20 patients with previously untreated hepatitis C, treatment with peginterferon alfa-2b (1 mcg/kg weekly) decreased fluoxetine (40 mg daily) half-life by 30% without a significant impact on other pharmacokinetic variables.<sup>1</sup> <br><br>It is uncertain whether this possible interaction results from a direct action of peginterferon alfa-2b on CYP2C9 or if another mechanism (e.g. disease related changes in CYP function) may be responsible. Peginterferon alfa-2b prescribing information indicates that treatment was associated with an average 28% increase in CYP2C9 activity in a clinical study (determined using tolbutamide metabolism), although this study was also conducted in subjects with hepatitis C.<sup>2</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Furlanut M, Soardo G, Donnini D, et al, “Fluoxetine Disposition in Patients With Chronic Hepatitis C Treated With Interferon-alpha,” <i>Clin Pharmacokinet</i>, 2010, 49(11):767-72. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=20923249\">[PubMed 20923249]</a></p>\n<p>2. Prescribing information. PegIntron (peginterferon alfa-2b). Kenilworth, NJ: Schering-Plough Corporation, 12/2008.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","5558":"<p><b>Title</b> Benzodiazepines / OLANZapine</p> \n<p><span style=\"color: red; font-weight: bold\">Dependencies</span> </p>\n<ul>\n <li><p><b>Route</b>: Clinical significance and severity of this interaction may be lower with oral olanzapine and/or oral benzodiazepines. Olanzapine prescribing information specifically recommends avoiding the (route-specific) combination of IM olanzapine with a parenteral benzodiazepine.</p></li>\n</ul>\n<p></p> \n<p><b>Risk Rating</b> X: Avoid combination</p> \n<p><b>Summary</b> OLANZapine may enhance the adverse/toxic effect of Benzodiazepines. <b>Severity</b> Major <b>Reliability Rating</b> Good </p> \n<p><b>Patient Management</b> Olanzapine prescribing information recommends to avoid concomitant use of parenteral benzodiazepines and intramuscular (IM) olanzapine due to risks of additive adverse effects (e.g., cardiorespiratory depression, excessive sedation). Additive pharmacologic effects might also be expected with oral use of these agents, but specific recommendations for management are lacking.</p>\n<div>\n <p><b>Benzodiazepines Interacting Members</b> ALPRAZolam, Bromazepam, ChlordiazePOXIDE, CloBAZam, ClonazePAM, Clorazepate, DiazePAM, Estazolam, Ethyl Loflazepate, Etizolam, Flunitrazepam, Flurazepam, Loprazolam, LORazepam, Lormetazepam, Midazolam, Nitrazepam, Nordazepam, Oxazepam, Prazepam, Quazepam, Temazepam, Tofisopam, Triazolam</p>\n</div> \n<p><b>Discussion</b> An analysis of safety data maintained by Eli Lilly &amp; Co., found 160 case reports of adverse events (including 29 fatalities) temporally associated with intramuscular (IM) olanzapine therapy between January 1, 2004 and September 30, 2005.<sup>1</sup> Concomitant use of IM olanzapine and benzodiazepines [oral, intravenous (IV) or IM] with or without other antipsychotic agents was noted in 24 of the 29 fatal events. The presence of underlying comorbidities and use of polypharmacy however makes it difficult establishing a causal relationship between treatment and event. <br><br>A case report describes a 31 year old female who fainted and lost consciousness for approximately two hours following oral administration of lorazepam (2.5 mg single dose) and olanzapine (25 mg in divided doses).<sup>2</sup> The patient was found to be hypotensive (BP 55/42) while unconscious. Olanzapine prescribing information recommends avoiding concomitant administration of IM olanzapine with parenteral benzodiazepines due to the risk of excessive sedation and cardiorespiratory depression.<sup>3</sup> The prescribing information provides no specific recommendations regarding oral administration of olanzapine and benzodiazepines, though it would seem prudent to consider the potential for additive pharmacologic effects with oral administration as well.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Marder SR, Sorsaburu S, Dunayevich E, et al, “Case Reports of Postmarketing Adverse Event Experiences With Olanzapine Intramuscular Treatment in Patients With Agitation,” <i>J Clin Psychiatry</i>, 2010, 71(4):433-41. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=20156413\">[PubMed 20156413]</a></p>\n<p>2. Berg JE, Slatsve K, Bjorland S, et al, “An Unexpected Reaction To Treatment With Benzodiazepines And Olanzapine In A Woman With A Manic Condition,” <i>Clin Neuropsychiatry</i>, 2009, 6(1):35-8. </p>\n<p>3. Prescribing information. Zyprexa (olanzapine). Indianapolis, IN: Eli Lilly and Company, May 2010.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","5562":"<p><b>Title</b> Dexamethasone (Systemic) / CycloSPORINE (Systemic)</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Dexamethasone (Systemic) may decrease the serum concentration of CycloSPORINE (Systemic). Dexamethasone (Systemic) may increase the serum concentration of CycloSPORINE (Systemic). CycloSPORINE (Systemic) may increase the serum concentration of Dexamethasone (Systemic). <b>Severity</b> Moderate <b>Reliability Rating</b> Good </p> \n<p><b>Patient Management</b> Monitor for changes in cyclosporine concentrations (likely an initial increase and possibly decreased thereafter), and for toxic effects of dexamethasone and/or cyclosporine, if these agents are used concomitantly.</p> \n<p><b>Discussion</b> Several studies have reported decreased clearance of prednisolone (25% to 30%) in organ transplant recipients receiving cyclosporine.<sup>1,2,3</sup> Cushingoid symptoms have been seen in association with this interaction.<sup>4</sup> In like fashion, increased serum cyclosporine concentrations (as much as 100%) and decreased clearance have been reported in patients while receiving prednisone or methylprednisolone.<sup>4,5,6,7,8,9</sup><br><br>Although the preponderance of published evidence points to an interaction between cyclosporine and prednisolone, three small studies have not a shown significant drug interaction.<sup>10,11,12</sup> It has been proposed that the drug interaction may be dependent on dose, route, disease course, or other factors but these factors have not been the subject of further study.<br><br>While multiple animal and in vitro studies generally support these reported effects of cyclosporine on corticosteroid concentrations and/or distribution,<sup>13,14,15,16</sup> several animal studies have reported that concurrent administration of the glucocorticoids dexamethasone and methylprednisolone with cyclosporine was associated with decreased cyclosporine absorption and/or bioavailability,<sup>17,18,19</sup> increased cyclosporine metabolism and/or clearance,<sup>19,20,21</sup> and decreased cyclosporine concentrations.<sup>19,22</sup> Of note, one study found that only higher-dose dexamethasone was associated with an increased cyclosporine clearance and decreased cyclosporine concentrations after intravenous cyclosporine administration, whereas the bioavailability of orally administered cyclosporine was significantly reduced by both lower- and higher-dose dexamethasone.<sup>19</sup> This apparent dose-dependent impact is supported by the finding in other studies that only higher-dose steroids have a significant impact on CYP3A (enzyme that is at least partially responsible for cyclosporine metabolism) activity/expression.<sup>17,20</sup><br><br>The exact explanation for these discrepant findings regarding the impact of corticosteroids on cyclosporine pharmacokinetics is unknown. Initial inhibition of cyclosporine CYP3A metabolism via competitive inhibition by corticosteroids, which are also CYP3A substrates may explain the observed increases in cyclosporine concentrations after initiation of corticosteroids. With longer-term concurrent use, the expected effects include induction of p-glycoprotein-mediated cyclosporine efflux, resulting in decreased cyclosporine absorption/bioavailability (at both lower and higher steroid doses), and induction of cyclosporine metabolism via CYP3A (primarily in the intestine, and likely only observed at higher steroid doses).<br><br>The most likely mechanism of how cyclosporine impacts corticosteroids is inhibition of p-glycoprotein-mediated corticosteroid efflux by cyclosporine. As a result, steroid concentrations in plasma, specific tissues/organs (e.g., brain), and/or cells (e.g., lymphocytes) may be increased, including most notably in those tissues/cells that express high levels of p-glycoprotein.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Langhoff E, Madsen S, Olgaard K, et al, “Clinical Results and Cyclosporine Effect on Prednisolone Metabolism,” <i>Kidney Int</i>, 1984, 26:642. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=3887391\">[PubMed 3887391]</a></p>\n<p>2. Langhoff E, Madsen S, Flachs H, et al, “Inhibition of Prednisolone Metabolism by Cyclosporine in Kidney-Transplanted Patients,” <i>Transplantation</i>, 1985, 39:107-9. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=3880958\">[PubMed 3880958]</a></p>\n<p>3. Ost L, “Impairment of Prednisolone Metabolism by Cyclosporine Treatment in Renal Graft Recipients,” <i>Transplantation</i>, 1987, 44(4):533-5. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=3313841\">[PubMed 3313841]</a></p>\n<p>4. Ost L, Klintmalm G, and Ringden O, “Mutual Interaction between Prednisolone and Cyclosporine in Renal Transplant Patients,” <i>Transplant Proc</i>, 1985, 17:1252-5.</p>\n<p>5. Hricik DE, Moritz C, Mayes JT, et al, “Association of the Absence of Steroid Therapy With Increased Cyclosporine Blood Levels in Renal Transplant Recipients,” <i>Transplantation</i>, 1990, 49:221-3. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=2301016\">[PubMed 2301016]</a></p>\n<p>6. Klintmalm G and Sawe J, “High Dose Methylprednisolone Increases Plasma Cyclosporine Levels in Renal Transplant Recipients,” <i>Lancet</i>, 1984, i:731. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=6143058\">[PubMed 6143058]</a></p>\n<p>7. Durrant S, Chipping PM, Palmer S, et al, “Cyclosporine A, Methylprednisolone, and Convulsions,” <i>Lancet</i>, 1982, ii:829-30. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=6126705\">[PubMed 6126705]</a></p>\n<p>8. Hall TG, “Effect of Methylprednisolone on Cyclosporine Blood Levels,” <i>Pharmacotherapy</i>, 1990, 10:248. </p>\n<p>9. Ptachcinski RJ, Venkataramanan R, Burckart GJ, et al, “Cyclosporine--High-Dose Steroid Interaction in Renal Transplant Recipients: Assessment by HPLC,” <i>Transplant Proc</i>, 1987, 19(1 Pt 2):1728-9. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=3274417\">[PubMed 3274417]</a></p>\n<p>10. Frey FJ, Schnetzer A, Horber FF, et al, “Evidence that Cyclosporine Does Not Affect the Metabolism of Prednisolone after Renal Transplantation,” <i>Transplantation</i>, 1987, 43(4):494-8. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=3554641\">[PubMed 3554641]</a></p>\n<p>11. Rocci ML Jr, Tietze KJ, Lee J, et al, “The Effect of Cyclosporine on the Pharmacokinetics of Prednisolone in Renal Transplant Patients,” <i>Transplantation</i>, 1988, 45(3):656-60. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=3279590\">[PubMed 3279590]</a></p>\n<p>12. Arnold JC, O'Grady JG, Tredger JM, et al, “Effects of Low-Dose Prednisolone on Cyclosporine Pharmacokinetics in Liver Transplant Recipients: Radioimmunoassay with Specific and Non-Specific Monoclonal Antibodies,” <i>Eur J Clin Pharmacol</i>, 1990, 39(3):257-60. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=2257862\">[PubMed 2257862]</a></p>\n<p>13. Bernards CM, “Cyclosporine-A-Mediated Inhibition of P-glycoprotein Increases Methylprednisolone Entry into the Central Nervous System,” <i>Spinal Cord</i>, 2006, 44(7):414-20. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=16331311\">[PubMed 16331311]</a></p>\n<p>14. Mark PJ, Waddell BJ, “P-glycoprotein Restricts Access of Cortisol and Dexamethasone to the Glucocorticoid Receptor in Placental BeWo Cells,” <i>Endocrinology</i>, 2006, 147(11):5147-52. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=16873536\">[PubMed 16873536]</a></p>\n<p>15. Tsujimura S, Saito K, Nakayamada S, et al, “Transcriptional Regulation of Multidrug Resistance-1 Gene by Interleukin-2 in Lymphocytes,” <i>Genes Cells</i>, 2004, 9(12):1265-73. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=15569157\">[PubMed 15569157]</a></p>\n<p>16. Maillefert JF, Duchamp O, Solary E, et al, “Effects of Cyclosporin at Various Concentrations on Dexamethasone Intracellular Uptake in Multidrug Resistant Cells,” <i>Ann Rheum Dis</i>, 2000, 59(2):146-8. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=10666173\">[PubMed 10666173]</a></p>\n<p>17. Jin M, Shimada T, Yokogawa K, et al, “Contributions of Intestinal P-glycoprotein and CYP3A to Oral Bioavailability of Cyclosporin A in Mice Treated With or Without Dexamethasone,” <i>Int J Pharm</i>, 2006, 309(1-2):81-6. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=16384676\">[PubMed 16384676]</a></p>\n<p>18. Jin M, Shimada T, Yokogawa K, et al, “Site-Dependent Contributions of P-glycoprotein and CYP3A to Cyclosporin A Absorption, and Effect of Dexamethasone in Small Intestine of Mice,” <i>Biochem Pharmacol</i>, 2006, 72(8):1042-50. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=16939683\">[PubMed 16939683]</a></p>\n<p>19. Yokogawa K, Shimada T, Higashi Y, et al, “Modulation of mdr1a and CYP3A Gene Expression in the Intestine and Liver as Possible Cause of Changes in the Cyclosporin A Disposition Kinetics by Dexamethasone,” <i>Biochem Pharmacol</i>, 2002, 63(4):777-83. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=11992648\">[PubMed 11992648]</a></p>\n<p>20. Konishi H, Sumi M, Shibata N, et al, “Influence of Intravenous Methylprednisolone Pulse Treatment on the Disposition of Ciclosporin and Hepatic CYP3A Activity in Rats,” <i>J Pharm Pharmacol</i>, 2004, 56(4):477-83. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=15099443\">[PubMed 15099443]</a></p>\n<p>21. Kolars JC, Stetson PL, Rush BD, et al, “Cyclosporine Metabolism by P450IIIA in Rat Enterocytes--Another Determinant of Oral Bioavailability?” <i>Transplantation</i>, 1992, 53(3):596-602. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=1549853\">[PubMed 1549853]</a></p>\n<p>22. Konishi H, Sumi M, Shibata N, et al, “Decrease in Oral Bioavailability of Ciclosporin by Intravenous Pulse of Methylprednisolone Succinate in Rats,” <i>J Pharm Pharmacol</i>, 2004, 56(10):1259-66. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=15482640\">[PubMed 15482640]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","5564":"<p><b>Title</b> Everolimus / Grapefruit Juice</p> \n<p></p> \n<p><b>Risk Rating</b> X: Avoid combination</p> \n<p><b>Summary</b> Grapefruit Juice may increase the serum concentration of Everolimus. <b>Severity</b> Major <b>Reliability Rating</b> Fair: Reported in the prescribing information </p> \n<p><b>Patient Management</b> Avoid concurrent use of everolimus with grapefruit juice.</p> \n<p><b>Discussion</b> Due to the potential for grapefruit juice to increase everolimus concentrations, concurrent use of grapefruit juice with everolimus is not recommended.<sup>1,2</sup><br><br>Everolimus is a substrate for CYP3A4 and p-glycoprotein, and grapefruit juice is an inhibitor of both CYP3A4 and p-glycoprotein.<sup>1,2</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Prescribing information. Afinitor (everolimus). East Hanover, NJ: Novartis Pharmaceuticals Corporation, 10/2010.</p>\n<p>2. Prescribing information. Zortress (everolimus). East Hanover, NJ: Novartis Pharmaceuticals Corporation, 03/2010.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","5565":"<p><b>Title</b> Everolimus / St John's Wort</p> \n<p></p> \n<p><b>Risk Rating</b> X: Avoid combination</p> \n<p><b>Summary</b> St John's Wort may decrease the serum concentration of Everolimus. <b>Severity</b> Major <b>Reliability Rating</b> Fair: Reported in the prescribing information </p> \n<p><b>Patient Management</b> Concurrent use of Afinitor branded everolimus with St Johns wort is not recommended. Zortress branded everolimus prescribing information cautions that use with St Johns wort may decrease everolimus concentrations, though no specific dose adjustments are recommended. Monitor patient response and everolimus trough concentrations (optimally 4-5 days after initiation of a p-glycoprotein inhibitor), and adjust everolimus dose as necessary.</p> \n<p><b>Discussion</b> According to prescribing information for the Afinitor branded everolimus product, concurrent use of St Johns wort with everolimus is not recommended due to the potential for St Johns wort to variably decrease everolimus concentrations.<sup>1</sup> Though prescribing information for the Zortress branded everolimus product does not specifically recommend against such concurrent use, it does caution that St Johns wort may interact with everolimus, potentially requiring additional monitoring and dose adjustment.<sup>2</sup><br><br>Everolimus is a substrate for CYP3A4 and p-glycoprotein, and St Johns wort is an inducer of both CYP3A4 and p-glycoprotein.<sup>1,2</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Prescribing information. Afinitor (everolimus). East Hanover, NJ: Novartis Pharmaceuticals Corporation, 10/2010.</p>\n<p>2. Prescribing information. Zortress (everolimus). East Hanover, NJ: Novartis Pharmaceuticals Corporation, 03/2010.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","5566":"<p><b>Title</b> CARBOplatin / SORAfenib</p> \n<p><span style=\"color: red; font-weight: bold\">Dependencies</span> </p>\n<ul>\n <li><p><b>Additional drug/group</b>: Concurrent use of sorafenib with carboplatin is contraindicated, but only when paclitaxel is also used. This contraindication is also specific to patients with squamous cell lung cancer.</p></li>\n</ul>\n<p></p> \n<p><b>Risk Rating</b> X: Avoid combination</p> \n<p><b>Summary</b> SORAfenib may enhance the adverse/toxic effect of CARBOplatin. <b>Severity</b> Major <b>Reliability Rating</b> Good </p> \n<p><b>Patient Management</b> Concurrent use of sorafenib with carboplatin and paclitaxel in patients with squamous cell lung cancer is contraindicated. The use of this combination in other settings is not specifically contraindicated, but any such use should be approached with added caution.</p> \n<p><b>Discussion</b> Sorafenib prescribing information cautions that use with carboplatin and paclitaxel in patients with squamous cell lung cancer is contraindicated.<sup>1</sup> This contraindication is based primarily on a trial that of 926 patients with stage IIIB-IV non-small cell lung cancer who were randomized to sorafenib or placebo added to carboplatin (AUC 6)and paclitaxel (200 mg/m<sup>2</sup>). The trial was stopped early because survival was not improved by the addition of sorafenib, and a subgroup analysis of patients with squamous cell lung cancer revealed increased mortality with concurrent sorafenib [HR (95% CI) = 1.85 (1.22-2.81)].<sup>2</sup> Sorafenib prescribing information also notes that this combination was associated with a mean 30% increase in paclitaxel AUC, 50% increase in sorafenib AUC, and no significant change in carboplatin exposure.<sup>1</sup><br><br>Several other small to moderate sized clinical trials have also evaluated this combination, with mixed findings. One small study of patients with advanced ovarian carcinoma was stopped after the enrollment of only 4 patients due to severe toxicities; no patients completed the entire planned treatment regimen.<sup>3</sup> Conversely, other studies have found this combination to be associated with a clinically acceptable toxicity profile, though not always with any evidence of clinical improvement.<sup>4,5,6</sup> Of note, two of these studies noted no evidence of any significant pharmacokinetic changes with this combination,<sup>4,5</sup> which is somewhat conflicting with findings reported in the sorafenib prescribing information.<br><br>The specific mechanism(s) for this observed interaction between sorafenib and combined carboplatin and paclitaxel is not clear.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Prescribing information. Nexavar (sorafenib). Wayne, NJ: Bayer HealthCare Pharmaceuticals Inc., 10/2010.</p>\n<p>2. Scagliotti G, Novello S, von Pawel J, et al, “Phase III Study of Carboplatin and Paclitaxel Alone or with Sorafenib in Advanced Non-Small-Cell Lung Cancer,” <i>J Clin Oncol</i>, 2010, 28(11):1835-42. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=20212250\">[PubMed 20212250]</a></p>\n<p>3. Polcher M, Eckhardt M, Coch C, et al, “Sorafenib in combination with carboplatin and paclitaxel as neoadjuvant chemotherapy in patients with advanced ovarian cancer,” <i>Cancer Chemother Pharmacol</i>, 2010, 66(1):203-7. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=20204367\">[PubMed 20204367]</a></p>\n<p>4. Flaherty KT, Schiller J, Schuchter LM, et al, “A Phase I Trial of the Oral, Multikinase Inhibitor Sorafenib in Combination with Carboplatin and Paclitaxel,” <i>Clin Cancer Res</i>, 2008, 14(15):4836-42. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=18676756\">[PubMed 18676756]</a></p>\n<p>5. Hauschild A, Agarwala SS, Trefzer U, et al, “Results of a Phase III, Randomized, Placebo-Controlled Study of Sorafenib in Combination with Carboplatin and Paclitaxel as Second-Line Treatment in Patients with Unresectable Stage III or Stage IV Melanoma,” <i>J Clin Oncol</i>, 2009, 27(17):2823-30. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=19349552\">[PubMed 19349552]</a></p>\n<p>6. Okamoto I, Miyazaki M, Morinaga R, et al, “Phase I Clinical and Pharmacokinetic Study of Sorafenib in Combination with Carboplatin and Paclitaxel in Patients with Advanced Non-Small Cell Lung Cancer,” <i>Invest New Drugs</i>, 2010, 28(6):844-53. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=19760364\">[PubMed 19760364]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","5567":"<p><b>Title</b> PACLitaxel (Conventional) / SORAfenib</p> \n<p><span style=\"color: red; font-weight: bold\">Dependencies</span> </p>\n<ul>\n <li><p><b>Additional drug/group</b>: Concurrent use of sorafenib with paclitaxel is contraindicated, but only when carboplatin is also used. This contraindication is also specific to patients with squamous cell lung cancer.</p></li>\n</ul>\n<p></p> \n<p><b>Risk Rating</b> X: Avoid combination</p> \n<p><b>Summary</b> SORAfenib may enhance the adverse/toxic effect of PACLitaxel (Conventional). <b>Severity</b> Major <b>Reliability Rating</b> Good </p> \n<p><b>Patient Management</b> Concurrent use of sorafenib with carboplatin and paclitaxel in patients with squamous cell lung cancer is contraindicated. The use of this combination in other settings is not specifically contraindicated, but any such use should be approached with added caution.</p> \n<p><b>Discussion</b> Sorafenib prescribing information cautions that use with carboplatin and paclitaxel in patients with squamous cell lung cancer is contraindicated.<sup>1</sup> This contraindication is based primarily on a trial that of 926 patients with stage IIIB-IV non-small cell lung cancer who were randomized to sorafenib or placebo added to carboplatin (AUC 6)and paclitaxel (200 mg/m<sup>2</sup>). The trial was stopped early because survival was not improved by the addition of sorafenib, and a subgroup analysis of patients with squamous cell lung cancer revealed increased mortality with concurrent sorafenib [HR (95% CI) = 1.85 (1.22-2.81)].<sup>2</sup> Sorafenib prescribing information also notes that this combination was associated with a mean 30% increase in paclitaxel AUC, 50% increase in sorafenib AUC, and no significant change in carboplatin exposure.<sup>1</sup><br><br>Several other small to moderate sized clinical trials have also evaluated this combination, with mixed findings. One small study of patients with advanced ovarian carcinoma was stopped after the enrollment of only 4 patients due to severe toxicities; no patients completed the entire planned treatment regimen.<sup>3</sup> Conversely, other studies have found this combination to be associated with a clinically acceptable toxicity profile, though not always with any evidence of clinical improvement.<sup>4,5,6</sup> Of note, two of these studies noted no evidence of any significant pharmacokinetic changes with this combination,<sup>4,5</sup> which is somewhat conflicting with findings reported in the sorafenib prescribing information.<br><br>The specific mechanism(s) for this observed interaction between sorafenib and combined carboplatin and paclitaxel is not clear.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Prescribing information. Nexavar (sorafenib). Wayne, NJ: Bayer HealthCare Pharmaceuticals Inc., 10/2010.</p>\n<p>2. Scagliotti G, Novello S, von Pawel J, et al, “Phase III Study of Carboplatin and Paclitaxel Alone or with Sorafenib in Advanced Non-Small-Cell Lung Cancer,” <i>J Clin Oncol</i>, 2010, 28(11):1835-42. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=20212250\">[PubMed 20212250]</a></p>\n<p>3. Polcher M, Eckhardt M, Coch C, et al, “Sorafenib in combination with carboplatin and paclitaxel as neoadjuvant chemotherapy in patients with advanced ovarian cancer,” <i>Cancer Chemother Pharmacol</i>, 2010, 66(1):203-7. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=20204367\">[PubMed 20204367]</a></p>\n<p>4. Flaherty KT, Schiller J, Schuchter LM, et al, “A Phase I Trial of the Oral, Multikinase Inhibitor Sorafenib in Combination with Carboplatin and Paclitaxel,” <i>Clin Cancer Res</i>, 2008, 14(15):4836-42. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=18676756\">[PubMed 18676756]</a></p>\n<p>5. Hauschild A, Agarwala SS, Trefzer U, et al, “Results of a Phase III, Randomized, Placebo-Controlled Study of Sorafenib in Combination with Carboplatin and Paclitaxel as Second-Line Treatment in Patients with Unresectable Stage III or Stage IV Melanoma,” <i>J Clin Oncol</i>, 2009, 27(17):2823-30. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=19349552\">[PubMed 19349552]</a></p>\n<p>6. Okamoto I, Miyazaki M, Morinaga R, et al, “Phase I Clinical and Pharmacokinetic Study of Sorafenib in Combination with Carboplatin and Paclitaxel in Patients with Advanced Non-Small Cell Lung Cancer,” <i>Invest New Drugs</i>, 2010, 28(6):844-53. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=19760364\">[PubMed 19760364]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","5568":"<p><b>Title</b> SORAfenib / Neomycin</p> \n<p><span style=\"color: red; font-weight: bold\">Dependencies</span> </p>\n<ul>\n <li><p><b>Route</b>: This interaction appears to be limited to oral neomycin.</p></li>\n</ul>\n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Neomycin may decrease the serum concentration of SORAfenib. <b>Severity</b> Moderate <b>Reliability Rating</b> Fair: Reported in the prescribing information </p> \n<p><b>Patient Management</b> Carefully consider the need for concurrent use of these agents, and if this combination is used, monitor patients more closely for inadequate clinical response to sorafenib.</p> \n<p><b>Discussion</b> According to data in the sorafenib prescribing information, sorafenib AUC was an average of 54% lower when administered to healthy volunteers who had been treated with oral neomycin (1 g three times/day x 5 days).<sup>1</sup><br><br>The specific mechanism of this apparent interaction is unknown.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Prescribing information. Nexavar (sorafenib). Wayne, NJ: Bayer HealthCare Pharmaceuticals Inc., 10/2010.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","5578":"<p><b>Title</b> Pancuronium / Theophylline Derivatives</p> \n<p></p> \n<p><b>Risk Rating</b> D: Consider therapy modification</p> \n<p><b>Summary</b> Theophylline Derivatives may enhance the adverse/toxic effect of Pancuronium. Theophylline Derivatives may diminish the neuromuscular-blocking effect of Pancuronium. <b>Severity</b> Major <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Pancuronium dosage adjustment may be necessary to induce paralysis in patients receiving concomitant theophylline derivatives. Monitor closely for adverse effects (e.g., cardiac effects) with concomitant use of these agents.</p>\n<div>\n <p><b>Theophylline Derivatives Interacting Members</b> Acebrophylline, Aminophylline, Dyphylline, Theophylline</p>\n</div> \n<p><b>Discussion</b> Administration of pancuronium (up to 11 mg in one hour) failed to induce paralysis in a 48 year old male receiving continuous intravenous (IV) aminophylline.<sup>1</sup> Prior to the initiation of aminophylline therapy, administration of pancuronium (8 mg) had successfully induced clinical paralysis in this patient. Theophylline prescribing information cautions that the non-depolarizing neuromuscular blocking effects of pancuronium may be antagonized with concomitant use of theophylline and that larger doses of pancuronium may be necessary to achieve neuromuscular blockade.<sup>2</sup> The manufacturer labeling suggests the antagonistic effects may be due to theophylline mediated inhibition of phosphodiesterase.<br><br>As theophylline and pancuronium are associated with cardiac side effects (e.g., tachycardia), it would seem prudent to exercise caution when adjusting pancuronium dosages in patients receiving theophylline derivatives. Tachycardia (HR 180) was observed within minutes of administration of pancuronium (8 mg) in a 61 year old male receiving oral aminophylline therapy.<sup>3</sup> The patient had not experienced tachyarrhythmia when administered pancuronium (without concomitant aminophylline) during a previous hospital stay. While suggesting a drug interaction between the two agents, the authors of this case report acknowledge that pre-existing atrial ectopy and premedication with atropine may have played a predisposing role in the observed tachyarrhythmia.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Daller JA, Erstad B, Rosado L, et al, “Aminophylline Antagonizes the Neuromuscular Blockade of Pancuronium but not Vecuronium,” <i>Crit Care Med</i>, 1991, 19(7):983-5. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=1675977\">[PubMed 1675977]</a></p>\n<p>2. Prescribing information. Uniphyl (theophylline). Stamford, CT: Purdue Pharmaceutical Products L.P., March, 2010.</p>\n<p>3. Belani KG, Anderson WW, and Buckley JJ, “Adverse Drug Interaction Involving Pancuronium and Aminophylline,” <i>Anesth Analg</i>, 1982, 61(5):473-4. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=7199873\">[PubMed 7199873]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","5579":"<p><b>Title</b> Alpha1-Blockers / Alpha1-Blockers</p> \n<p></p> \n<p><b>Risk Rating</b> X: Avoid combination</p> \n<p><b>Summary</b> Alpha1-Blockers may enhance the antihypertensive effect of other Alpha1-Blockers. <b>Severity</b> Major <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Avoid concomitant use of alpha1- blockers. Additive pharmacologic effects (e.g., hypotension, syncope) might be anticipated.</p>\n<div>\n <p><b>Alpha1-Blockers Interacting Members</b> Alfuzosin, Doxazosin, Indoramin, Moxisylyte, Naftopidil, Nicergoline, Phenoxybenzamine, Phentolamine, Prazosin, Silodosin, Tamsulosin, Terazosin</p>\n</div> \n<p><b>Discussion</b> The US prescribing information for several alpha1- blocking agents<sup>1,2,3</sup> recommends against concomitant use with other alpha1- blockers. Alfuzosin Canadian product monograph specifically contraindicates concurrent use with other alpha1- blocking agents.<sup>4</sup> Drug interaction studies between these agents are lacking and additive pharmacologic effects (eg, hypotension, syncope) might be anticipated with concomitant use.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Prescribing information. Uroxatral (alfuzosin). Bridgewater, NJ: Sanofi-Aventis LLC., August 2008.</p>\n<p>2. Prescribing information. Rapaflo (silodosin). Corona, CA: Watson Pharmaceuticals, Inc., September 2008.</p>\n<p>3. Prescribing information. Flomax (tamsulosin). Ridgefield, CT: Boehringer Ingelheim Pharmaceuticals, Inc., March 2008.</p>\n<p>4. Product monograph. APO-Alfuzosin (alfuzosin). Weston, Ontario: Apotex Inc., August 2008.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","5580":"<p><b>Title</b> Warfarin / Mirtazapine</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Mirtazapine may enhance the anticoagulant effect of Warfarin. <b>Severity</b> Moderate <b>Reliability Rating</b> Fair: Reported in the prescribing information </p> \n<p><b>Patient Management</b> Monitor for possible INR elevations in patients treated concomitantly with mirtazapine and warfarin.</p> \n<p><b>Discussion</b> In a study described in mirtazapine prescribing information, administration of mirtazapine (30 mg orally daily) with warfarin increased INR by 0.2 at steady state in 16 healthy volunteers.<sup>1</sup> The mechanism and clinical significance of this interaction are unknown.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Prescribing information. Remeron (mirtazapine). Kenilworth, NJ: Schering-Plough Corporation, 06/2010.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","5581":"<p><b>Title</b> Lactulose / Aluminum Hydroxide</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Aluminum Hydroxide may diminish the therapeutic effect of Lactulose. <b>Severity</b> Moderate <b>Reliability Rating</b> Poor </p> \n<p><b>Patient Management</b> Consider monitoring for decreased therapeutic effects of lactulose in patients treated concomitantly with aluminum hydroxide.</p> \n<p><b>Discussion</b> Prescribing information for lactulose products states that use with a “non-absorbable” antacid may inhibit a desired drop in colonic pH caused by lactulose treatment.<sup>1,2</sup> A study in rats demonstrated that pretreatment with aluminum/magnesium hydroxide prevented this drop in colonic pH.<sup>3</sup> Lactulose prescribing information cites preliminary data in humans indicating a similar effect.<sup>1,2</sup><br><br>Lactulose is broken down into lactic, acetic, and formic acids by colonic bacteria.<sup>1,2</sup> The resultant acidification of the colonic contents may create a pH gradient that extracts ammonia from the blood and traps it in the colon as ammonium, which is subsequently eliminated in stool.<sup>1</sup> Lactulose prescribing information proposes this as the mechanism by which lactulose may work to reduce portal-systemic encephalopathy.<sup>1</sup> Treatment with antacid agents that are incompletely absorbed could theoretically prevent acidification of the colonic contents by lactulose and thereby decrease its effectiveness. The clinical impact of this effect, if any, is unknown. The impact of antacids on laxative effects of lactulose is also unknown.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Prescribing information. Enulose (lactulose). Baltimore, MD: Actavis Mid Atlantic LLC, 01/06.</p>\n<p>2. Prescribing information. Lactulose. Columbus, OH: Roxane Laboratories, Inc, August 2009.</p>\n<p>3. Mann NS, Borkar BB, Narenderan KP, et al, “Effect of Lactulose, Neomycin and Antacid on Colonic pH Recorded Continuously With an Implanted Electrode,” <i>Am J Gastroenterol</i>, 1979, 72(2):141-5. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=38663\">[PubMed 38663]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","5582":"<p><b>Title</b> Lactulose / Magnesium Hydroxide</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Magnesium Hydroxide may diminish the therapeutic effect of Lactulose. <b>Severity</b> Moderate <b>Reliability Rating</b> Poor </p> \n<p><b>Patient Management</b> Consider monitoring for decreased therapeutic effects of lactulose in patients treated concomitantly with magnesium hydroxide.</p> \n<p><b>Discussion</b> Prescribing information for lactulose products states that use with a “non-absorbable” antacid may inhibit a desired drop in colonic pH caused by lactulose treatment.<sup>1,2</sup> A study in rats demonstrated that pretreatment with aluminum/magnesium hydroxide prevented this drop in colonic pH.<sup>3</sup> Lactulose prescribing information cites preliminary data in humans indicating a similar effect.<sup>1,2</sup><br><br>Lactulose is broken down into lactic, acetic, and formic acids by colonic bacteria.<sup>1,2</sup> The resultant acidification of the colonic contents may create a pH gradient that extracts ammonia from the blood and traps it in the colon as ammonium, which is subsequently eliminated in stool.<sup>1</sup> Lactulose prescribing information proposes this as the mechanism by which lactulose may work to reduce portal-systemic encephalopathy.<sup>1</sup> Treatment with antacid agents that are incompletely absorbed could theoretically prevent acidification of the colonic contents by lactulose and thereby decrease its effectiveness. The clinical impact of this effect, if any, is unknown. The impact of antacids on laxative effects of lactulose is also unknown.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Prescribing information. Enulose (lactulose). Baltimore, MD: Actavis Mid Atlantic LLC, 01/06.</p>\n<p>2. Prescribing information. Lactulose. Columbus, OH: Roxane Laboratories, Inc, August 2009.</p>\n<p>3. Mann NS, Borkar BB, Narenderan KP, et al, “Effect of Lactulose, Neomycin and Antacid on Colonic pH Recorded Continuously With an Implanted Electrode,” <i>Am J Gastroenterol</i>, 1979, 72(2):141-5. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=38663\">[PubMed 38663]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","5583":"<p><b>Title</b> Lactulose / Neomycin</p> \n<p></p> \n<p><b>Risk Rating</b> B: No action needed</p> \n<p><b>Summary</b> Neomycin may diminish the therapeutic effect of Lactulose. <b>Severity</b> Minor <b>Reliability Rating</b> Good </p> \n<p><b>Patient Management</b> No action required.</p> \n<p><b>Discussion</b> Prescribing information for lactulose states that use with neomycin may inhibit bacterial activation of lactulose and acidification of the colonic contents.<sup>1</sup> A study in rats demonstrated that pretreatment with neomycin prevented the drop in colonic pH associated with lactulose treatment.<sup>2</sup> <br><br>In a study of 9 patients with chronic portal-systemic encephalopathy, lactulose (15 g orally three times daily) and neomycin (250 mg orally four times daily) separately resulted in approximate 14% decreases in arterial ammonia concentrations.<sup>3</sup> Addition of lactulose to ongoing neomycin treatment resulted in an approximate 50% additional decrease in arterial ammonia. Lactulose administration caused a drop in colonic pH to below 5 regardless of neomycin coadministration. In a study of 6 patients with stable cirrhosis, addition of neomycin (4 g orally daily) to lactulose (36-80 g orally daily, titrated to 2-4 loose bowel movements daily) increased fecal nitrogen excretion and decreased colonic urea production (a proposed marker of intestinal ammonia production).<sup>4</sup> A follow up study of 8 patients with stable cirrhosis showed that addition of neomycin (4 g orally daily) to lactulose (average 63 g orally daily) increased fecal nitrogen content and decreased urea production without affecting stool pH.<sup>5</sup> <br><br>Lactulose is broken down into lactic, acetic, and formic acids by colonic bacteria.<sup>6</sup> The resultant acidification of the colonic contents may create a pH gradient that favors extraction of ammonia from the blood, where it can be subsequently trapped as ammonium and eliminated in stool.<sup>1</sup> Theoretically, eradication of lactulose-fermenting bacteria could decrease lactulose conversion and thereby decrease its therapeutic effects.<sup>1</sup> However, preliminary data indicate that neomycin may not eradicate all lactulose-fermenting colonic bacteria,<sup>7,8</sup> there are several proposed mechanisms of action for lactulose which would not require bacterial fermentation,<sup>7,8</sup> and the preponderance of clinical data indicate a likely beneficial rather than detrimental effect of coadministration.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Prescribing information. Enulose (lactulose). Baltimore, MD: Actavis Mid Atlantic LLC, 01/06.</p>\n<p>2. Mann NS, Borkar BB, Narenderan KP, et al, “Effect of Lactulose, Neomycin and Antacid on Colonic pH Recorded Continuously With an Implanted Electrode,” <i>Am J Gastroenterol</i>, 1979, 72(2):141-5. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=38663\">[PubMed 38663]</a></p>\n<p>3. Pirotte J, Guffens JM and Devos J, “Comparative Study of Basal Arterial Ammonemia and of Orally-Induced Hyperammonemia in Chronic Portal Systemic Encephalopathy, Treated With Neomycin, Lactulose, and an Association of Neomycin and Lactulose,” <i>Digestion</i>, 1974, 10(6):435-44. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=4448315\">[PubMed 4448315]</a></p>\n<p>4. Weber FL Jr, Fresard KM and Lally BR, “Effects of Lactulose and Neomycin on Urea Metabolism in Cirrhotic Subjects,” <i>Gastroenterology</i>, 1982, 82(2):213-7. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=7054022\">[PubMed 7054022]</a></p>\n<p>5. Weber FL Jr, Banwell JG, Fresard KM, et al, “Nitrogen in Fecal Bacterial, Fiber, and Soluble Fractions of Patients With Cirrhosis: Effects of Lactulose and Lactulose Plus Neomycin,” <i>J Lab Clin Med</i>, 1987, 110(3):259-63. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=3611949\">[PubMed 3611949]</a></p>\n<p>6. Prescribing information. Lactulose. Columbus, OH: Roxane Laboratories, Inc, August 2009.</p>\n<p>7. Capocaccia L and Riggio O, “Nonabsorbable Disaccharides Plus Neomycin in Hepatic Encephalopathy: Do They Enhance Each Other?” <i>Hepatology</i>, 1990, 12(2):368-70. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=2391075\">[PubMed 2391075]</a></p>\n<p>8. Martin AJ, “Portal Systemic Encephalopathy--Should Lactulose and Neomycin be Used Together,” <i>Br J Clin Pract</i>, 1981, 35(9):323-4. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=7326185\">[PubMed 7326185]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","5584":"<p><b>Title</b> CarBAMazepine / Zolpidem</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Zolpidem may enhance the CNS depressant effect of CarBAMazepine. CarBAMazepine may decrease the serum concentration of Zolpidem. <b>Severity</b> Moderate <b>Reliability Rating</b> Good </p> \n<p><b>Patient Management</b> Monitor response to zolpidem in patients receiving carbamazepine. Carbamazepine decreases zolpidem serum concentrations but may enhance its CNS depressant effects, the net impact of which is unknown. A reduced Intermezzo brand sublingual zolpidem dose of 1.75 mg is recommended for men using sublingual zolpidem who are also receiving other CNS depressants. No specific dose reduction is recommended for women using Intermezzo together with other CNS depressants.</p> \n<p><b>Discussion</b> In a clinical study of 18 healthy volunteers, administration of carbamazepine (400 mg orally daily for 15 days) decreased the maximum concentration and AUC of zolpidem (5 mg single oral dose) by 41% and 57%, respectively.<sup>1</sup><br><br>The likely primary mechanism of pharmacokinetic interaction between these agents is carbamazepine induction of CYP3A4 mediated zolpidem metabolism. Both drugs are also associated with CNS depressant effects which may increase with coadministration.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Vlase L, Popa A, Neag M, et al, “Pharmacokinetic Interaction Between Zolpidem and Carbamazepine in Healthy Volunteers,” <i>J Clin Pharmacol</i>, 2010 Nov 22. Epub. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=21098143\">[PubMed 21098143]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","5587":"<p><b>Title</b> Ulipristal / CYP3A4 Inducers (Strong)</p> \n<p></p> \n<p><b>Risk Rating</b> X: Avoid combination</p> \n<p><b>Summary</b> CYP3A4 Inducers (Strong) may decrease the serum concentration of Ulipristal. <b>Severity</b> Major <b>Reliability Rating</b> Fair: Reported in the prescribing information </p> \n<p><b>Patient Management</b> Avoid the use of ulipristal in combination with strong CYP3A4 inducers. Concurrent use may result in impaired ulipristal clinical effectiveness.</p>\n<div>\n <p><b>CYP3A4 Inducers (Strong) Interacting Members</b> Apalutamide, CarBAMazepine, Enzalutamide, Fosphenytoin, Lumacaftor, Mitotane, PHENobarbital, Phenytoin, Primidone, RifAMPin</p>\n</div> \n<p><b>Discussion</b> In a clinical study summarized in ulipristal US prescribing information, coadministration of rifampin (600 mg daily for 9 days) decreased the maximum concentration and AUC of ulipristal acetate by 90% and 93%, respectively, and those of its active monodemethyl metabolite by 84% and 90%, respectively.<sup>1,2</sup> The suspected primary mechanism of this interaction is rifampin induction of CYP3A4 mediated ulipristal metabolism. Ulipristal US and Canadian product labels recommend avoiding its use in combination with any strong CYP3A4 inducer.<sup>1,2</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. <i>ella</i> (ulipristal acetate) [prescribing information]. Morristown, NJ: Watson Pharma, Inc; June 2014.</p>\n<p>2. <i>Fibristal</i> (ulipristal acetate) [product monograph]. Mississauga, ON: Actavis Specialty Pharmaceuticals Co; June 2013.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","5591":"<p><b>Title</b> Fingolimod / Verapamil</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Verapamil may enhance the bradycardic effect of Fingolimod. <b>Severity</b> Moderate <b>Reliability Rating</b> Fair: Reported in the prescribing information </p> \n<p><b>Patient Management</b> Obtain a baseline ECG, if no recent ECG is available, in patients initiating fingolimod during treatment with verapamil. Monitor for development of bradycardia and atrioventricular block during concomitant treatment, particularly in the first 6 hours following the first dose of fingolimod (or within the first 6 hours following the first fingolimod dose after a treatment interruption of 2 weeks or greater).</p> \n<p><b>Discussion</b> Prescribing information for fingolimod recommends obtaining a baseline ECG, if no recent ECG is available, in patients initiating fingolimod who are at high risk of bradycardia (e.g. those receiving verapamil).<sup>1</sup> Carefully monitor for development of bradycardia and atrioventricular block, particularly in the first 6 hours following the first dose of fingolimod (or within the first 6 hours following the first fingolimod dose after a treatment interruption of 2 weeks or greater).</p> \n<p><b>Footnotes</b> </p>\n<p>1. Prescribing information. Gilenya (fingolimod). East Hanover, NJ: Novartis Pharmaceuticals Corporation, September 2010.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","5592":"<p><b>Title</b> Fingolimod / DilTIAZem</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> DilTIAZem may enhance the bradycardic effect of Fingolimod. <b>Severity</b> Moderate <b>Reliability Rating</b> Fair: Reported in the prescribing information </p> \n<p><b>Patient Management</b> Obtain a baseline ECG, if no recent ECG is available, in patients initiating fingolimod during treatment with diltiazem. Monitor for development of bradycardia and atrioventricular block, particularly in the first 6 hours following the first dose of fingolimod (or within the first 6 hours following the first fingolimod dose after a treatment interruption of 2 weeks or greater).</p> \n<p><b>Discussion</b> Prescribing information for fingolimod recommends obtaining a baseline ECG, if no recent ECG is available, in patients initiating fingolimod who are at high risk of bradycardia (e.g. those receiving diltiazem).<sup>1</sup> Carefully monitor for development of bradycardia and atrioventricular block, particularly in the first 6 hours following the first dose of fingolimod (or within the first 6 hours following the first fingolimod dose after a treatment interruption of 2 weeks or greater).</p> \n<p><b>Footnotes</b> </p>\n<p>1. Prescribing information. Gilenya (fingolimod). East Hanover, NJ: Novartis Pharmaceuticals Corporation, September 2010.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","5593":"<p><b>Title</b> CycloSPORINE (Systemic) / Modafinil</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Modafinil may decrease the serum concentration of CycloSPORINE (Systemic). <b>Severity</b> Moderate <b>Reliability Rating</b> Fair: Reported in the prescribing information </p> \n<p><b>Patient Management</b> Monitor cyclosporine concentrations closely when starting or stopping concurrent modafinil. Monitor patients closely for signs/symptoms of diminished clinical response to cyclosporine with use of this combination.</p> \n<p><b>Discussion</b> According to modafinil prescribing information, a patient experienced a 50% reduction in cyclosporine concentrations following one month of concurrent modafinil (200 mg/day).<sup>1</sup> Though specific study data with cyclosporine are not available, modafinil has been shown to modestly reduce the concentrations of other drugs that, like cyclosporine, are metabolized by CYP3A4.<sup>1,2,3</sup><br><br>The likely mechanism of this apparent interaction is induction of CYP3A4-mediated drug metabolism by modafinil.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Prescribing information. Provigil (modafinil). Frazer, PA: Cephalon, Inc., October 2010.</p>\n<p>2. Robertson P Jr, Hellriegel ET, Arora S, et al, “Effect of Modafinil on the Pharmacokinetics of Ethinyl Estradiol and Triazolam in Healthy Volunteers,” <i>Clin Pharmacol Ther</i>, 2002, 71(1):46-56. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=11823757\">[PubMed 11823757]</a></p>\n<p>3. Robertson P, DeCory HH, Madan A, et al, “In Vitro Inhibition and Induction of Human Hepatic Cytochrome P450 Enzymes by Modafinil,” <i>Drug Metab Dispos</i>, 2000, 28(6):664-71. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=10820139\">[PubMed 10820139]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","5596":"<p><b>Title</b> CycloSPORINE (Systemic) / Armodafinil</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Armodafinil may decrease the serum concentration of CycloSPORINE (Systemic). <b>Severity</b> Moderate <b>Reliability Rating</b> Fair: Reported in the prescribing information </p> \n<p><b>Patient Management</b> Monitor cyclosporine concentrations closely when starting or stopping concurrent armodafinil. Monitor patients closely for signs/symptoms of diminished clinical response to cyclosporine with use of this combination.</p> \n<p><b>Discussion</b> According to modafinil prescribing information, a patient experienced a 50% reduction in cyclosporine concentrations following one month of concurrent modafinil (200 mg/day).<sup>1</sup> Though specific study data with cyclosporine are not available, both armodafinil and modafinil have been shown to modestly reduce the concentrations of other drugs that, like cyclosporine, are metabolized by CYP3A4.<sup>1,2,3,4,5</sup> As a result, the armodafinil prescribing information recommends caution when using armodafinil together with cyclosporine.<sup>2</sup><br><br>The likely mechanism of this apparent interaction is induction of CYP3A4-mediated drug metabolism by armodafinil.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Prescribing information. Provigil (modafinil). Frazer, PA: Cephalon, Inc., October 2010.</p>\n<p>2. Prescribing information. Nuvigil (armodafinil). Frazer, PA: Cephalon, Inc., October 2010.</p>\n<p>3. Darwish M, Kirby M, Robertson P Jr, et al, “Interaction Profile of Armodafinil with Medications Metabolized by Cytochrome P450 Enzymes 1A2, 3A4 and 2C19 in Healthy Subjects,” <i>Clin Pharmacokinet</i>, 2008, 47(1):61-74. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=18076219\">[PubMed 18076219]</a></p>\n<p>4. Robertson P, DeCory HH, Madan A, et al, “In Vitro Inhibition and Induction of Human Hepatic Cytochrome P450 Enzymes by Modafinil,” <i>Drug Metab Dispos</i>, 2000, 28(6):664-71. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=10820139\">[PubMed 10820139]</a></p>\n<p>5. Robertson P Jr, Hellriegel ET, Arora S, et al, “Effect of Modafinil on the Pharmacokinetics of Ethinyl Estradiol and Triazolam in Healthy Volunteers,” <i>Clin Pharmacol Ther</i>, 2002, 71(1):46-56. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=11823757\">[PubMed 11823757]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","5597":"<p><b>Title</b> Acetaminophen / MetyraPONE</p> \n<p><span style=\"color: red; font-weight: bold\">Dependencies</span> </p>\n<ul>\n <li><p><b>Dose</b>: The clinical significance of this interaction may be greater with larger acetaminophen doses.</p></li>\n</ul>\n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> MetyraPONE may increase the serum concentration of Acetaminophen. More importantly, by inhibiting the conjugative metabolism of acetaminophen, metyrapone may shift the metabolism towards the oxidative route that produces a hepatotoxic metabolite. <b>Severity</b> Moderate <b>Reliability Rating</b> Good </p> \n<p><b>Patient Management</b> Use caution with concurrent use of metyrapone and acetaminophen; the risk is likely to be greatest in patients using moderate or high doses of acetaminophen.</p> \n<p><b>Discussion</b> Metyrapone prescribing information cautions that metyrapone may increase the risk for acetaminophen toxicity due to the ability of metyrapone to inhibit the glucuronidation of acetaminophen<sup>1</sup> Study data from both humans and rats have shown that metyrapone inhibits acetaminophen glucuronidation.<sup>2,3</sup> The impact that such an impairment of this conjugation-type metabolism has on the oxidation of acetaminophen to its toxic NAPQI metabolite is unclear, but at least one study has suggested that enhanced oxidative metabolism is possible.<sup>2</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Prescribing information. Metopirone (metyrapone). East Hanover, NJ: Novartis Pharmaceuticals Corporation, November 2010.</p>\n<p>2. Galinsky RE, Nelson EB, Rollins DE, “Pharmacokinetic Consequences and Toxicologic Implications of Metyrapone-Induced Alterations of Acetaminophen Elimination in Man,” <i>Eur J Clin Pharmacol</i>, 1987, 33(4):391-6. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=3443145\">[PubMed 3443145]</a></p>\n<p>3. Galinsky RE, Corcoran GB, “Suppression of Acetaminophen Conjugation and of Conjugate Elimination in the Rat by Metyrapone, A Classical P-450 Inhibitor,” <i>Drug Metab Dispos</i>, 1988, 16(3):348-54. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=2900724\">[PubMed 2900724]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>"}